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1 Abstract	
	Lysosome-related	 organelles	 (LROs)	 are	 a	 heterogeneous	 group	 of	 organelles	that	have	important	functions	in	a	number	of	specialised	cell	types.	LROs,	despite	their	distinct	 features	and	morphology,	have	been	grouped	together	due	 to	 the	observation	 that	 they	 are	 simultaneously	 functionally	 perturbed	 by	 single	mutations	in	a	number	of	genetic	disorders,	yet	as	a	group	they	are	still	poorly	understood.			Firstly,	 it	 was	 investigated	 whether	 the	 genes	 that	 are	 important	 for	 the	formation/maturation	 of	 other	 LROs	 can	 also	 affect	 Weibel-Palade	 bodies	(WPBs)	an	endothelial	LRO	 that	 is	 critical	 to	haemostasis	and	 inflammation.	 In	the	genetic	disorder	Hermansky	Pudlak	syndrome	(HPS)	a	number	of	LROs	are	affected,	but	the	effect	of	these	mutations	on	WPBs	is	not	yet	established.	It	was	investigated	whether	 these	 genes	 are	 indeed	 important	 for	 the	 biogenesis	 and	function	of	WPBs,	potentially	 revealing	a	new	aspect	of	 the	disease	phenotype.	siRNA	ablation	in	human	endothelial	cells	of	genes	identified	as	involved	in	LRO	biogenesis	 proved	 to	 give	 inconclusive	 results	 as	 to	 their	 importance	 in	WPB	formation	and	function.			Secondly,	the	understanding	of	LRO-related	genetic	disorders	would	be	aided	by	an	 improvement	 in	 diagnostics.	 The	 diagnosis	 of	 platelet	 storage	 disorders	(PSDs)	 is	 currently	 limited	 to	 the	 observation	 of	 symptoms	 (e.g.	 a	 bleeding	disorder	or	albinism)	that	are	often	shared	with	other,	more	common	diseases.	Most	 HPS	 patients	 are	 initially	 misdiagnosed	 and	 many	 see	 4	 to	 6	 specialists	before	 being	 correctly	 identified.	 I	 investigated	 whether	 Super	 Resolution	Microscopy,	 allowing	 images	 to	 be	 taken	 with	 a	 higher	 resolution	 than	the	diffraction	 limit	 (<200	nm),	 has	 the	 potential	 for	 improving	 the	 imaging	 of	platelet	granules	and	thereby	the	diagnosis	and	characterisation	of	LRO-related	disorders.	 The	 use	 of	 structured	 illumination	 microscopy,	 coupled	 with	
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automated	 image	 analysis	 bioinformatics	 allowed	 for	 a	 highly	 efficient	differentiation	between	control	and	patient	platelets.		
	 5	
Table	of	Contents	
1	 Abstract	.......................................................................................................................................	3	
2	 Introduction	...........................................................................................................................	12	
2.1	 Lysosome-related	organelles	..........................................................................................................	12	
2.2	 Melanosomes	.........................................................................................................................................	15	
2.3	 Haemostasis	...........................................................................................................................................	17	
2.4	 Platelet	granules	..................................................................................................................................	18	2.4.1	 Alpha	Granules	.......................................................................................................................	19	2.4.2	 Dense	Granules	......................................................................................................................	20	2.4.3	 Weibel-Palade	Bodies	..........................................................................................................	21	
2.5	 LRO	associated	disorders	..................................................................................................................	27	2.5.1	 Grey	Platelet	Syndrome	......................................................................................................	27	2.5.2	 Hermansky	Pudlak	Syndrome	.........................................................................................	28	2.5.3	 BLOC-1	.......................................................................................................................................	32	2.5.4	 BLOC-2	.......................................................................................................................................	33	2.5.5	 BLOC-3	.......................................................................................................................................	33	
2.6	 Other	HPS-related	complexes	and	proteins	..............................................................................	34	2.6.1	 Adaptor	Protein-3	.................................................................................................................	34	2.6.2	 Rab27	.........................................................................................................................................	35	2.6.3	 Gunmetal	(Rab	geranylgeranyl	transferase)	.............................................................	35	
2.7	 Morphometric	Analyses	....................................................................................................................	36	2.7.1	 Quantitative	image	analysis	.............................................................................................	36	2.7.2	 Super	Resolution	Microscopy	..........................................................................................	37	
3	 Aims	...........................................................................................................................................	40	
4	 Methods	....................................................................................................................................	41	
4.1	 Preparing	Platelet	and	HUVEC	cultures	....................................................................................	41	4.1.1	 Preparing	HUVECs	from	primary	stocks	....................................................................	41	4.1.2	 Preparing	platelets	from	platelet	rich	plasma	(PRP)	............................................	41	
4.2	 siRNA	protocol	......................................................................................................................................	42	4.2.1	 Nucleofection	..........................................................................................................................	42	4.2.2	 siRNA	sequences	...................................................................................................................	43	
4.3	 Fluorescence	Microscopy	..................................................................................................................	44	4.3.1	 Immunofluorescence	microscopy	..................................................................................	44	
	 6	
4.3.2	 dSTORM	.....................................................................................................................................	45	4.3.3	 Structure	Illumination	Microscopy	...............................................................................	46	
4.4	 Electron	Microscopy	...........................................................................................................................	46	4.4.1	 TEM	imaging	of	sectioned	platelets	..............................................................................	46	4.4.2	 TEM	of	platelets	prepared	by	whole	mount	..............................................................	47	
4.5	 Image	analysis	studies	.......................................................................................................................	50	4.5.1	 High	throughput	morphology	of	WPBs	.......................................................................	50	4.5.2	 Automated	image	analysis	of	Platelet	CD63	positive	structures	.....................	50	4.5.3	 CD63	distribution	in	platelets	.........................................................................................	51	4.5.4	 Exocytic	site	analysis	...........................................................................................................	52	4.5.5	 Colocalisation	study	.............................................................................................................	52	
4.6	 Molecular	Biology	................................................................................................................................	52	4.6.1	 Primer	design	..........................................................................................................................	52	4.6.2	 RNA	extraction	.......................................................................................................................	53	4.6.3	 Reverse	transcription	..........................................................................................................	53	4.6.4	 qPCR	............................................................................................................................................	53	
4.7	 Biochemistry	..........................................................................................................................................	55	4.7.1	 vWF	secretion	assay	............................................................................................................	55	4.7.2	 vWF	ELISA	................................................................................................................................	56	4.7.3	 Multimer	gel	analysis	..........................................................................................................	57	
4.8	 Patients	.....................................................................................................................................................	58	4.8.1	 Exome	sequencing	of	HPS	patients	...............................................................................	58	4.8.2	 Controls	and	HPS	patients	for	platelet	studies	.........................................................	59	
5	 Chapter	1	Are	genes	associated	with	HPS	important	for	WPB	function?	..........	60	
5.1	 Introduction	...........................................................................................................................................	60	5.1.1	 Methodology	employed	......................................................................................................	63	
5.2	 Results	-	A	potential	role	for	BLOC-1	in	WPB	function	........................................................	65	5.2.1	 vWF	secretion	assays	in	HUVECs	depleted	of	BLOC-1	..........................................	65	
5.3	 Results	-	A	potential	role	for	BLOC-3	in	WPB	function	........................................................	76	
5.4	 Discussion	................................................................................................................................................	81	
6	 Chapter	 2	 A	 Super	 Resolution	 method	 to	 study	 Platelet	 Granules	 and	 their	
related	disorders	.........................................................................................................................	85	
6.1	 Introduction	...........................................................................................................................................	85	6.1.1	 Alpha	granules	........................................................................................................................	85	6.1.2	 Dense	granules	.......................................................................................................................	87	
	 7	
6.1.3	 Currently	available	PSD	diagnostic	tools	....................................................................	87	
6.2	 Results	.......................................................................................................................................................	91	6.2.1	 Imaging	platelet	alpha	granules	by	TEM	....................................................................	92	6.2.2	 Imaging	platelet	dense	granules	by	Whole	mount	EM	.........................................	93	6.2.3	 Imaging	platelet	alpha	granules	by	dSTORM	............................................................	93	6.2.4	 STORM	imaging	of	platelets	from	patients	with	GPS	............................................	96	6.2.5	 Imaging	CD63	in	platelets	by	SIM	................................................................................	100	6.2.6	 Imaging	CD63	in	patients	with	HPS	............................................................................	106	
6.3	 Discussion	.............................................................................................................................................	114	
7	 Summary	................................................................................................................................	121	
8	 Bibliography	.........................................................................................................................	124																
	 8	
List	of	Figures	
Figure	1	LRO	Morphology	............................................................................................................	13	Figure	2	Melanosome	Biogenesis	..............................................................................................	16	Figure	3	Weibel-Palade	Body	biogenesis	..............................................................................	21	Figure	4	vWF	Domain	Structure	–	formation	and	maturation	of	WPBs	..................	22	Figure	5	WPB	biogenesis	and	the	trafficking	machinery	involved	............................	24	Figure	6	HPS	patient	-	albinism	and	platelet	granule	deficiency	................................	29	Figure	7	HPS	-	nomenclature,	complexes	and	symptoms	..............................................	31	Figure	8	dSTORM	imaging	of	fixed	COS-7	cells.	..................................................................	38	Figure	9	Concept	of	resolution	enhancement	by	structured	illumination	..............	39	Figure	10	Gene	locations	targetted	by	siRNA	sequences	...............................................	43	Figure	11	Dilution	Series	of	platelets	after	centrifugation	on	EM	copper	grids	...	48	Figure	12	Whole	mount	EM	counting	criteria	.....................................................................	49	Figure	13	Whole	mount	EM	of	platelets	–	manipulating	contrast	for	counting	...	49	Figure	14	Patient	1	HPS1	mutations	........................................................................................	58	Figure	15	Patient	2	HPS6	mutations	........................................................................................	59	Figure	16	Patient	3	HPS5	mutation	..........................................................................................	59	Figure	17	BLOC-1	KD	in	HEK293	cells	-	vWF	secretion	assay	.....................................	65	Figure	18	BLOC-1	KD	HUVECs	–	100	pmol	of	siRNA	-	vWF	secretion	assay	..........	67	Figure	19	BLOC-1	KD	HUVECs	–	200	pmol	of	siRNA	-	vWF	secretion	assay	..........	68	Figure	20	Pallidin	2	siRNA	quantification	.............................................................................	69	Figure	21	Pallidin	2	KD	in	HUVECs	-	vWF	secretion	assay	............................................	70	Figure	22	Pallidin	2,3	and	4	KD	in	HUVECs	–	vWF	secretion	assays	.........................	71	Figure	23	Exocytic	Site	analysis	in	Pallidin	2	KD	HUVECs	.............................................	72	Figure	24	Pallidin	2	KD	in	HUVECs	–	WPB	morphometric	analysis	..........................	73	Figure	25	Pallidin	2	KD	in	HUVECs	–	Multimer	Gel	...........................................................	74	Figure	 26	 Correlation	 between	 pallidin	 KD	 efficiency	 and	 vWF	 secretion	 in	HUVECs	.......................................................................................................................................	76	Figure	27	Western	Blot	to	measure	HPS1	and	HPS4	antibody	specificity	..............	77	Figure	28	HPS1.2	KD	in	HUVECs	–	vWF	secretion	assays	..............................................	78	Figure	29	HPS1.2,	1.3	and	1.5	KD	in	HUVECs	–	vWF	secretion	assays	.....................	79	
	 9	
Figure	30	Dense	Granule	counting	in	a	test	sample	..........................................................	89	Figure	31	Thin	Section	TEM	image	of	a	Control	Platelet	................................................	92	Figure	32	Whole	mount	EM	of	platelets	.................................................................................	93	Figure	33	dSTORM	image	of	platelet	immunolabelled	with	vWF	...............................	94	Figure	34	dSTORM	imaging	of	vWF	in	platelets	.................................................................	95	Figure	35	dSTORM	imaging	of	vWF	and	tubulin	in	platelets	........................................	96	Figure	36	TEM	of	Control	and	GPS	platelets	........................................................................	98	Figure	37	GPS	patient	platelets	–	dSTORM	labelled	with	vWF	and	P-Selectin	.....	98	Figure	38	Imaging	CD63	in	platelets	by	SIM	......................................................................	100	Figure	39	Platelet	tubulin	segmentation	.............................................................................	101	Figure	40	Platelet	CD63	segmentation	.................................................................................	101	Figure	41	SIM	Segmentation	workflow	................................................................................	102	Figure	42	Fixed	Platelets	imaged	by	Whole	mount	EM	.................................................	103	Figure	43	Mepacrine	labelling	of	platelets	..........................................................................	104	Figure	44	Immunofluorescent	colocalisation	of	CD63	in	Platelets	..........................	105	Figure	45	Whole	mount	EM	of	Platelets	...............................................................................	107	Figure	46	Whole	mount	EM	analysis	.....................................................................................	108	Figure	47	SIM	imaging	of	platelets	from	control	and	HPS	patients	.........................	109	Figure	48	Analysis	of	SIM	data	.................................................................................................	110	Figure	49	Schematic	of	Radial	profile	algorithm.	.............................................................	112	Figure	50	CD63	at	the	platelet	surface	in	HPS	platelets	................................................	113	Figure	51	Publications	related	to	SIM	...................................................................................	120				
	 10	
List	of	Tables	
Table	1	LRO	Tissue	Distribution	and	Physiological	Function	.......................................	14	Table	2	siRNA	sequences	..............................................................................................................	43	Table	3	Primary	Antibodies	used	..............................................................................................	44	Table	4	Secondary	Antibodies	used	.........................................................................................	45	Table	5	Gene	Specific	Primers	sequences	.............................................................................	55	Table	6	BLOC-1	KD	in	HUVECs	–	100	pmol	of	siRNA	.......................................................	67	Table	7	BLOC-1	KD	in	HUVECs	–	200	pmol	of	siRNA	.......................................................	68	Table	8		Pallidin	2	KD	in	HUVECs	..............................................................................................	70	Table	9	Pallidin	2,	3	and	4	KDs	in	HUVECs	...........................................................................	71	Table	10	Pallidin	KD	experiments	summary	.......................................................................	75	Table	11	HPS1.1	and	HPS1.2	KD	qPCR	...................................................................................	77	Table	12	HPS1.2	KD	in	HUVECs	–	vWF	secretion	assays	................................................	78	Table	13	HPS1.2,	1.3	and	1.5	KD	in	HUVECs	–	vWF	secretion	assays	.......................	79	Table	14	Colocalisation	of	CD63	with	other	platelet	granule	markers	..................	105													
	 11	
List	of	Abbreviations			ARC	–	Arthrogryposis,	Renal	dysfunction	and	cholestasis	BEACH	–	Beige	and	Chediak	Higashi	BLOC	–	Biogenesis	of	Lysosome	Related	Organelle	Complex	BSA	–	Bovine	Serum	Albumin	CHS	–	Chediak-Higashi	Syndrome	ELISA	-	Enzyme-linked	immunosorbent	assay	GFP	–	Green	Fluorescent	Protein	GPS	–	Grey	Platelet	Syndrome	HPS	–	Hermansky	Pudlak	Syndrome	KD	-	Knockdown	KO	–	Knockout	LTA	–	Light	Transmission	Aggregometry	LROs	–	Lysosome	Related	Organelles	LYST	-	Lysosomal	trafficking	regulator	MKs	-	Megakaryocytes	MVBs	–Multi	Vesicular	Bodies	
NBEAL2	-	neuro	beachin-like	2	PBS	–	Phosphate-buffered	Saline	PSD	–	Platelet	storage	pool	disorder	RT-PCR	–	Reverse	Transcription	Polymerase	Chain	Reaction	SIM	–	Structured-illumination	Microscopy	SDS	-	Sodium	dodecyl	sulphate		SRM	–	Super	Resolution	Microscopy	TGN	–	Trans	Golgi	Network	vWD	–	von	Willebrand’s	Disease	vWF	–	von	Willebrand’s	Factor	WPBs	–	Weibel	Palade	Bodies	WT	–	Wild	Type	
	 12	
2 Introduction	
2.1 Lysosome-related	organelles	
	Lysosomes	 are	membrane-bound	 cytoplasmic	 organelles	 containing	 hydrolytic	enzymes	 that	 are	 primarily	 involved	 in	 intracellular	 protein	 degradation	 (1).	Lysosome-related	organelles	(LROs)	are	distinct	types	of	cytoplasmic	organelles,	they	 are	 related	 to	 lysosomes,	 yet	 are	 functionally,	 morphologically	 and/or	compositionally	 distinct	 both	 from	 lysosomes	 and	 from	 each	 other	 (Table	 1).	Whilst	many	properties	of	LROs	are	shared	with	lysosomes,	LROs	are	defined	by	the	fact	that	they	perform	specific	functions	unrelated	to	degradation.		What	LROs	have	 in	 common	 is	 that	 some,	 if	 not	 all,	 of	 their	 content	 is	derived	from	 the	 endosomal	 system	 (2)	 and	 all	 LROs	 progressively	 mature	 from	precursors	 by	 acquiring	 specialised	 cargoes	 and	 generating	 a	 lumenal	environment	 conducive	 to	 their	 function.	 Within	 their	 host	 cells,	 LROs	 can	produce	 completely	 novel	 morphological	 features	 (Figure	 1)	 such	 as	 the	proteinacious	 tubules	 of	 Weibel-Palade	 bodies	 (WPBs)	 and	 the	 lipid	 swirls	within	lamellar	bodies	(1).		
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Figure	1	LRO	Morphology	
	Despite	 their	 shared	 machinery	 and	 links	 to	 genetic	 disorders,	 LROs	 exhibit	 a	 variety	 of	 morphological	 features.	(a)	Melanosomes;	(b)	Azurophilic	 granules;	(c)	Cytolytic	 granules;	(d)	MHC	 class	 II	 compartments	 (here	 MIICs	 are	immunogold	labelled	for	MHC	class	II	molecules)	and	(e)	WPBs.	Figure	from	(2)					
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Table	1	LRO	Tissue	Distribution	and	Physiological	Function	
Organelle	 Tissue	Distribution	 Physiological	function	
Lytic	Granules	 Cytotoxic	T	lymphocytes,	NK	cells	 Destruction	of	virally	infected	or	cancerous	target	cells	
Dense	Granules	
(also	known	as	
dense	bodies	or	
delta	granules)	
Platelets,	megakaryocytes	 Release	of	ATP,	ADP,	serotonin	and	calcium	for	blood	clotting	
Alpha	Granules	 Platelets,	megakaryocytes	 Fibrinogen	and	von	Willebrand	factor	release	for	platelet	adhesion	and	blood	clotting	
Basophilic	
granules	 Basophils,	mast	cells	 Triggered	release	of	histamines,	other	inflammatory	stimuli	
MHC	class	II	
compartments	
Antigen	presenting	cells	(dendritic	cells,	B	lymphocytes,	macrophages)	 Processing	and	presentation	of	antigens	to	CD4+	lymphocytes	for	immune	regulation	
Lamellar	
Bodies	 Lung	epithelial	type	II	cells	 Storage	and	secretion	of	surfactant	
Weibel	Palade	
Bodies	 Endothelial	cells	 Storage	and	regulated	release	of	haemostatic	and	pro-inflammatory	factors	into	blood	
Melanosomes	 Melanocytes,	retinal	and	iris	pigment	epithelial	cells	 Intracellular	melanin	biosynthesis	and	storage	and	transfer	to	keratinocytes	
Osteoclast	
Granules	 Osteoclasts	 Bone	resorption	and	remodelling	
Pigment	
Granules	 Drosophila	melanogaster	eye	cells	 Eye	Pigmentation	
Acrosomes	 Sperm	Cells	 Fertilisation,	fusion	of	sperm	and	egg	
Fat	Storage	
Organelle	 Caenorhabditis	elegans	gut	cells	 Fat	Storage	
Inhibitory	
Lysosomes	 Dendritic	cells	 Control	the	pH	of	the	phagosome		The	cell	types	in	which	LROs	are	located	in	the	human	body	and	their	functions	within	those	tissues	are	displayed.	Table	adapted	from	(2)		Historically,	research	on	LROs	has	been	focused	on	their	specialist	 functions	as	opposed	 to	 the	 similarities	 within	 this	 group	 as	 a	 whole.	 However,	 the	observation	 that	 single	 mutations	 are	 capable	 of	 disrupting	 the	 biogenesis	 of	many	 of	 these	 organelles	 simultaneously	 has	 sparked	 interest	 within	 the	 cell	biology	 community.	 An	 example	 of	 this	 is	 shown	 by	 Hermansky	 Pudlak	Syndrome	 (HPS),	 in	 which	 mutations	 that	 affect	 components	 of	 the	 cell’s	membrane	 trafficking	 machinery	 are	 capable	 of	 disrupting	 the	 function	 of	 a	number	of	LROs	(3).	The	characterisation	of	these	organelles	was	facilitated	by	research	on	the	coat-colour	mutants	of	mice	that	were	shown	to	exhibit	the	same	cluster	of	pigment	and	bleeding	disorders	as	their	human	counterparts	(as	well	as	with	 the	Drosophila	melanogaster	 eye	 colour	variants	 and	genetic	 studies	 in	yeast)	(4).	These	discoveries	have	emphasised	the	similarities	between	LROs,	yet	despite	 this,	 the	 molecular	 and	 cellular	 basis	 for	 the	 LROs	 relationship	 to	lysosomes	and	their	diversity	still	remain	poorly	understood.		Because	 the	 study	 of	 LROs	has	 been	historically	 allied	with	 an	 interest	 in	 coat	colour	 genetics	 (5),	 a	major	 focus	of	 research	has	been	melanosomes;	 the	LRO	
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found	in	the	melanocytes	of	the	eye	and	skin	and	pigmented	epithelial	cells	of	the	retina	 (iris	 and	 ciliary	 body	 of	 the	 eye)	 in	 which	 melanin	 pigments	 are	synthesised	 and	 stored.	 The	 pigments	 formed	 by	 melanosomes	 are	 the	 key	determinant	 of	 skin	 and	 hair	 colour	 in	mammals,	 as	 well	 as	 providing	 photo-protection	 against	 ionising	 radiation	 (1).	 Initially	 the	 research	 that	 focused	 on	the	melanosome	not	only	drove	“LROs”	as	an	area	of	research	(6)	but	also,	after	observations	 involving	 the	 whole	 group	 of	 LROs	 had	 been	 collected,	 these	organelles	 became	 once	 again	 the	 reference	 and	 focal	 point	 for	 studies	 in	 this	area	(7).	Much	of	what	we	know	today	about	LROs	has	thus	been	due	to	efforts	to	further	understand	the	mechanisms	behind	the	biogenesis	and	maturation	of	the	melanosome	and	they	therefore	provide	a	natural	reference/start	point	for	any	LRO-related	investigation.		
2.2 Melanosomes		In	a	typical	cell	(and	in	melanocytes)	the	early	endosomes	(EE,	Figure	2),	consist	of	 tubular	 domains	 and	 vacuolar	 domains.	 Intralumenal	 vesicles	 (ILVs)	 form	from	 the	 vacuolar	 domains	 by	membrane	 invagination	 in	 regions	 immediately	adjacent	to	bilayered	clathrin	and	Hrs-containing	coats	(black	arrows,	Figure	2).	These	 vacuolar	 domains	 can	 mature	 to	 form	 late	 endosomal	 multi-vesicular	bodies,	the	lumenal	contents	of	which	are	degraded	upon	fusion	with	lysosomes.		 	
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Figure	2	Melanosome	Biogenesis	 	
		Maturation	 stages	 of	 Lysosomes	 (blue	 arrows)	 and	 Melanosomes	 (red	 arrows)	 from	 early	 endosomes/stage	 1	melanosomes.	 Early	 endosomes	 (EE)	 form	 from	 membranes	 derived	 by	 internalisation	 from	 the	 plasma	 membrane	(dashed	arrows	red	and	blue)	and	also	from	membranes	formed	by	the	secretory	pathway	(not	shown).	EE	are	comprised	of	 tubular	 domains	 and	 vacuolar	 domains;	 from	 which	 internal	 vesicles	 form	 by	 the	 invagination	 of	 the	 limiting	membrane	 in	 regions	 adjacent	 to	 bilayered	 clathrin-and	 Hrs-containing	 coat	 regions	 (black	 arrows).	 These	 vacuolar	domains	mature	 into	 late	 endosomal	multi-vesicular	 bodies	 (MVBs).	 The	 lumenal	 contents	 of	 the	MVBs	 degrade	 after	fusion	with	 lysosomes.	 In	pigment	 cells,	 the	vacuolar	domains	of	EEs	 can	also	be	 categorised	as	 Stage	 I	melanosomes.	They	are	unique	from	vacuolar	early	endosomes	of	other	cells	as	they	contain	fibrils	that	protrude	from	internal	vesicles.	The	fibrils	elongate	and	assemble	into	sheets	(Stage	II	Melansomes).	The	delivery	of	contents	to	Stage	II	melanosomes	by	tubular	intermediates	from	EE	(as	shown)	or	recycling	endosomes	(not	shown)	results	in	the	deposition	of	melanins	on	the	 fibrils	 in	 Stage	 III	melanosomes.	The	 continuation	of	 this	process	 leads	 to	 the	 formation	of	 Stage	 IV	melanosomes.	Figure	adapted	from	(8).			Melanosomes	share	a	number	of	features	with	lysosomes,	including	the	presence	of	 lysosomal	proteins,	an	acidic	 luminal	environment,	accessibility	 to	endocytic	tracers,	 and	 the	 ability	 to	 fuse	 with	 phagosomes	 (1).	 The	 maturation	 of	melanosomes	 takes	place	 in	 four	distinct	 stages	 (Figure	2),	 beginning	with	 the	development	of	 the	vacuolar	domains	(stage	I)	 into	nonpigmented	stage	II	pre-melanosomes,	in	which	the	ILVs	scaffold	the	polymerisation	of	amyloid	fibrils	by	the	 pigment	 cell-specific	 protein	 PMEL	 (9).	 Pmel-/-	 mice	 form	 round	melanosomes	that	lack	characteristic	striations,	yet	still	remain	segregated	from	
Early	Endosome/	
Stage	1	Melanosome	
MVB	
Lysosome	
Early	Endosome/	
Stage	I	Melanosome	
Stage	II	Melanosome	
Stage	III	Melanosome	
Stage	IV	Melanosome	
Fibrils	
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the	 endosomal	 system	 (10).	 The	 delivery	 of	 cargo	 to	 stage	 II	 melanosomes	results	in	the	deposition	of	melanins	on	the	fibrils	in	stage	III	melanosomes	and	finally	 in	 stage	 IV	 melanosomes,	 this	 continued	 deposition	 of	 melanin	 masks	internal	 structure.	 Not	 only	 do	 melanosome	 biogenesis	 pathways	 involve	complex	early	endosomes,	which	sort	cargo	to	multiple	destinations	via	multiple	exit	routes	but	also	multiple	parallel	pathways.	As	a	result,	it	has	proved	complex	to	 separate	 the	 effects	 of	 mutations	 on	 melanosome	 cargo	 delivery	 from	mutations	that	effect	the	recycling	pathways	that	retrieve	key	components	from	melanosomes	to	supply	further	rounds	of	cargo	delivery	(11).	Melanin	synthesis	in	 stages	 III	 and	 IV	 requires	 the	 selective	 targeting	 of	 integral	 membrane	melanogenic	 enzymes,	 such	 as	 tyrosinase	 and	 tyrosinase-related	 protein	 1	(Tyrp1),	 and	 other	 components	 that	 regulate	 enzyme	 activity,	 from	 early	endosomal	intermediates	to	stage	II	melanosomes	(12)	via	recycling	endosomes	(13).	 Defects	 in	 the	 trafficking	 of	 melanosomal	 cargoes	 such	 as	 Tyrp1	 to	melanosomes	during	melanosome	biogenesis	underlie	oculocutaneous	albinism	in	HPS	(14).	The	ability	to	sort	these	macromolecules	correctly	is	only	found	in	a	sub-set	 of	 specialised	 pigment	 host	 cells	 and	 to	 achieve	 this,	 these	 cells	 must	correctly	 distinguish	 macromolecules	 that	 are	 destined	 for	 conventional	lysosomes	 from	 those	 destined	 for	 the	 melanosome	 (15).	 The	 need	 for	 this	sorting	 can	 be	 demonstrated	 when	 melanosomal	 proteins	 are	 expressed	ectopically	 in	non-pigment	cells	 (16–18)	where	 they	 localise	 to	 late	endosomes	and	lysosomes.		Research	 on	 LROs,	 though	 initially	 focused	 on	 the	 melanosomes,	 progressed	further	to	include	a	larger	group	of	specialised	organelles	in	host	cells.	The	LROs	that	are	the	focus	in	this	thesis	are	the	WPBs,	platelet	dense	granules	and	platelet	alpha	granules,	all	of	which	are	primarily	involved	in	the	process	of	haemostasis.		
2.3 Haemostasis		Haemostasis	 is	 a	 complex	 physiological	 process	 that	 involves	 the	 tightly	regulated	processes	of	blood	clotting,	platelet	activation	and	vascular	repair	(19).	Following	 damage	 to	 the	 cell	 layer	 that	 lines	 the	 vascular	 walls,	 endothelial	
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activation	 leads	 to	 the	 exocytosis	 of	 the	 WPB	 in	 which	 vWF	 is	 stored.	 This,	together	with	any	vWF	bound	to	the	subendothelial	matrix	exposed	by	damage,	recruits	platelets	 from	 the	blood.	This	 capture	 and	adhesion	of	platelets	 in	 the	blood	 flow	 causes	 them	 to	 change	 their	 shape	 and	 to	 form	 pseudopods.	 The	signalling	initiated	by	platelet	activation	also	causes	activation	of	integrin	αIIbβ3	and	 the	 secretion	 of	 bioactive	 molecules	 (20)	 from	 their	 preformed	 LROs,	cytoplasmic	 dense	 and	 alpha	 granules,	 which	 amplify	 aggregation.	 Multiple	flowing	 platelets	 then	 aggregate	 via	 fibrinogen	 bridges	 through	 the	 action	 of	thrombin	 and	 contract	 to	 form	 a	 tightly	 packed	 thrombus	 termed	 the	 platelet	plug	 (21).	 The	 accumulated	 platelet	 plug	 temporarily	 functions	 to	 prevent	bleeding,	 however,	 it	 is	 easily	 dislodged	 from	 the	 vessel	 wall	 and	 thus,	 a	secondary	 haemostatic	 response	 is	 required	 (22).	 After	 the	 platelet	 plug	 is	formed,	the	proteolytic	coagulation	cascade	leads	to	the	deposition	of	 insoluble	fibrin	that	strengthens	and	stabilises	the	thrombus	and	in	turn	acts	as	adhesion	sites	 for	 coagulation	 factors.	 This	 process	 of	 fibrin	 generation	 occurs	simultaneously	to	platelet	aggregation	(23)	and	is	activated	within	seconds	of	an	injury,	is	tightly	regulated	and	importantly	is	localised	to	the	site	of	injury	(24).	This	process	of	haemostasis	is	critical	to	cover	a	break	in	the	vessel	wall (25)	and	is	 reliant	 on	LROs	 such	 as	platelet	 granules	 and	WPBs,	which	 are	discussed	 in	detail	below.	
2.4 Platelet	granules		Platelets	are	small	(2-5	μM)	anuclear	secretory	cell	fragments	that	originate	from	megakaryocytes	(MKs).	During	maturation,	MKs	grow	in	size	and	replicate	their	DNA	without	 cytokinesis	 (polyploidy)	 through	a	process	 called	endomitosis.	As	MKs	mature,	 they	develop	a	highly	 invaginated	demarcation	membrane	system	whilst	 their	cytoplasm	concurrently	becomes	filled	with	platelet	granules.	They	have	an	average	lifespan	of	about	10	days	before	removal	by	the	spleen	(26)	and	each	day	an	adult	produces	about	100	billion	platelets	(27).	Platelets	play	a	vital	role	in	regulating	haemostasis.			
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The	 contents	 of	 platelets	 include	 an	 open	 canalicular	 system,	 a	 dense	 tubular	system	and	secretory	granules,	from	which	bioactive	molecules	are	released	and	in	 turn	 most	 platelet	 functions	 are	 mediated.	 Platelet	 granules	 originate	 from	multi-vesicular	bodies	(MVBs)/late	endosomes	in	MKs,	but	little	is	known	about	the	exact	mechanisms	by	which	granule	cargo	is	sorted	and	trafficked	(20).	In	the	MKs,	granules	are	formed	from	the	budding	of	small	vesicles	containing	granule	cargo	 from	the	 trans-Golgi	network	 (28,	29).	This	cargo	 is	delivered	directly	 to	MVBs,	 where	 the	 proteins	 are	 sorted	 and	 packaged	 into	 granules	 (30).	Historically,	platelet	granules	have	been	classified	into	distinct	groups	based	on	their	 content	 and	 appearance	 by	 electron	 microscopy	 (EM);	 dense	 granules,	alpha	granules,	MVBs,	lysosomes	(25),	and	more	recently,	T	granules	(31).	Alpha	granules	and	dense	granules	are	both	categorised	as	LROs	as	 they	derive	 from	similar	precursors	and	share	fusion	machinery	important	for	secretion,	but	their	formation	is	differentially	regulated	(32).	 	The	 critical	 role	 played	 by	 platelets	 in	 haemostasis	 is	 dependent	 on	 platelet	granule	 integrity;	 deficiencies	 in	 these	 organelles,	 including	 abnormalities	 in	granule	 number	 or	 size,	 are	 associated	 with	 bleeding	 symptoms	 (33).	 	 Most	inherited	 platelet	 storage	 pool	 disorders	 (PSDs)	 disrupt	 the	 function	 of	 either	alpha	 or	 dense	 granules,	 but	 not	 both,	 suggesting	 the	 existence	 of	 distinct	granule	 biogenesis	 pathways	 for	 the	 two	 subtypes.	 For	 example,	 in	 genetic	disorders	 such	 as	 HPS	 and	 Chediak-Higashi	 Syndrome	 (CHS)	 the	 absence	 of	dense	granules	(1,	3,	34–36)	significantly	slows	the	rate	of	effective	haemostasis	at	 the	 site	 of	 an	 injury	 (37),	 and	 in	 Grey	 Platelet	 Syndrome	 (GPS)	 patients	similarly	suffer	from	a	bleeding	disorder	which	is	caused	by	an	underlying	defect	in	the	ability	of	platelets	to	store	alpha	granule	proteins	(38).		
2.4.1 Alpha	Granules		Alpha	 granules	 have	 the	 properties	 of	 both	 secretory	 organelles	 and	 late	endosomes,	which	qualify	 their	 characterization	as	an	LRO.	Alpha	granules	are	the	 major	 storage	 and	 secretory	 organelle	 in	 the	 platelet,	 being	 the	 most	abundant	 granules;	 numbering	 around	 50-80	 per	 platelet	 (39).	 Formed	 from	
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multi-vesicular	precursor	organelles,	 alpha	granule	 contents	are	acquired	 from	both	the	endocytic	and	biosynthetic	routes	(30).	 	Alpha	granules	contain	over	300	distinct	molecules,	which	makes	up	the	bulk	of	the	 platelet	 secretome	 (40).	 These	 include	 haemostatic	 factors,	 angiogenic	factors,	 anti-angiogenic	 factors,	 growth	 factors,	 proteases,	 necrotic	 factors	 and	other	 cytokines	 (40).	 Little	 is	 known	 about	 the	 mechanism	 of	 alpha	 granule	biogenesis	 (41),	 which	 is	 affected	 in	 three	 inherited	 human	 disorders:	 Quebec	Platelet	 Disorder,	 GPS	 and	 arthrogryposis,	 renal	 dysfunction	 and	 cholestasis	(ARC)	 syndrome.	 In	 GPS	 the	 amount	 of	 protein	 synthesised	 in	 MKs	 is	significantly	 reduced,	 although	 endocytosed	 alpha	 granule	 content	 is	 less	affected.	It	has	recently	been	demonstrated	that	mutations	in	the	Neurobeachin-like	2	(NBEAL2)	gene	cause	GPS	(42)	and	these	mutations	appear	to	be	involved	in	 the	 packing	 of	 endogenously	 synthesised	 secretory	 proteins	 into	developing	alpha	 granules	 (for	 a	 continued	 platelet	 alpha	 granule	 introduction	also	see	6.1.1).	
2.4.2 Dense	Granules	
 Dense	granules	are	around	150	nm	in	size,	originate	from	endosomal	precursors	and	belong	 to	 a	 secretory	 compartment	 from	which	 content	 is	 released	during	platelet	 activation	 (29).	 Dense	 granules	 are	 typically	 identified	 using	 Electron	Microscopy	(EM)	and	are	recognizable	by	the	presence	of	a	very	electron-dense	core,	 which	 is	 caused	 by	 their	 high	 calcium	 and	 phosphate	 content.	 	 Dense	granules	are	acidic	and	therefore	accumulate	acidic	dyes	such	as	mepacrine	(43)	and	 acridine	 orange	 (44).	 Their	 content	 is	 simpler	 than	 alpha	 granules	 and	contains	a variety	of	important	haemostatically	active	substances.		Platelet	dense	granules	 release	 their	 contents	 into	 the	 extracellular	medium	 upon	 activation,	these	 include;	 serotonin,	 histamine,	 catecholamines	 (45),	 adenosine	 5′-diphosphate	 (ADP),	 adenosine	 5′-triphosphate	 (ATP),	 polyphosphate	 (46),	magnesium	 pyrosphate	 and	 calcium	 (47).	 	 	 ADP	 secreted	 from	 platelet	 dense	granules	 stimulates	 platelets	 arriving	 at	 the	 site	 of	 injury,	 amplifying	 the	response	 of	 platelets	 to	 primary	 agonists	 and	 facilitating	 the	 formation	 of	 the	platelet	plug	(48). Dense	granules	also	contain	the	lysosomal	membrane	proteins	
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CD63	 (35)	 and	 LAMP1/2	(49),	 but	 also	 non-lysosomal	 proteins	 such	 as	 P-selectin,	GPIb	and	αII-β3	integrin	(50);	which	are	translocated	to	the	cell	surface	upon	platelet	activation.	Dense	granules	also	carry	Rab27a	and	b	(51,	52)	which	are	required	for	content	release	(see	also	2.6.2),	Rab	proteins	are	defined	as	Ras-like	 monomeric	 GTPases	 and	 have	 been	 implicated	 in	 the	 control	 of	 protein	trafficking	 as	 regulators	 of	 vesicular	 transport	 such	 as	 vesicle	 budding,	movement,	 and	 docking/fusion	 (53)	 (for	 a	 continued	 platelet	 dense	 granule	introduction	also	see	6.1.2). 	Melanosomes	and	platelet	granules	are	closely	related	and	are	both	formed	from	endosomes	that	are	transformed	by	the	delivery	of	specialised	cargo.	However,	there	are	other	LROs,	such	as	WPBs,	that	are	more	distantly	related.	WPBs	carry	proteins	such	as	P-selectin,	Rab27a	and	CD63	common	to	other	LROs	however,	unusual	for	an	LRO,	they	do	not	originate	from	the	endosome	but	are	formed	at	the	Golgi.	
2.4.3 Weibel-Palade	Bodies		Figure	3	Weibel-Palade	Body	biogenesis	
		Biogenesis	of	WPBs	 in	cultured	human	endothelial	cells	seen	by	high-pressure	 freezing/freeze	substitution.	 (A)	Tubule	formation	in	the	Trans-Golgi	Network	(TGN).	(B)	Immature	WPB	with	electron-lucent	interior.	(C)	Immature	WPB	with	Clathrin-	coated	bud	(D)	Mature	WPB	demonstrating	an	increase	in	electron	density	that	occurs	during	maturation.	Bars,	200	nm.	Figure	from	(54).		Ewald	 Weibel	 and	 George	 Palade	 first	 described	 WPBs	 in	 1964	 (55),	 as	 ‘an	unknown	rod-shaped	cytoplasmic	component,	which	consists	of	a	bundle	of	fine	tubules,	enveloped	by	a	tight	 fitting	membrane’.	 In	1982,	WPBs	were	 identified	as	the	storage	organelle	for	von	Willebrand	factor	(vWF)	protein	(56).	
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organised packing of VWF tubules (Zenner et al., 2007). The high
degree of organisation in the WPBs competent for release is likely
to be important for forming long strings rather than tangles of
VWF. Compaction and organisation of VWF thus seems to be an
ongoing process, beginning with tubulation and multimerisation in
the TGN, followed by further multimerisation in WPBs, and
culminating as the tubules themselves become compacted as the
organelle matures. The compression of the space between the
tubules may not fully explain the increase in electron density; a
search for new components recruited to the peripheral WPBs may
thus be warranted.
Moving images of WPBs (Romani de Wit et al., 2003b; Zenner
et al., 2007) suggest that although the WPBs are unable to curl they
can bend at hinge points. These hinge points coincide with an
interruption to the VWF tubules; tubules do not turn the corner in
parallel with the limiting membrane but stop at the bend. Each
piece of the bending cigar has its own set of tubules that roughly
parallel the long axis of that individual section. The hinges may
allow WPBs to move around the cell effectively (Zenner et al.,
2007). Many of these observations have recently been confirmed
by a tomographic analysis of WPBs (Valentijn et al., 2007).
Role of AP1 in WPB formation
The ability of VWF to drive the formation of pseudo-WPBs by
heterologous expression is consistent with the formation of WPBs
being driven by a selective aggregation of contents. This supports
the model of secretory granule biogenesis that relies on sorting by
selective retention (reviewed by Arvan and Castle, 1998).
However, cytoplasmic machinery is also crucial for WPB
formation. Clathrin and the heterotetrameric adaptor protein (AP)
complex AP1 help form vesicles that transport proteins between
post-Golgi compartments (reviewed by Edeling et al., 2006; Traub,
2005) and recently were also implicated in WPB biogenesis (Lui-
Roberts et al., 2005). Immature WPBs in the perinuclear region of
the cell are extensively coated with clathrin and AP1. The extent
to which the immature WPB surface is covered with clathrin
suggests a structural role for this coat. By disrupting clathrin
function using a dominant negative AP180 construct (Ford et al.,
2001) or interfering with AP1 function using an siRNA (Hirst et
al., 2003), one can inhibit WPB formation and regulated secretion
of VWF (Lui-Roberts et al., 2005). Interference with AP1/clathrin
function prevents the formation of the large cigar-shaped
structures. Instead, small rounded VWF-positive punctae are seen
within the cytoplasm by light microscopy, and secretion through
the constitutive secretory pathway is increased (Lui-Roberts et al.,
2005). Since there is a very clear correlation between the cigar
shape of the WPB and the presence of tubules, the implication of
these data is that folding VWF into tubules requires AP1/clathrin.
Once a WPB is properly formed, it does not require the coat to
maintai  its cigar shape, because brefeldin A treatment, which
releases all clathrin coats (Robinson and Kreis, 1992), does not
deform preformed WPBs (Lui-Roberts et al., 2005).
The AP1/clathrin coat might provide a stabilising scaffold for
the initial folding of VWF into the tubules that drives the formation
of cigar-shaped WPBs (Lui-Roberts et al., 2005). The extensive
coating on forming WPBs is consistent with this hypothesis, as are
images such as that in Fig. 2A showing that the elongated bud
surrounding a newly forming tubule is coated. In this latter case, it
almost looks as though the tubule is preventing scission, allowing
the extension of a rounded bud into the elongated shape seen here
– could this be the very beginning of WPB formation? This role
for AP1/clathrin, as with the shape of the WPB, may be endothelial
specific, since a dominant negative clathrin hub construct
expressed in pancreatic !-cells affects neither the storage nor the
stimulated secretion of insulin (Molinete et al., 2001). WPBs may
well be different from conventional secretory granules.
The way in which clathrin is used in formation of WPBs – both
in the scale and the curvature of the coating – is different from its
role in formation of small ‘conventional’ transport vesicles.
Whether any of the known AP1 effectors [e.g. aftiphilin (Mattera
et al., 2004), "-synergin (Page et al., 1999), p200 (Lui et al., 2003),
epsinR (Hirst et al., 2003; Kalthoff et al., 2002; Mills et al., 2003;
Wasiak et al., 2002) and PACS1 (Crump et al., 2003)] are involved
in the adaptor complex used to form WPBs is not yet established.
Indeed, WPBs may be a fruitful context for screens for novel AP1-
interacting proteins. In addition, since heterologous expression of
VWF can drive WPB formation, which is in turn dependent on
AP1, it will be interesting to discover how a soluble cargo protein
might drive the recruitment of a protein complex to the other side
of the membrane that surrounds it. Finally, HPF/FS analyses
Journal of Cell Science 121 (1)
Fig. 2. Biogenesis of WPBs in cultured human endothelial cells seen by HPF/FS. (A) Tubule formation in the TGN and the cooperation of AP1 and clathrin in
initial formation. (B) Immature WPB with electron-lucent interior, but with a membranous stalk still attaching it to the TGN. (C) Immature WPB with clathrin-
coated bud, which is presumably involved in retrieval of material not required in the mature WPBs. (D) Mature WPB showing the remarkable increase in electron
density that occurs duri g maturation. Bars, 200 nm.
-	
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Deficiencies,	 either	 quantitative	 or	 qualitative,	 in	 vWF	 are	 responsible	 for	 von	Willebrand’s	 disease	 (VWD),	 which	 is	 the	 most	 common	 inherited	 bleeding	disorder	in	humans,	occurring	in	approximately	1	out	of	every	100-1,000	people	and	affects	both	males	and	females	(57).	Figure	4	vWF	Domain	Structure	–	formation	and	maturation	of	WPBs	
	(A)	Schematic	representation	of	 the	domain	arrangement	of	vWF.	vWF	is	a	mosaic	protein	composed	of	many	types	of	domains.	Many	of	these	domains	have	specific	functions	in	haemostasis;	others	function	in	formation	during	biosynthesis	and	 give	 vWF	 the	 length	 and	 flexibility	 that	 enable	 a	 transition	 that	 activates	 haemostasis,	 The	 different	 domains	 are	arranged	 in	 the	 order:	 D1-D2-D′-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK,	 with	 the	 D1-D2	 domains	 representing	 the	propeptide	 and	 the	 remainder	 corresponding	 to	 the	 mature	 VWF	 subunit	 (58).	 	 (B)	 Step	 1:	 Dimerisation,	 Step	 2:	Multimerisation,	Step	3:	Packaging	into	Ministacks,	Step	4:	Co-packaging.	(Final	black	arrow)	A	multimer	Gel	can	be	used	to	determine	multimers	formed	and	can	be	an	indicator	of	vWD	(see	4.7.3	for	method)	Figure	from	(59)			vWF	 is	 synthesised	 as	 350	 kDa	 monomers,	 which	 are	 co-translationally	translocated	 into	 the	 Endoplasmic	 Reticulum	 where	 they	 dimerise	 (54).	 Upon	arrival	 in	 the	Golgi	 apparatus,	 the	presence	of	 an	acidic	pH	and	 relatively	high	calcium	concentrations	 promote	 the	 organisation	 of	 the	 pro-dimers	 into	 a	dimeric	bouquet	structure	(60),	 in	which	the	dimers	are	aligned	into	a	side-by-side	manner	(Figure	4,	step	1)	and	organise	into	a	right-handed	helical	structure,	
A 
B 
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which	enables	a	100-fold	compaction	of	the	protein.	In	this	helical	structure,	the	wall	of	a	hollow	tube	is	formed	by	the	pro-peptide	(D1-D2	domains)	and	the	D′-D3	 domains.	 The	 remaining	 A1-CK	 domains	 project	 out	 from	 the	 helical	structure,	and	are	located	in	the	area	between	the	tubules	(Figure	4,	step	2).	The	assembly	 into	 tubules	 allows	 for	 controlled	 formation	 of	 disulphide	 bonds	between	 the	 dimers,	 and	 thus	 concatamerisation	 of	 the	 vWF	 into	much	 larger	assemblies-	"multimerisation"	(61).	vWF	is	capable	of	forming	multimers	of	up	to	20	 million	 Da,	 or	 50-mers	 of	 dimers	 (62).	 On	 a	 macro	 level,	 this	 set	 of	biochemical	 transformations	 are	 being	 carried	 out	 on	 quanta	 of	 vWF	 (63),	boluses	 of	 material	 that	 are	 sized	 by	 the	 transfer	 of	 this	 protein	 through	 the	ministacks	 that	 are	 linked	 within	 the	 Golgi	 ribbon.	 In	 parallel,	 as	 vWF	 passes	through	 the	 Golgi,	 maturation	 of	 the	N-linked	 glycans	 proceeds	 while	O-linked	carbohydrate	structures	are	also	added	to	the	protein	(Figure	4,	step	3)	Finally,	in	a	late	but	poorly	defined	stage,	the	proteolytic	separation	of	the	pro-	peptide	from	 mature	 vWF	 subunits	 is	 mediated	 by	 Furin	 (Figure	 4,	 step	 4).	 Once	delivered	 to	 the	 TGN,	 where	 they	 are	 present	 within	 a	 continuous	 lumen,	 the	adjacent	 quanta	 now	 become	 transformed	 into	 tubules/multimers	 that	 can	 be	co-packaged	together	into	forming	organelles,	where	the	number	of	quanta	that	become	co-packaged	define	WPB	length	(63).			Acidic	 pH	 is	 required	 for	 the	 conformational	 changes	 that	 lead	 to	 compaction	(60),	tubulation	(64)	and	multimerisation	of	vWF	(65).	The	importance	of	this	is	demonstrated	 by	 introducing	 a	weak	 base	 such	 as	 ammonium	 chloride,	which	raises	the	pH	in	the	Golgi,	leading	to	a	complete	halt	in	WPB	formation	(63).	The	formation	of	WPBs	is	completely	dependent	on	the	N-terminus-driven	tubulation	of	 vWF	 subunits	 and	 the	 oxido-reductase	 activity	 of	 the	 pro-peptide	 but	surprisingly,	is	not	dependent	on	high	levels	of	multimerisation.	Tubulation	and	multimerisation	 are	 independent	 processes	 and	 this	 is	 highlighted	when	 these	processes	are	differentially	inhibited.	Treatment	with	monensin,	which	disrupts	the	 interaction	 between	 the	 pro-peptide	 and	mature	 vWF	has	 no	 effect	 on	 the	formation	of	disulphide	bonds,	disrupts	tubulation	and	subsequently	post-Golgi	WPBs	are	dramatically	rounded	(66).	When	cells	are	treated	with	dithiothreitol	(DTT),	which	conversely	disrupts	disulphide	bridge	formation	yet	does	not	affect	
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interactions	between	the	pro-peptide	and	mature	vWF,	the	elongation	of	WPBs	is	not	 reduced	 (67).	 Yet	 if	 dimerisation	 is	 prevented,	 by	 the	 expression	 of	 vWF	lacking	 the	 CK	 domain,	 rod-shaped	 granules	 containing	 vWF	 tubules	 are	 still	formed.	Both	dimerisation	and	multimerisation	require	an	interaction	of	the	pro-peptide	with	the	mature	protein,	which	can	explain	why	mutations	that	appear	to	affect	multimerisation	can	also	affect	tubulation	(67).			
WPB	biogenesis	and	the	trafficking	machinery	involved		Figure	5	WPB	biogenesis	and	the	trafficking	machinery	involved	
	
WPB	formation	and	maturation.	WPB	associated	machinery	displayed	in	right	panel	and	their	location	within	the	process	of	WPB	biogenesis	from	the	Golgi	to	the	plasma	membrane.	Figure	from	(68)		
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To	 achieve	 the	 correct	 formation	 of	 WPBs	 at	 the	 TGN,	 Clathrin	 (a	 molecular	scaffold	protein)	and	the	AP-1	adaptor	are	required	and	likely	act	as	an	external	scaffold	(69).	The	depletion	of	the	AP-1	effectors	aftiphilin/γ-synergin	in	HEK293	cells	 leads	 to	 the	 production	 of	 pseudo-WPBs	 that	 are	 morphologically	indistinguishable	 from	 controls	 and	 show	 normal	 acquisition	 of	 all	 the	 known	components	 of	 WPBs,	 including	 P-selectin,	 CD63,	 and	 Rab27a	 (an	 isoform	 of	Rab27)	 (70).	 These	 organelles,	 however,	 fail	 to	 respond	 to	 secretagogue,	releasing	their	content	in	an	unregulated	manner	(70).	Further,	in	contrast	to	AP-1	 knockdown	 (KD),	 aftiphilin/γ-synergin	 depletion	 leads	 to	 an	 increase	 in	 the	release	 of	 highly	multimerised	 vWF	 (a	 feature	 unique	 to	mature	WPBs)	 in	 the	absence	of	secretagogue	(70). 	Microtubules	 are	 thought	 to	 be	 principally	 responsible	 for	 WPB	 long-range	motion,	and	treating	cells	with	nocodazole,	an	antineoplastic	agent	that	disrupts	the	polymerisation	of	microtubules,	prevents	WPB	transport	over	long	distances	(71).	 Unidirectional	 transport	 to	 the	 cell	 periphery	 is	 induced	 by	aurintricaboxylic	 acid	 treatment,	 which	 inhibits	 kinesin	 motor	 proteins,	suggesting	that	microtubule-dependent	transport	of	WPBs	is	a	balance	between	kinesin	and	dynein	(Figure	5),	the	plus	and	minus	end	directed	motors	(71).				Upon	 fusion	with	 the	 plasma	membrane,	 the	 shift	 in	 pH	 (from	 around	 the	 5.5	found	 within	 the	 organelles	 to	 the	 7.4	 of	 the	 extracellular	 environment	 (72))	prompts	 the	dissociation	of	pro-peptide	 from	the	mature	vWF,	uncoiling	of	 the	tubules	and	release	of	this	cargo,	that	then	appears	as	vWF	strings	that	can	be	up	to	1	mm	long	(73).	These	strings	are	anchored	to	the	endothelial	surface,	where	they	 recruit	 platelets,	 contributing	 to	 the	 formation	of	 a	 haemostatic	 plug,	 and	thus	reducing	bleeding	(see	2.3).			A	 correct	 biogenetic	 process	 is	 required	 for	 a	 fully	 functional	 organelle;	therefore,	 the	number	of	WPBs,	 the	 size	distribution	of	WPBs,	 the	amount	and	the	 multimeric	 composition	 of	 vWF	 secreted	 in	 the	 absence	 or	 presence	 of	agonists	 can	 all	 be	 used	 as	 indicators	 of	 defects	 in	 proteins	 important	 for	biogenesis.	In	addition	to	vWF,	a	number	of	proteins	are	recruited	to	WPBs	at	the	
	 26	
TGN.	 The	 best	 studied	 of	 these	 is	 the	 transmembrane	 cell	 adhesion	molecule,	P-selectin.	 At	 the	 TGN	 the	 leukocyte	 receptor	 P-selectin	 is	 sorted	 into	 forming	WPBs	 by	 direct	 physical	 interaction	 with	 vWF	 multimers	 (74).	 Upon	 WPB	exocytosis,	 P-selectin	 rapidly	 diffuses	 into	 the	 plasma	 membrane	 to	 initiate	leukocyte	 recruitment	 (75–77).	 Leukocytes	bind	 to	P-selectin	molecules	 on	 the	inner	 wall	 of	 the	 vessel,	 this	 causes	 the	 leukocytes	 to	 slow	 down	 and	 begin	‘’rolling’’	along	the	vessel	wall.			All	 LROs	 progressively	 mature	 from	 precursors,	 although	 the	 origin	 of	 these	precursors	differs	(9).	The	observation	that	WPBs	are	capable	of	acquiring	new	components	by	post-Golgi	trafficking,	a	typical	characteristic	of	LROs,	adds	to	the	suggestion	that	WPBs	should	fall	within	this	classification.	The	two	best-known	examples	of	this	are	the	recruitment	of	Rab27a	(and	its	effectors)	and	CD63.			Rab27a	 is	 recruited	 to	 mature	 WPBs	 (78)	 and	 other	 LROs	 (see	 2.6.2)	 and	 is	important	for	controlling	exocytosis	(79).	Rab27a	is	required	for	the	formation	of	a	 complex	 with	 MyRIP/MyoVa	 that	 peripherally	 anchors	 WPBs	 (Figure	 5)	 to	actin	 stress	 fibres	 (80).	 Rab27a	 siRNA	 ablation	 results	 in	 an	 increase	 in	 both	basal	 and	 stimulated	 secretion	 of	 vWF;	 however,	 in	 these	 circumstances,	 the	number	of	high	molecular	weight	multimers	of	vWF	is	reduced	and	vWF	string	length	is	shortened	(81).			CD63	 is	 a	 tetraspanin,	 so	 called	 because	 of	 their	 common	 feature	 of	 four	membrane-spanning	 regions.	 They	 are	 involved	 in	 a	 number	 of	 cellular	processes	 including	 cell	 adhesion	 and	 differentiation	 (82)	 and	 have	 been	described	as	 ‘molecular	organisers’	 (83),	acting	within	 the	plane	of	 the	bi-layer	on	other	membrane	proteins.	Besides	its	universal	localisation	to	endosomes	and	lysosomes,	 CD63	 has	 been	 found	 in	 mature	 WPBs	 (and	 other	 LROs	 such	 as	melanosomes	 and	 platelet	 granules)	 to	 where	 it	 is	 recruited	 in	 an	 AP-3-dependent	manner,	 thus	distinguishing	 it	 from	P-Selectin	which	 is	 recruited	 to	forming	WPBs	 at	 the	 TGN	 (74).	 Silencing	 of	 CD63	 affects	 P-selectin-dependent	leukocyte	 rolling,	 revealing	 that	 CD63	 is	 an	 essential	 cofactor	 for	 P-Selectin	
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receptor	 function	 at	 the	 cell	 surface	 (84),	 acting	 by	 clustering	 the	 leukocyte	receptor	to	increase	its	avidity.		Even	though	the	cargo	delivered	to	LROs	can	be	used	to	help	define	this	group,	it	is	 often	 difficult	 to	 define	 whether	 an	 organelle	 is	 indeed	 an	 LRO	 or	 not.	 The	identification	 and	 classification	 of	 these	 organelles	 has	 also	 been	 facilitated	 by	the	observation	that	most	are	affected	by	a	small	cluster	of	genetic	disorders		
2.5 LRO	associated	disorders	
2.5.1 Grey	Platelet	Syndrome		Clinical	features	of	GPS	include	a	mild	to	moderate	bleeding	syndrome,	enlarged	platelets	 in	 fewer	 numbers,	 myelofibrosis	 (a	 disorder	 of	 hematopoiesis),	emperipolesis	(an	intact	cell	within	the	cytoplasm	of	another	cell)	of	leukocytes	by	MKs	 and	 splenomegaly	 (enlargement	 of	 the	 spleen)	 (85).	 GPS	was	 given	 its	name	 due	 to	 the	 grey	 appearance	 of	 patient’s	 platelets	 in	 a	 peripheral	 blood	smear	(38).	GPS	platelets	are	hypogranular	(86)	and	highly	variable	in	their	size	and	morphology.	 Immuno-electron	microscopic	 analysis	 has	 shown	 that	 alpha	granule	numbers	appear	significantly	reduced	and	lacking	content	(87),	however	dense	granules,	lysosomes	and	peroxisomes	are	present	in	typical	numbers	(88)	.	In	GPS,	the	alpha	granule	cargo	is	deposited	primarily	into	the	bone	marrow;	the	granule	membrane	constituents	including	P-selectin	remain	but	are	abnormally	distributed	in	MKs	(89).	The	empty	alpha	granules	have	been	shown	to	be	able	to	re-distribute	and	 fuse	with	 the	platelet	 cell	 surface	membrane	upon	activation,	reinforcing	the	idea	that	GPS	is	not	a	secretion	problem	but	a	storage	deficiency	(90).		Next	generation	sequencing	 techniques	recently	 identified	 the	genetic	basis	 for	GPS;	 mutations	 in	 the	 NBEAL2	 gene,	 which	 encodes	 a	 BEACH/ARM/WD40	domain	protein.	This	 family	of	proteins	have	highly	conserved	regions	 that	are	crucial	 for	 protein-protein	 interactions,	 membrane	 dynamics	 and	 vesicle	trafficking	 (42).	 NBEAL2	 is	 predicted	 to	 regulate	 platelet	 alpha	 granule	
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biogenesis	 given	 their	 aberrant	 features	 in	 GPS,	 however,	 the	 underlying	mechanism	 is	 still	 unknown.	 Nbeal2(-/-)	 mice	 display	 the	 characteristics	 of	human	GPS,	with	 defective	 alpha	 granule	 biogenesis	 in	MKs	 and	 their	 absence	from	 platelets	 (91).	 The	 presence	 of	 P-selectin	 and	 the	 normal	 levels	 of	 the	Sec1/Munc18	 protein	 VPS33B	 and	 it's	 binding	 partner	 VPS16B	 (proteins	required	 for	 alpha	 granule	 biogenesis	 (92))	 	 in	 Nbeal2(-/-)	 mouse	 platelets	suggests	 that	 NBEAL2	 acts	 independently	 of	 these	 and	 at	 a	 later	 stage	 of	 the	biogenesis	 of	 alpha	 granules	 (93).	 NBEAL2	belongs	 to	 the	 same	 gene	 family	as	LYST	(or	CHS1	 gene)	 the	 target	 gene	 for	mutations	 leading	 to	platelet	 dense	granule	deficiency	 in	CHS (89).	Other	LROs,	 such	as	melanosomes	and	 those	 in	the	immune	system,	are	also	defective	when	this	close	relative,	LYST,	is	defective,	further	reiterating	the	classification	of	LROs	as	a	group.	The	prototype	syndrome	by	which	LROs	were	initially	clustered	was,	however,	HPS. 
2.5.2 Hermansky	Pudlak	Syndrome	
	Hermansky	Pudlak	Syndrome	(HPS),	the	main	focus	of	the	work	in	this	PhD,	is	an	autosomal	 recessive	 disorder	 affecting	 a	 number	 of	 proteins	 related	 to	 LRO	function.	 It	 was	 discovered	 by	 Hermansky	 and	 Pudlak	 in	 1959	 (94)	 and	 yet	relatively	little	is	understood	about	the	mechanisms	of	this	genetic	disorder.	The	largest	 groups	 of	 patients	 with	 HPS	 originate	 from	 the	 north-western	 region	Puerto	Rico,	where	its	frequency	is	estimated	to	be	1:1800	(37)	probably	due	to	a	 founder	 effect.	 The	 overall	 frequency	 of	 HPS	 in	 the	 human	 population	 is	speculated	 to	 be	 around	 1	 in	 500,000	 (95),	 however	 as	 many	 patients	 are	misdiagnosed,	the	actual	numbers	are	suspected	to	be	higher.									
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	Figure	6	HPS	patient	-	albinism	and	platelet	granule	deficiency	
	A)	HPS	patients	displaying	 albinism	as	 seen	by	pale	hair	 colour	B)	All	HPS	patients	demonstrate	 a	 reduction	 in	dense	granules	 in	 platelets	 as	 observed	 by	 whole	 mount	 microscopy,	 an	 example	 of	 a	 HPS1	 patient	 (C)	 with	 a	 dramatic	reduction	in	dense	granules,	note	the	absence	of	dense	spots	compared	to	the	control	(B).	Images	from	hpsnetwork.org	(95). 
 The	 symptoms	 of	 HPS	 typically	 include;	 eye	 and	 skin	 albinism,	 visual	impairment,	 a	bleeding	disorder,	 inflammatory	bowel	disease	and	 lung	 fibrosis	(Figure	7	(37)).	In	rare	cases,	immunodeficiency	has	also	been	observed	(96).	It	is	 common	 for	HPS	patients	 to	be	misdiagnosed	with	Oculocutaneous	albinism	and	 Ocular	 Albinism	 as	 the	 criteria	 for	 diagnosing	 these	 disorders	 is	indistinguishable	 from	 the	 albinism	 seen	 in	HPS	 (97).	 In	 2013	 it	was	 reported	that	76%	of	patients	with	HPS	were	initially	misdiagnosed	and	28%	of	patients	had	to	see	between	four	and	six	specialists	before	receiving	the	correct	diagnosis	(98). 		The	broad	range	of	 symptoms	exhibited	by	HPS	patients	are	suggestive	of	HPS	proteins	 functioning	 in	 a	 diverse	 set	 of	 cellular	 processes,	 including	 the	biogenesis,	secretion	and	trafficking	of	LROs	such	as	melanosomes	and	platelet	granules.	 Indeed,	 platelets	 in	 HPS	 have	 been	 shown	 to	 have	 a	 reduction	 in	platelet	 dense	 granules	 as	 visualised	by	whole	mount	EM	 (36),	 yet	 despite	 the	storage/release	 of	 serotonin	 and	 adenine	 nucleotides	 being	 defective,	 alpha	granules	 are	 unaffected	 (99).	 It	 is	 still	 to	 be	 determined	 whether	 the	 only	function	of	the	HPS	proteins	is	the	regulation	of	the	biogenesis	of	LROs;	the	fact	that	 these	genes	are	expressed	ubiquitously	 throughout	 the	body	suggests	 that	they	 may	 fulfil	 a	 number	 of	 other	 more	 general	 functions.	 Pigment	 deficient	mouse	models,	 that	have	been	attributed	to	HPS	(Figure	7)	have	not	only	been	
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proven	useful	for	studies	investigating	the	function	of	the	HPS	genes	but	also	to	further	our	understanding	of	the	regulation	and	biosynthesis	of	LROs	in	general	(4,	34).	 There	 are	 currently	 9	 genes	 (a	 recent	 publication	 has	 suggested	 there	may	now	be	10	(100))	that	have	been	associated	with	HPS	in	humans	(Figure	7).	All	HPS	mutations	result	in	albinism,	visual	impairment	and	a	bleeding	disorder	(37).	However,	only	HPS1,	2	and	4	have	been	associated	with	 lung	 fibrosis,	 the	most	 life	 threatening	of	 the	HPS	 symptoms.	Biochemical	 studies	have	 revealed	that	 the	 genes	 HPS1-9	 all	 encode	 proteins	 that	 can	 be	 grouped	 into	 the	biogenesis	of	 lysosome	related	organelle	 complexes	 (BLOCs)	1-3	 (101)	and	 the	adaptor	protein,	AP-3	(Figure	7).	The	pigment	deficient	mouse	models	have	also	predicted	 and	 revealed	 a	 number	 of	 other	 potential	 HPS	 proteins	 that	 are	 not	part	of	the	BLOC	or	AP-3	complexes,	such	as	Rab27a	(102),	RabGGTase	(103)	and	VPS33a	 (a	 subunit	 of	 the	 class	 C	 core	 vacuole/endosome	 tethering	 (CORVET)	complex	 and	 the	 mammalian	 homotypic	 fusion	 and	 vacuole	 protein	 sorting	(HOPS)	 complex)	 (summarised	 in	 Figure	 7)	 the	 characteristics	 of	 these	complexes	and	associated	proteins	are	discussed	below.	
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	Figure	7	HPS	-	nomenclature,	complexes	and	symptoms		
	HPS	summary	-		(A)	HPS	subunits,	human	genes	and	corresponding	mouse	models,	(B)	HPS	complexes	and	representative	structure	 (3),	 (C)	Symptoms	displayed	 in	HPS	mouse	models,	 (D)	Symptoms	displayed	 in	Human	HPS	and	related	HPS	genes	and	BLOCs.	(A,B,D)	BLOC-1	Grey,	BLOC-2	Blue,	BLOC-3	Red,	AP-3	Green.	
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	2.5.3 BLOC-1	
	BLOC-1	 is	 comprised	 of	 eight	 subunits	 named	 BLOS1,	 BLOS2,	 BLOS3	 (HPS8),	pallidin	 (HPS9),	 snapin,	 muted,	 cappuccino,	 and	 dysbindin	 (HPS7)	 (Figure	 7)	(104–107).	 The	 eight	 subunits	 appear	 predominantly	 alpha	helical	 in	 structure	(108)	 and	 appear	 as	 a	 linear	 chain	 of	 eight	 globular	 domain	∼300	Å	 long	 and	
∼30	Å	 in diameter	which	 localise	 to	 early	 endosomal	 tubules.	Two	 stable	 sub-complexes	 have	 been	 identified,	 pallidin-Cappuccino-BLOS1	 and	 dysbindin-Snapin-BLOS2	(107).			BLOC-1	expression	is	ubiquitous,	yet	disruption	of	BLOC-1	function	has	currently	manifested	 itself	 with	 overt	 phenotypes	 in	 only	 a	 subset	 of	 cell	 types	 such	 as	neurons,	 melanocytes	 and	 platelets	 (14).	 Although	 the	 mechanisms	 are	 still	unclear,	 BLOC-1	 is	 thought	 to	 have	 several	 interaction	 partners	 including	‘Soluble	 N-ethylmaleimide-sensitive	 factor	 activating	 protein	 receptors’	(SNAREs)	(109),	a	large	group	of	membrane-bound	proteins	that	mediate	fusion	throughout	the	secretory	and	endocytic	pathways	and	are	also	important	in	the	biogenesis	 of	 LROs	 such	 as	 melanosomes	 and	 platelet	 dense	 granules	 (110).	Despite	 its	 association	 with	 LRO	 function,	 BLOC-1	 is	 not	 associated	 with	lysosomes	(111,	112). 
 Mouse	 mutants	 defective	 in	 BLOC-1	 components	 have	 the	 most	 severe	phenotypes.	Recently	Delevoye	et	al.	(14)	confirmed	the	importance	of	BLOC-1’s	function	 in	 the	 formation	of	 recycling	 endosomes	and	demonstrated	 its	 role	 in	bringing	together	the	actin	and	microtubule	cytoskeletons	to	generate	recycling	endosomes	in	HeLa	cells.	BLOC-1	is	also	required	for	cargo-specific	sorting	from	vacuolar	 early	 endosomes	 toward	LROs	 (113)	 and	BLOC-1-deficient	 fibroblasts	have	demonstrated	an	altered	 intracellular	distribution	or	 cell	 accumulation	of	endosomal	proteins	(111).	It	is	clear	that	there	is	a	link	between	BLOC-1	and	AP-3	function	(see	also	2.6.1),	as	BLOC-1	alters	the	targeting	of	AP-3	cargoes	such	as	LAMP1,	 phosphatidylinositol-4-kinase	 type	 II	 alpha	 and	VAMP7-TI	 in	 neuronal	
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cells	(114).	Di	Pietro	et	al.	(111)	demonstrated	that	not	only	can	BLOC-1	interact	physically	and	functionally	with	AP-3	to	facilitate	the	trafficking	of	CD63	and	of	the	melanosomal	membrane	protein	Tyrp1	but	 it	can	also	act	 independently	of	AP-3,	 interacting	 directly	 with	 BLOC-2	 to	 facilitate	 Tyrp1	 trafficking	 to	melanosomes.	
2.5.4 BLOC-2	
 BLOC-2	contains	the	proteins	HPS3,	HPS5	and	HPS6	as	subunits	and	is	the	least	understood	of	the	three	BLOC	complexes	(115).	BLOC-2	is	thought	to	play	more	of	 a	 regulatory	 role	 in	 LRO	 biogenesis	 due	 to	 the	 lack	 of	 lung	 fibrosis	 seen	 in	patients	containing	 the	relevant	mutations	(116).	BLOC-2	deficient	mice	have	a	less	severe	pigment	phenotype	and	platelet	aggregation	defects	than	other	BLOC	deficient	 mouse	 models.	 BLOC-2	 complex	 proteins	 lack	 obvious	 structural	features	 apart	 from	 the	WD40	domains	 in	HPS5	 (117)	 and	 a	 potential	 clathrin	binding	 domain	 in	 HPS3	 (118).	 Interestingly,	 BLOC-2	 has	 been	 shown	 to	associate	with	 other	 components	 required	 for	 LRO	biogenesis	 such	 as	 the	Rab	GTPases	 Rab32	 and	 Rab38	 (119)	 and	 a	 number	 of	 the	 components	 of	 BLOC-1	(111,	114,	120).	However,	the	precise	role	of	BLOC-2	in	LRO-related	disorders	is	still	unknown.	
2.5.5 BLOC-3	
 BLOC-3	 is	 a	 complex	 comprised	 of	 only	 two	 proteins,	 HPS1	 and	 HPS4.	 An	interaction	 between	 HPS1	 and	 HPS4	 was	 demonstrated	 by	 co-immunoprecipitation	 of	 endogenous	 proteins	 in	 either	 soluble	 or	 membrane-associated	forms	and	by	co-migration	on	a	sucrose	gradient	(121).	The	size	of	the	BLOC-3	complex	is	∼175	kDa	as	calculated	from	sedimentation	velocity	and	gel	filtration	analyses,	this	also	corresponds	to	the	combined	molecular	mass	of	one	copy	of	each	of	the	HPS1	and	HPS4	polypeptides	(122). BLOC-3	has	been	shown	to	 function	 as	 a	 guanine	 nucleotide	 exchange	 factor,	 stimulating	 the	 release	of	guanosine	diphosphate	 (GDP)	 to	 allow	 binding	 of	guanosine	triphosphate	(GTP)	 for	 the	 Rab	 GTPases	 Rab32	 and	 Rab38	 (123),	 which	 are	 important	 in	regulating	the	fusion	of	vesicles	delivering	cargo	to	maturing	dense	granule-like	
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compartments	 in	 a	 MK	 cell	 line	 (122).	 An	 interaction	 screen	 also	 revealed	 a	specific	 and	 strong	 interaction	 of	 BLOC-3	 with	 the	 GTP-bound	 form	 of	 the	endosomal	GTPase,	Rab9	(124).	Despite	these	findings,	the	function	of	BLOC-3	in	MKs	and	platelets	is	largely	unknown	(32). 
2.6 Other	HPS-related	complexes	and	proteins	
2.6.1 Adaptor	Protein-3	
 The	 Adaptor	 Protein	 (AP)	 complexes	 are	 heterotetrameric	 protein	 complexes	that	mediate	 intracellular	membrane	 trafficking	 along	 endocytic	 and	 secretory	transport	pathways	(125).	Five	AP	complexes	have	been	identified	(126),	AP-1-5,	each	 composed	 by	 two	 large	 subunits	 (one	 each	 of	 γ/α/δ/ε/ζ	 and	 β1-5,	respectively),	 one	 medium-sized	 subunit	 (μ1–5)	 and	 one	 small-sized	 subunit	(σ1–5).			Deficiency	of	 the	AP-3β3A	subunit	 in	AP-3,	 results	 in	HPS2	(127,	128)	and	 in	a	recent	publication,	mutations	in	AP-3δ1	have	been	proposed	to	cause	a	new	HPS	subtype,	 HPS10	 (100).	 AP-3	 has	 been	 shown	 to	 play	 an	 important	 role	 in	 the	budding	of	vesicles	from	early	endosomal	compartments	and	marks	the	exit	site	for	 lysosomal	 membrane	 proteins	 from	 endosome-associated	 tubules	 (129).	 A	common	 feature	 of	 all	 HPS	 patients	 is	 that	 the	 lamellar	 bodies,	 LROs	 found	 in	type	 II	 pneumocytes	 and	 keratinocytes,	 are	 enlarged	 and	 have	 increased	phospholipid	content	(130).	This	enlargement	of	lamellar	bodies	has	been	shown	to	be	even	more	pronounced	in	HPS2	patients	compared	to	other	HPS	subtypes	and	also	in	the	corresponding	mouse	model	(Pearl)	in	which	AP-3	is	significantly	reduced	 in	 the	 surfactant-secreting	alveolar	 type	 2	 cells.	 AP-3	 has	 also	 been	shown	to	have	a	role	in	WPB	biogenesis	(74).	In	most	cells,	intracellular	CD63	is	predominantly	 associated	 with	 late	 endosome	 and	 lysosomal	 membranes,	however,	in	endothelial	cells	approximately	30%	is	trafficked	to	WPBs	in	an	AP-3-dependent	manner	(131).	When	AP-3	is	depleted	in	HUVECs	using	siRNA,	this	dramatically	reduces	the	delivery	of	CD63	to	the	WPBs	(74)	demonstrating	that	AP-3	functions	in	the	delivery	of	cargo	to	LROs.	
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2.6.2 Rab27		Rab27	 has	 two	 isoforms	 Rab27a	 and	 Rab27b,	 is	 widely	 expressed	 (132,	 133),		and	is	involved	in	the	functioning	of	several	LROs	(134–136)	as	well	as	secretory	granules	 (137–139),	 as	 already	discussed	 in	 the	 context	 of	WPBs	 (see	2.4.3).	A	single	point	mutation	in	the	mouse	orthologue	of	Rab27a	(102)	is	responsible	for	the	phenotypes	of	ashen	mice,	 including	hypopigmentation,	prolonged	bleeding	times	and	a	PSD.	The	Ashen	mouse	has	been	used	as	a	model	for	HPS		(Figure	7)	and	for	a	subset	of	Griscelli	syndrome	patients.	Platelets	of	mice	with	the	ashen	mutation	 have	 greatly	 reduced	 amounts	 of	 dense	 granule	 components	 such	 as	serotonin	 and	 adenine	 nucleotides	 though	 near-normal	 numbers	 of	 dense	granules.	 Thus,	 essentially	 normal	 numbers	 of	 platelet	 dense	 granules	 are	produced	but	the	granule	interiors	are	abnormal	(140).	In	melanocytes	the	actin-based	migration	of	melanosomes	to	the	cell	periphery	is	affected	when	depleted	of	Rab27a	(141).		
2.6.3 Gunmetal	(Rab	geranylgeranyl	transferase)		Another	mouse	model	that	has	been	associated	with	HPS	is	the	gunmetal	mouse	(Rggtagm).	 These	 mice	 possess	 a	 mutation	 in	 the	 alpha	 subunit	 of	 Rab	geranylgeranyl	 transferase	 (RGGT),	 a	 heterodimeric	 enzyme	 that	 adds	 prenyl	groups	 to	 the	 carboxyl	 termini	 of	 Rab	 GTPases	 (103).	 This	 mouse	 model	 is	defined	as	having	a	HPS-like	phenotype	due	to	the	fact	that	the	reduced	level	of	RGGT	 activity	 affects	 only	 a	 few	LROs,	 in	 particular	melanocytes	 and	platelets.	The	 bleeding	 disorder	 in	 these	mice	 involves	macrothrombocytopenia	 (142),	 a	reduction	 in	 platelet	 dense	 and	 alpha	 granule	 contents,	 and	 morphological	defects	in	MKs	that	affect	platelet	maturation	(143).	In	platelets,	a	few	Rabs,	such	as	Rab27a	 (see	also	2.6.2),	 are	affected	by	 the	 reduction	 in	 functionality	of	 the	enzyme.	 Both	 Rab27a	 and	 Rab27b	 are	 found	 associated	 with	 the	 limiting	membrane	of	platelet	dense	granules	and	to	a	lesser	degree	with	alpha	granules	(53).	Due	to	the	Rab	involvement	in	protein	trafficking,	decreased	association	of	Rab27a	 or	 other	 Rabs	 with	 membranes	 likely	 results	 in	 impaired	 delivery	 of	proteins	to	LROs	(1).	
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2.7 Morphometric	Analyses	
 Having	 discussed	 the	 machinery	 and	 the	 biological	 context	 in	 which	 it	 is	operating,	 it	 is	 important	to	 introduce	the	technical	advances	that	underpinned	the	 results	 achieved	 in	 this	 thesis.	 The	 analysis	 of	 LROs	 and	 their	 defects	 has	been	 transformed	 in	 recent	 years	 by	 two	 technological	 advances;	 firstly,	advancements	 in	quantitative	 image	analysis	 and	 secondly,	 the	breaking	of	 the	diffraction	 barrier	 in	 light	 microscopy.	 A	 brief	 introduction	 to	 these	 rapidly	evolving	areas	follows. 
2.7.1 Quantitative	image	analysis		In	relation	to	an	organelle	such	as	platelet	granules	or	WPBs,	morphology	refers	to	the	form	and	structure	of	said	object.	Using	mathematical	tools	it	is	possible	to	gather	 a	 vast	 amount	 of	 information	 from	 images	 by	 extracting	morphometric	data	from	segmented	objects	(identified	by	a	unique	feature	such	as	a	fluorescent	tag).	This	allows	detection	of	subtle	phenotypes	that	are	unlikely	to	be	apparent	by	eye.	Advantages	of	this	approach	are	that;	automated	computational	analysis	does	 not	 suffer	 from	 subjective	 bias,	 image	 analysis	 is	 relatively	 quick	 and	multiple	 features	 can	be	analysed	 in	parallel.	These	 tools	were	essential	 in	 the	quantitative	analysis	of	LRO	defects	observed	by	microscopy.		To	extract	morphological	features,	a	number	of	steps	are	typically	performed	to	reduce	noise	and	enhance	contrast,	to	maximize	the	isolation	of	a	given	feature	and	obtain	quantitative	data.	Methods	of	analyses	prevalent	in	this	thesis	include	the	collection	of	information	related	to	the	feret		diameter	(defined	as	the	longest	diameter	across	a	WPB	in	2D	projection)	of	WPBs	(see	Figure	24),	the	number	of	exocytic	 sites	 detected	 at	 the	 cell	 surface	 (see	 Figure	 23)	 and	 the	 successful	development	of	a	novel	tool	to	facilitate	the	automated	detection	of	the	number	and	 location	 of	 fluorescently	 labelled	 proteins	 within	 platelets	 using	 ‘Super	Resolution	Microscopy’	(SRM)	(see	Chapter	2).	
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2.7.2 Super	Resolution	Microscopy		For	 a	 greater	 part	 of	 the	 20th	 century	 scientists	 believed	 that,	 in	 optical	microscopes,	it	would	never	be	possible	to	be	able	to	observe	things	smaller	than	roughly	 half	 the	 wavelength	 of	 light	 (200	 nm)	 as	 described	 by	 Ernst	 Abbe	 in	1873	(144)	.	In	reality,	a	microscope’s	resolution	(as	defined	by	the	point	spread	function)	is	dependent	on	the	numerical	aperture	of	the	lens	and	the	wavelength	of	 light	used	to	 illuminate	the	sample;	 this	 typically	restricts	resolution	to	200-300	 nm	 laterally	 and	 500-700	 nm	 axially	 (145).	 To	 resolve	 and	 count	 platelet	granules	 (around	50-200	nm	 in	diameter)	a	sub-diffraction	 limit	approach	was	required.	 In	 recent	 years,	 principally	 3	 techniques	 have	 made	 sub-diffraction	limit	 resolution	 a	 reality;	 Stimulated	 depletion	 microscopy	 (STED)	 (146),	Structured	illumination	microscopy	(SIM)	(147)	and	Single	Molecule	Localization	Microscopy	(SMLM)	(148);	 the	 latter	 two	of	 these	were	employed	 in	 this	study	(see	Chapter	2)	and	are	introduced	below.		
2.7.2.1 Super	Resolution	–	Localisation	microscopy		If	 a	number	of	molecules	are	close	enough	 together	 that	 the	diffraction-limited	spots	between	them	overlap,	 then	the	ability	 to	resolve	 individual	molecules	 in	the	 sample	 is	 impaired.	 However,	 the	 purpose	 of	 localization	microscopy	 is	 to	find	a	way	 in	which	 the	diffraction-limited	spots	are	different	 from	each	other,	once	this	 is	achieved	it	 is	 then	possible	to	 isolate	them	in	a	higher	dimensional	space.	 Once	 they	 are	 isolated	 it	 is	 possible	 to	 find	 the	 centre	 of	 each	 of	 the	diffraction-limited	spots	with	a	much	greater	accuracy	than	the	width	of	the	spot.	This	 allows	 the	 ability	 to	 plot	 the	 co-ordinates	 of	 all	 the	 molecules	 with	 a	precision	 greater	 than	 that	 of	 the	 diffraction	 limit.	 There	 are	 a	 number	 of	localisation	 microscopy	 techniques	 that	 have	 been	 developed	 to	 achieve	 this,	including	 Photo-activated	 Light	 Microscopy	 (PALM)	 (148,	 149)	 and	 Stochastic	Optical	 Reconstruction	 Microscopy	 (STORM)	 (150,	 151).	 During	 my	 PhD	 the	
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localisation	 technique	 used	 was	 Direct	 Stochastic	 Optical	 Reconstruction	Microscopy	(dSTORM).			Figure	8	dSTORM	imaging	of	fixed	COS-7	cells.	
	Microtubules	stained	with	Alexa	Fluor	647	labelled	antibodies	and	imaged	using	dSTORM.	Temporal	separation	of	single	emitters	 localised	 precisely	 by	 data	 modelling	 enables	 image	 reconstruction	 with	 superior	 resolution.	 Light-induced	reversible	photoswitching	is	achieved	in	the	absence	of	an	activator	fluorophore	in	aqueous	buffer	and	in	the	presence	of	millimolar	concentrations	of	a	reducing	thiol	compound	such	as	DTT,	glutathione,	or	mercaptoethylamine.	The	reducing	thiol	compound	efficiently	quenches	the	fluorophore's	triplet	state	and	generates	a	stable	non-fluorescent	reduced	state	(dark	state)	and	requires	high	laser	power.	Figure	from	(152)	
	dSTORM	utilises	fluorophores	that	can	be	operated	as	reversible	photoswitches.	The	 localisation	 of	 individual	 fluorophores	 can	 be	 identified	 because	 the	fluorophores	will	blink	and	thus	can	be	separated	temporally.	dSTORM	relies	on	the	 transfer	of	 the	majority	of	 fluorophores	 to	a	non-fluorescent	dark	 state	 for	several	 seconds	 and	 precise	 localisation	 of	 individual	 fluorophores.	 The	resolution	 that	 can	 be	 achieved	 depends	 not	 only	 on	 the	 brightness	 of	 the	fluorophores,	but	also	on	the	labelling	density	and	the	stability	or	lifetime	of	the	non-fluorescent	 dark	 state	 (153).	 Using	 this	 method,	 a	 large	 number	 of	fluorophore	positions	can	be	localised	over	thousands	of	frames.	These	localised	positions	 can	 be	 used	 to	 build	 up	 an	 image	 of	 the	 sample	with	 a	 resolution	 of	below	30	nm	in	the	xy	plane	(148).	 	
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2.7.2.2 Structure-illumination	microscopy		Figure	9	Concept	of	resolution	enhancement	by	structured	illumination		
	A	 fine	 grating	 is	 placed	 in	 an	 intermediate	 image	 plane	 of	 a	 widefield	 microscope,	 or	 is	 created	 using	 a	 spatial	 light	modulator	 (147,	 154).	 If	 the	 sample	 is	 illuminated	 with	 such	 structured	 light,	 moiré	 fringes	 will	 appear	 (a),	 which	represent	 information	that	has	changed	position	in	reciprocal	space.	The	amounts	of	that	movement	correspond	to	the	three	Fourier	components	of	the	illumination	(b).	The	position	of	the	two	side	components	(c)	is	restricted	by	the	same	circle	(dashed	line)	that	defines	the	observable	region.	The	observable	region	will	thus	contain,	in	addition	to	the	normal	(lower	spatial	frequency)	information,	moved	information	that	originates	in	two	(higher	spatial	frequency)	offset	regions	(d).	Multiple	 images	 are	 taken	 across	 different	 grating	 angles	 and	 phase	 positions	 (e).	 Adapted	 from	Gustafsson	 et	 al.	(147)		Structured-illumination	 microscopy	 (SIM)	 is	 a	 technique	 that	 utilises	 both	widefield	 imaging	 and	 the	 illumination	 of	 a	 sample	 with	 a	 known	 pattern	 of	excitation	 light	 (155).	 SIM	 has	 an	 advantage	 over	 other	 SRM	 techniques,	 as	sample	 preparation	 is	 relatively	 simple	 and	 the	 acquisition	 time	 of	 SIM	 as	 a	comparable	 imaging	method	 is	 substantially	 shorter	 than	 localisation	methods.	Standard	 fluorophores	 can	 be	 used,	 no	 switching	 buffer	 is	 required	 and	 slides	that	 are	 prepared	 for	 typical	 light	 microscopy	 can	 be	 imaged	 without	 any	additional	preparation.	A	series	of	images	are	recorded	where	the	light	pattern	is	moved	 along	 the	 sample	 laterally	 and	 rotated	 in	 a	 number	 of	 different	 angles	(Figure	9).	A	SIM	image	is	reconstructed	using	the	higher	frequency	information	gained	 from	 moiré	 fringes	 after	 imaging	 with	 structured	 light.	 By	 using	 an	algorithm	that	carries	out	frequency	shifting	and	deconvolution,	high	frequency	information	gained	 from	moiré	 fringes	 can	be	extracted	and	a	 sectioned	 image	with	 typically	 double	 the	 resolution	 in	 x,y	 and	 z	 can	 be	 produced	 (154).	 The	maximum	spatial	frequency	which	the	objective	can	transmit	will,	along	with	the	wavelength	of	 light	used,	determine	the	resolution	of	 the	system	(156)	and	the	improvement	 is	 typically	double	 in	 the	 xy	plane	 (around	100	nm)	 than	 that	 of	diffraction-limited	techniques	(147).	
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3 Aims	
This	 thesis	 focuses	 on	 investigating	 LROs,	 a	 group	 of	 organelles	 for	which	 the	relationship	with	each	other,	and	function	is	still	not	fully	understood.	Two	LROs	were	 the	 main	 focus	 of	 this	 work,	 the	 WPBs	 of	 endothelial	 cells	 and	 platelet	granules.	This	thesis	has	three	key	aims	-		
1. To	investigate	if	the	mutated	genes	that	disrupt	LRO	function	in	HPS	are	also	important	to	the	biogenesis	and	function	of	WPBs	in	endothelial	cells. 
 
2. To	 develop	 an	 SRM-based	 methodology	 to	 image	 platelets	 that	 will	significantly	improve	our	ability	to	gather	quantitative	data	about	platelet	granules	as	compared	to	current	commonly	used	techniques. 	
3. To	test	whether	SRM	is	a	viable	tool	for	diagnosing	patients	with	a	PSD. 											
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4 Methods		
4.1 Preparing	Platelet	and	HUVEC	cultures		
4.1.1 Preparing	HUVECs	from	primary	stocks	
 HUVECs	pooled	from	multiple	donors	(Lonza)	were	grown	on	1%	(w/v)	porcine	gelatin-coated	15	cm	dishes	(Nunc)	at	37oC	and	5%	CO2.	For	the	preparation	of	working	stocks,	HUVECs	were	thawed	onto	15	cm	dishes	coated	with	1%	(w/v)	porcine	 gelatin	 (Sigma)	 and	 grown	 in	 TCS	 Large	 Vessel	 Endothelial	 Cell	 Basal	Medium	with	Amphotericin	B/Gentamycin	medium.	Confluent	dishes	were	split	1:6	and	maintained	in	HUVEC	growth	medium	(HGM,	Medium	199	(M199)	with	Earle’s	modified	salts	(GIBCO)	20%	(v/v)	foetal	bovine	serum	(FCS,	BioWest),	30 μg/ml	 endothelial	 cell	 growth	 supplement	 and	 10	 U/ml	 heparin	 (Sigma)).	Confluent	 dishes	were	 trypsinised	 and	 centrifuged	 at	 1000	 rpm	 for	 3	minutes.	The	 cell	 pellet	 was	 resuspended	 in	 FCS	 plus	 10%	 (v/v)	 dimethyl	 sulphoxide	(DMSO)	 and	 1	 ml	 aliquots	 of	 HUVEC	 suspension	 stored	 in	 cryotubes	 at	 -80oC	before	 being	 transferred	 to	 liquid	 nitrogen	 after	 24	 hours	 for	 long-term	 use	(usually	3-6	months).		Working	stocks	were	thawed	at	37oC	in	a	water	bath	and	added	to	1%	(w/v)	porcine	gelatin	coated	dishes	containing	30	ml	of	37oC	HGM.	Dishes	were	incubated	at	37oC	and	5%	CO2.	To	try	and	ensure	reproducibility,	all	HUVECs	 in	 this	PhD	were	only	passaged	once	before	starting	any	experimental	protocol,	 i.e.	 grown	 to	 confluency	 from	 a	 working	 stock	 without	 any	 further	splitting,	 cells	 stocks	 would	 be	 mixed	 to	 reduce	 any	 effect	 of	 heterogeneity	between	vials	if	more	than	one	vial	was	required.		
4.1.2 Preparing	platelets	from	platelet	rich	plasma	(PRP)		Platelet	preparation	protocol	adapted	 from	discussion	with	and	protocols	 from	Holly	Smith	(Paul	Gissen	Lab	LMCB)	and	phlebotomy	training	undertaken	at	UCL	hospital.	Acid	Citrate	Dextrose	(ACD)	and	HEPES	Tyrode’s	Buffer	were	first	kept	at	 37oC	 before	 starting	 the	 platelet	 isolation.	 All	 volunteers	 from	 the	 LMCB	department	 at	 UCL	 or	 patients	 from	 the	 Royal	 Free	 hospital	 had	 their	 blood	
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taken	 by	 myself,	 or	 a	 nurse,	 using	 the	 phlebotomy	 technique	 taught	 at	 UCL	Hospital	 and	 the	 Royal	 Free	Hospital.	 For	 the	 purpose	 of	 immunofluorescence	studies	 the	 following	 steps	 were	 undertaken;	 using	 a	 syringe	 and	 vacutainer,	blood	 was	 taken	 by	 venepuncture	 from	 the	 antecubital	 vein;	 if	 at	 first	 the	venepuncture	was	unsuccessful	the	other	arm	was	used.	The	first	vacutainer	was	discarded	 to	 ensure	 the	 absence	 of	 tissue	 contaminants	 and	 following	 this	 the	minimum	amount	of	blood	was	taken	that	was	required	for	the	experiment.	Each	volunteer/patient’s	blood	was	taken	with	a	minimum	of	three	months	between	each	sample	taken.	Blood	was	either	taken	into	ACD	containing	vacutainers	or	7	ml	 of	 whole	 blood	 was	 immediately	 transferred	 into	 a	 10	 ml	 Falcon	 tube	containing	1	ml	of	ACD.	Blood	was	then	centrifuged	at	180xg	for	17	minutes	and	the	PRP	was	collected	using	a	1	ml	Pipette.	The	PRP	was	then	left	for	30	minutes	at	room	temperature	without	any	disturbance	to	minimise	activation.	After	this	the	PRP	was	typically	diluted	at	a	concentration	of	1:10,	1:50,	1:100	and	1:500	in	HEPES	Tyrode’s	buffer	with	0.1%	glucose	and	fixed	with	4%	Paraformaldehyde	(PFA,	TAAB	Laboratories	Equipment	Ltd.)	in	PBS	(phosphate	buffered	saline)	at	a	 final	 concentration	 of	 4%.	 	 10	 minutes	 into	 the	 fixation	 the	 platelets	 were	transferred	 to	 a	 12	 or	 24	well	 dish	 containing	 Poly-L-Lysine	 coated	 coverslips	and	centrifuged	at	600xg	for	5	minutes	in	a	Beckman-Coulter	Allegra	6R	at	4oC.	The	remaining	platelets	and	fixative	were	aspirated	from	each	well,	and	without	washing,	 fresh	PBS	was	added	 to	each	well	 and	 the	plate	was	 left	 at	4oC	 for	at	least	12	hours	to	allow	the	remaining	platelets	to	further	adhere.	The	coverslips	were	 then	removed	 from	the	dish	and	permeabilised	with	0.2%	TX-100	 in	PBS	for	 10	minutes.	 This	 was	 followed	 by	 incubation	with	 primary	 and	 secondary	antibodies	(as	described	in	4.3.1)	the	samples	were	stored	in	the	dark	at	4oC	or	imaged	directly.			
4.2 siRNA	protocol	
4.2.1 Nucleofection		For	transient	transfections,	HUVECs	were	grown	to	confluency.	Cells	were	rinsed	with	PBS	and	incubated	with	Trypsin‐EDTA	(ethylenediaminetetraacetic	acid)	
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for	 3-5	 minutes	 to	 lift	 cells.	 The	 trypsin	 was	 neutralised	 with	 HGM	 and	 the	HUVECs	counted	using	a	ScepterTM	automated	cell	counter	and	60	μm	sensors	(Millipore).	HUVECs	were	spun	for	3	minutes	at	1000	rpm	and	pelleted	HUVECs	were	resuspended	in	nucleofection	buffer	at	a	concentration	of	1	million	cells	per	100 μl.	Nucleofection	was	performed	using	200-1000	pmol	of	 siRNA	or	2-5	μg	DNA	construct	and	100	μl	cell	suspension	in	a	cuvette	with	an	Amaxa	Biosystems	Nucleofector,	 program	 U ‐ 001.	 Cells	 were	 immediately	 rescued	 after	nucleofection	with	HGM	and	plated	typically	on	12	well	plates	(Nunc).	The	siRNA	sequences	used	in	this	study	are	outlined	below.	
4.2.2 siRNA	sequences		All	sequences	ordered	from	MWG	Eurofins	apart	from	Pallidin	(Qiagen)		Table	2	siRNA	sequences		No.	 	 Target	sequence	5’	to	3’	0	 Luciferase	(Firefly)	 CGUACGCGGAAUACUUCG	1	 Pallidin	 AAAAGTGCATGTACGGGAAAT	2	 Pallidin	2	 AACTGCAGCAGAAGAGGCAAA	3	 Pallidin	3	 AAGGAUUGCUUUCUCAUUAUU	4	 Pallidin	4	 GAAGGAGUUUGAAAGAGAA	5	 HPS1.1	 ACUAAGGUCUGGUCUCUGA	6	 HPS1.2	 CUUCCUGUAUGUCCUUCAC	7	 HPS1.3	 CTCCATGACGATGCTGGAGAA	8	 HPS1.5	 UGAAGUUCGGGCAGUCAGA		Figure	10	Gene	locations	targetted	by	siRNA	sequences	
		Gene	 structure	 for	Pallidin	 (HPS9)	and	HPS1	with	 the	 location	of	 the	 siRNAs	 (Table	2)	used	 in	 this	 study.	Numbers	of	siRNAs	correspond	to	numbers	in	table	2.			
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4.3 Fluorescence	Microscopy	
4.3.1 Immunofluorescence	microscopy	
	HUVECs	were	first	permeabilised	for	5	minutes	using	PBS/0.1%	Triton	with	the	cells	‘’face	up’’	sitting	on	a	layer	of	Parafilm	M®	.	PBS/0.1%	Triton	was	aspirated	using	a	glass	pipette	connected	to	a	suction	pump	and	blocked	for	up	to	1	hour	with	filtered	2%	BSA	in	PBS/0.1%	Triton.		Following	this	a	primary	antibody	was	added	 in	 2%	 BSA/PBS/0.1%	 Triton	 for	 45	 minutes	 to	 1	 hour	 (50-100	 μl	 per	coverslip).	 After	 aspirating	 and	 washing	 4	 times	 with	 PBS/0.1%	 Triton	 the	secondary	 antibody	was	 added	 in	 2%	BSA/PBS/0.1%	 Triton	 for	 45	minutes-1	hour	 at	 room	 temperature	 (50-100	 μl	 per	 coverslip),	 secondary	 antibody	was	always	 added	 in	 a	 concentration	 of	 1:500.	 Finally	 the	 secondary	 antibody	solution	was	aspirated	and	cells	were	washed	a	further	four	times	with	PBS/0.1X	Triton	before	mounting	onto	slides	with	around	3-10	μl	of	Prolong	gold	antifade	solution	and	left	to	dry	overnight	at	room	temperature	in	the	dark.	The	following	day	slides	were	transferred	to	a	slide	holder	and	kept	at	4oC	until	needed.			Table	3	Primary	Antibodies	used	
Antigen	 Raised	in	 Clone	 Source	 Dilution		 Rabbit	 Polyclonal	 DAKO	 1:10000	vWF	 Mouse	 21-43	 Serotec	 1:500		 Sheep	 Polyclonal	 Serotec	 1:1000	β	Tubulin	 Mouse	 TUB2.1	 Sigma	 1:100		 Sheep	 Polyclonal	 Cytoskeleton	 1:200	P-Selectin	 Mouse	 AK6	 Serotec	 1:100		 Sheep	 Polyclonal	 R&D	Systems	 1:100	CD63	 Mouse	 CLB	180	 AbCam	 1:100	TGN-46	 Sheep	 Polyclonal	 Abcam	 1:1000							
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Table	4	Secondary	Antibodies	used	
Antibody	 Raised	in	 Source	 Dilution	Anti-rabbit-A488	 Donkey	 Invitrogen	 1:500	Anti-rabbit-A568	 Donkey	 Invitrogen	 1:500	Anti-rabbit-Cy5	 Donkey	 Jackson	 1:500	Anti-mouse-A488	 Donkey	 Invitrogen	 1:500	Anti-sheep-A488	 Donkey	 Invitrogen	 1:500		For	 confocal	 imaging,	 cells	 were	 imaged	 on	 the	 Leica	 SPE3	 or	 SP5	 inverted	confocal	 laser	 scanning	 microscope.	 All	 images	 within	 an	 experiment	 were	acquired	 under	 the	 same	 laser	 conditions	 using	 a	 63x	 objective,	 1024	 x	 1024	pixel	 resolution	 and	 1x	 zoom.	 Over	 10	 fields	 of	 view	were	 typically	 taken	 per	condition	and	images	were	analysed	using	Image	J	or	Imaris	software.		
4.3.2 dSTORM	
	All	dSTORM	imaging	was	performed	in	collaboration	with	Dan	Metcalf	(National	Physics	 Laboratory).	 Fluorescence	 and	 excitation	 lights	 were	 spectrally	separated	by	a	full	multi-edge	filter	set	(LF405/488/561/635-A-000,	Semrock).	A	diode	laser	operating	at	640	nm	(iBeam	smart,	150mW,	Toptica	Photonic	AG)	was	 fibre	coupled,	expanded	and	 focused	at	 the	edge	of	 the	back	 focal	plane	of	the	 objective	 (UAPON	 100xOTIRF,	 NA=1.49).	 The	 beam	 size	 of	 the	 excitation	laser	 was	 matched	 to	 the	 field	 of	 view	 of	 the	 imaging	 system	 limited	 by	 the	detector	 chip	 size	 (16μm/pixel*512pixel).	 The	 power	 density	 of	 the	 excitation	laser	 on	 the	 sample	was	 approximately	 2	 kW/cm2.	 For	 data	 acquisition,	 a	 ROI	(128x128	 pixels)	 was	 used.	 Image	 files	 of	 fluorophore	 “blinking”	 events	(composed	usually	 of	 around	20000	 frames)	were	 captured	using	 a	 low-noise,	highly	sensitive	electron-multiplying	EMCCD	camera	(Andor	iXon	897)	at	frames	rates	of	54	per	second	with	10	ms	exposure	times.	The	 first	5000	frames	were	discounted	 to	 increase	 the	 chance	 of	 specific	 blinking	 events.	 The	 secondary	antibodies	 Alexa	 647	 (for	 dSTORM	 imaging	 of	 CD63)	 and	 Alexa	 488	 (for	widefield	 imaging	 of	 Tubulin)	 were	 used	 in	 a	 1:500	 dilution.	 Samples	 were	imaged	 in	 a	 photo-switching	 buffer	 containing	 50	 μg/ml	 (5	 units)	 glucose	
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oxidase,	 1	 μg/ml	 (40-60	 units)	 catalase	 and	 100	mM	mercaptoethylamine-HCl	(157).	 Images	 were	 reconstructed	 using	 the	 rainSTORM	 algorithm	 (157,	 158),	software	 version	 2-28,	 with	 super	 resolution	 pixel	 sizes	 of	 20	 nm.	 Mean	localization	precisions	were	around	25	nm,	giving	an	estimated	resolution	limit	of	 50-60	 nm	 (159).	 STORM	 data	 is	 displayed	 by	 histogram	 visualisation;	 i.e.	accepted	 localisations	 were	 assigned	 to	 20	 nm	 pixels,	 each	 localisation	corresponding	to	1	grey	scale	 intensity	value.	For	clarity	of	viewing	a	“red	hot”	lookup	 table	 and	 a	 contrast	 enhancement	 were	 applied	 (0.01-0.1%	 pixel	saturation)	in	ImageJ.	dSTORM	methodology	from	(63).	
	
4.3.3 Structure	Illumination	Microscopy	
	All	SIM	imaging	performed	in	collaboration	with	Mike	Shaw	(NPL).	Imaging	was	carried	out	using	an	inverted	widefield	fluorescence	microscope	(IX71,	Olympus)	modified	 for	 SIM,	 as	 previously	 described	 (160,	 161). Each	 super	 resolution	image	was	reconstructed	from	a	sequence	of	raw	images	of	the	sample	acquired	under	 excitation	 with	 nine	 different	 sinusoidal	 illumination	 patterns	 as	described	(154).	For	comparison,	widefield	images	were	created	by	summing	all	nine	 raw	 images.	 Out	 of	 focus	 light	 in	 each	 image	 was	 suppressed	 by	multiplication	 of	 the	 zero	 and	 first	 order	 SIM	 passbands	 by	 Gaussian	 and	complementary	inverted	Gaussian	functions	(161).	The	two-colour	images	were	acquired	sequentially	under	excitation	of	the	sample	with	laser	 light	at	488	nm	and	561	nm.	Image	z-stacks	were	obtained	by	axially	translating	the	specimen	in	0.2	μm	steps	using	a	piezoelectric	translation	stage	(NanoScanZ,	Prior	Scientific).		
4.4 Electron	Microscopy	
4.4.1 TEM	imaging	of	sectioned	platelets		All	EM	preparation	performed	in	collaboration	with	Jemima	Burden	(Head	of	EM	facility	LMCB).	PRP	was	prepared	and	an	equal	volume	of	0.1%	glutaraldehyde	in	0.1	M	Na	cacodylate	buffer	added	for	15	minutes	at	room	temperature.	Platelets	were	 then	 spun	 at	 1000xg	 for	 6	 minutes	 to	 pellet	 cells.	 The	 supernatant	 was	
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discarded	 and	 platelet	 pellet	 washed	 with	 500µl	 Na	 cacodylate	 buffer.	Supernatant	 removed	 and	 3%	 glutaraldehyde	 added	 in	 Na	 cacodylate	 buffer.	Platelets	were	 incubated	 at	 4oC	 for	 30	minutes	 and	 then	 spun	 at	 1000xg	 for	 5	minutes.	 The	 supernatant	 was	 removed	 and	 1%	 OsO4	 in	 0.1M	 Na	 cacodylate	buffer	was	added	for	1	hour	at	4oC.	Platelets	were	then	washed	three	times	for	10	minutes	with	0.1M	Na	cacodylate	buffer.	Samples	then	stored	for	a	maximum	of	 5	 days	 at	 4oC	 if	 required.	 The	 pellet	was	 then	 transferred	 into	 a	 5	ml	 glass	beaker.	70%	EtOH	was	added	for	10	minutes	followed	by	addition	of	80%	EtOH	for	 10	minutes	 and	 90%	EtOH	 for	 10	minutes,	 96%	EtOH	 for	 10	minutes	 and	finally	 three	 times	with	 100%	EtOH	 for	 10	minutes.	 Sample	was	 covered	with	Epon	and	left	for	at	least	2	hours	at	room	temperature.	The	sample	was	then	left	to	polymerise	in	the	fume	hood	oven	at	60oC	for	at	least	3	days	before	sectioning	using	a	Leica	UCT	ultramicrotome.	Sections	were	collected	on	copper	grids	and	imaged	 on	 a	 FEI	 T12	 Tecnai	 Spirit	 with	 a	 SIS	 morada	 11	 megapixel	 digital	camera. 
 
4.4.2 TEM	of	platelets	prepared	by	whole	mount	
	All	whole	mount	EM	performed	 in	 collaboration	with	 Jemima	Burden	 (Head	of	EM	facility	LMCB).	PRP	was	diluted	in	HEPES	Tyrode’s	buffer	and	centrifuged	at	600xg	for	5	minutes	in	a	Beckman	Coulter	Allegra	6R	onto	formvar	coated	mesh	copper	grids.	The	grids	were	washed	 twice	 in	water,	dried	 for	20	minutes	and	imaged	 directly	 by	 TEM	without	 fixation	 (Tecnai	 Spirit,	 FEI).	 Images	 of	 whole	mount	platelets	were	randomised	and	counted	by	one	analyst.	All	 images	were	counted	in	one	sitting	to	avoid	variation	in	counting	criteria.		Initial	 tests	 where	 neat	 concentrations	 of	 PRP	 were	 dropped	 on	 EM	 grids	 for	around	5	seconds	resulted	in	very	few	platelets	attaching	to	the	formvar	grid.	A	considerable	improvement	in	the	concentration	of	platelets	on	the	formvar	grid	was	 seen	 after	 centrifuging	 at	 600xg.	We	 subsequently	 used	 dilutions	 of	 1:10,	1:20,	1:100	and	1:1000	 	 (Figure	11)	and	 the	grid	with	 the	optimum	density	of	platelets	was	selected	and	imaged.	 	
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Figure	11	Dilution	Series	of	platelets	after	centrifugation	on	EM	copper	grids	
	An	 improvement	 in	analysing	a	 larger	number	of	platelets	was	achieved	when	platelets	were	centrifuged	at	600g	for	5	minutes	 in	a	Beckman	Coulter	Allegra	6R	onto	formvar	coated	mesh	copper	grids.	Here,	a	dilution	series	 is	shown	that	enabled	suitable	working	concentrations	to	be	selected	1:10	(A),	1:20	(B),	1:100	(C)	and	1:100	(D)		Images	 of	 platelets	 were	 then	 collected,	 and	 for	 the	 purpose	 of	 this	 study	 an	extremely	stringent	criteria	was	used	to	analyse	the	images	based	on	Hayward	et	al.	 (162).	 This	 was	 important	 as	 small	 differences	 in	 contrast	 could	 affect	 the	counting	of	 granules.	 Therefore,	 the	 only	 structures	 counted	were	 large,	 dense	and	 had	 a	 defined	 edge	 (see	 Figure	 12	 for	 an	 example	 of	 the	 criteria	 used);	importantly	 alpha	 granules	 can	 look	 large	 but	 not	 as	 dense	 and	 have	 a	 less	defined	edge.	I	performed	all	the	counting	without	knowledge	of	the	origin	of	the	platelets,	 in	a	 full	 set	of	 randomised	 images.	An	example	of	 the	criteria	used	 is	shown	is	shown	below.	 	
	
A B 
C D 
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Figure	12	Whole	mount	EM	counting	criteria	
	Whole	mount	EM	of	a	control	platelet	demonstrating	the	counting	criteria	employed	in	this	study.	Only	dense	structures	that	were	of	a	certain	contrast	with	a	defined	structure	and	size	were	counted	(black	arrows).	All	counting	was	performed	without	knowledge	of	the	origin	of	the	platelet,	in	a	full	set	of	randomised	images;	stringent	criteria	were	chosen,	as	there	are	many	structures	that	resemble	dense	granules	(white	arrows)	which	were	not	counted	but	could	affect	the	reliability	of	the	results	if	included.	Scale	bars:	1	μm		To	facilitate	counting,	the	contrast	of	the	image	was	manipulated	to	reveal	dense	granules	from	electron	dense	areas	(Figure	13),	this	was	performed	by	altering	the	brightness	and	contrast	settings	in	ImageJ	arbitrarily.	As	there	is	no	immuno-labelling	 or	 segmentation	 of	 the	 image,	 this	 relies	 on	 the	 subjectivity	 of	 the	individual.			Figure	13	Whole	mount	EM	of	platelets	–	manipulating	contrast	for	counting	
	Two	 images	 demonstrating	 the	 advantage	 of	 changing	 the	 contrast	 and	 also	 the	 subjectivity	 required	 when	 counting	dense	granules	in	platelets.	The	original	image	(A)	contains	a	few	dense	granules	that	are	hidden	by	background	electron	density	and	are	revealed	when	the	contrast	of	the	image	was	decreased	(B).		Scale	bars	1 μm.	
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4.5 Image	analysis	studies	
4.5.1 High	throughput	morphology	of	WPBs		All	high	throughput	morphology	analysis	performed	in	collaboration	with	Janos	Kriston-Vizi.	 Immunofluorescence	prepared	as	 in	(4.3.1).	 Images	were	acquired	using	an	Opera	high-content	screening	system	(Perkin	Elmer)	by	using	a	40X	air	objective	 (NA	 0.6).	 At	 least	 eight	 wells	 per	 condition	 were	 analysed	 per	experiment,	with	nine	 images	per	well.	Maximum	 feret	 diameter	 of	 each	 vWF-positive	 object	 was	 measured.	 At	 least	 10,000	 vWF-positive	 structures	 were	analysed	(as	in	(163).	A	high	performance	bare-bone	computer	system	equipped	with	 256	 GB	 RAM	 and	 four	 dodeca-core	 CPUs	 running	 at	 2.2	 GHz,	 allowing	parallelisation	of	computation	was	used	for	image	processing.	Image	processing	was	performed	using	ImageJ.	Flex	format	image	files	were	converted	to	Tagged	Image	Format	(TIF).	The	processing	steps	were	executed	as	detailed	in	Ferraro	et	al.	(63).	
4.5.2 Automated	image	analysis	of	Platelet	CD63	positive	structures		An	 automated	 workflow	 written	 as	 an	 ImageJ	 macro	 in	 collaboration	 with	William	Grimes	(see	(164)	for	more	detail)	and	was	used	to	segment	SIM	images	of	CD63	granules	and	assign	granules	to	their	constituent	platelets.		Platelets	 were	 segmented	 using	 the	 addition	 of	 the	 tubulin	 image	 to	 its	corresponding	CD63	image.	Uneven	background	illumination	was	removed	from	this	composite	image	using	a	rolling	ball	background	subtraction	with	a	radius	of	20	pixels	(165).	Image	noise	was	reduced	with	a	Gaussian	blurring	with	a	sigma	value	not	impacting	the	image	resolution	and	finally	a	minimum	error	threshold	was	 applied	 (166).	 The	 segmented	 tubulin-labelled	 structures	 in	 the	 binary	image	were	 filled	 and	 a	 watershed	 transform	 performed	 to	 separate	 touching	platelets.	To	demarcate	the	interior	of	the	platelet,	the	filled	area	was	eroded	to	avoid	 any	 contribution	 of	 CD63	 found	 at	 the	 platelet	 surface.	 Segmented	structures	with	an	area	of	 less	 than	2.0	μm2	 (average	diameter	of	platelets	2-3	μm	 (167),	 area	 ≥3.14	 μm2)	 or	 circularity	 (defined	 as	 4π(area/perimeter2)	 less	
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than	 0.7	 were	 removed	 (168),	 for	 the	 remaining	 foreground	 objects,	morphometric	measurements	were	taken.		Segmentation	 of	 CD63-positive	 structures	 for	 each	 of	 the	 seven	 control	 CD63	image	 data	 sets	 was	 performed	 according	 to	 a	 threshold	 value	 obtained	 from	Moment-preserving	thresholding	(169).	The	three	patient	data	threshold	values	were	 set	 according	 to	 control	 data	 that	 was	 acquired	 on	 the	 same	 day.	Segmented	 CD63	 granules	 that	 were	 overlapping	 were	 separated	 with	 a	watershed	 transform	 and	 areas	 smaller	 than	 0.01	 μm2	 were	 considered	background	 and	 removed	 (average	 diameter	 of	 dense	 granules	 150	 nm,	 area	≥0.018	 nm2).	 The	 platelet	 in	which	 each	 CD63	 granule	was	 located	was	 saved	and	morphometric	features	(including	area)	were	measured.	
4.5.3 CD63	distribution	in	platelets		CD63	distribution	analysis	performed	in	collaboration	with	William	Grimes	(see	(164)	for	more	detail).	Platelets	were	selected	with	circularity	>	0.85,	this	was	in	part	 to	 remove	any	platelets	 that	were	 activated	 from	 the	 analyses	but	 also	 to	remove	any	 tubulin-positive	 structures	 that	had	been	 incorrectly	 included.	For	the	CD63	channel	the	radial	profile	plugin	in	ImageJ	was	used	(170).	The	plugin	creates	 concentric	 rings	 from	 the	 centre	 of	 the	 platelet	 (see	 Figure	 49	 for	diagram)	and	in	each	ring	calculates	the	normalised	integrated	density	(the	sum	of	pixel	values	in	that	ring	divided	by	the	number	of	pixels	in	the	ring).	From	this	it	was	 possible	 to	 deduce	 a	measure	 of	 both	 the	 distance	 from	 the	 centre	 and	mean	pixel	intensity	within	each	ring.	In	addition	to	this,	the	same	radial	profile	information	was	generated	for	the	tubulin	channel,	any	radial	integrated	density	values	beyond	that	in	the	CD63	channel	were	removed	from	the	data	(these	are	considered	to	be	outside	the	platelet).	In	order	to	compare	spatial	distributions	across	different	segmented	platelets,	CD63	channel	pixel	values	were	normalised	by	the	total	integrated	signal	and	the	radial	distance	from	the	platelet	centre	was	normalised	to	the	maximum	radius	of	the	tubulin	ring.		
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4.5.4 Exocytic	site	analysis	
	HUVECs	 were	 seeded	 and	 prepared	 for	 immunofluorescence	 as	 above.	 Before	fixation,	cells	were	prepared	as	for	secretion	assays	(see	4.7.1),	by	washing	three	times	 with	 release	 media	 (RM).	 Cells	 were	 then	 stimulated	 with	 the	 desired	secretagogue	with	a	1:1000	concentration	of	vWF	rabbit	primary	antibody	for	30	minutes	in	RM.	The	cells	were	then	fixed	with	4%	PFA.	Cells	were	prepared	for	immunofluorescence	 as	 above	 using	 a	 vWF	 sheep	 primary	 antibody	 at	 a	concentration	 of	 1:5000	 to	 visualise	 total	 vWF.	 vWF	 at	 the	 cell	 surface	 was	stained	with	a	secondary	anti-rabbit	Alexa	647	antibody	and	total	vWF	stained	with	 a	 secondary	 anti-sheep	 Alexa	 488	 antibody	 at	 a	 concentration	 of	 1:500.	Images	 were	 analysed	 in	 ImageJ	 as	 follows;	 a	 background	 subtraction	 was	performed	using	 a	 sliding	parabloid	 rolling	ball	 analysis	with	 a	 sensitivity	of	1	pixel.	A	colocalised	pixel	map	was	then	generated	and	exocytic	sites	identified	by	segmenting	particles	greater	than	6	pixels	and	with	circularity	between	0.9-1.	
4.5.5 Colocalisation	study	
	To	 quantify	 colocalisation	 between	 fluorescent	markers	 imaged	 using	 confocal	microscopy,	raw	LIF	files	were	analysed	using	ImarisColoc.	The	determination	of	intensities	 to	 include	/	exclude	 from	the	study,	 i.e.	 the	 threshold	selection,	was	achieved	 by	 thresholding	 the	 source	 channels	 used	 in	 the	 analysis.	 This	 was	performed	by	automatically	selecting	the	thresholds	to	remove	user	bias,	 to	do	this	 ImarisColoc	 utilises	 the	 algorithms	 by	 Costes	 et.	 al	 (171)	 in	 the	 automatic	colocalisation	selection.	ImarisColoc	provides	a	number	of	statistical	parameters,	for	this	thesis	the	percentage	colocalised	and	Pearson’s	correlation	was	used.		
4.6 Molecular	Biology	
4.6.1 Primer	design		Primer	 pairs	 were	 designed	 to	 be	 18-25	 nucleotides	 long,	 have	 a	 Tm	 of	approximately	58oC,	have	a	G/C	rich	5’	end	to	assist	annealing	and	to	produce	an	amplicon	of	approximately	100-200	base	pairs	in	length	spanning	an	exon-exon	
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boundary	 to	 prevent	 amplification	 of	 genomic	 DNA.	 To	 identify	 exon/exon	boundaries,	 gene	 sequences	were	 obtained	 from	http://www.NCBI.nlm.nih.gov	/CCDS	 whilst	 http://www.basic.northwestern.edu/biotools/oligocalc.html	 was	used	 to	 check	 for	 potential	 hairpin	 loops	 and	 primer	 dimers.	 Primers	 were	ordered	from	MWG	Eurofins.	Successful	sequences	used	 in	this	study	are	 listed	below.	 Upon	 arrival,	 DNA	was	 dissolved	 in	 sterile,	 RNase-free	 HPLC	 ultrapure	water	(Alfa	Aesar)	at	a	concentration	of	100	μM	and	frozen	at	-20oC.	(68).	
4.6.2 RNA	extraction			Cells	were	grown	 to	90-100%	confluency	and	RNA	extracted	24-48	hours	post	transfection	using	a	QIAGEN	RNeasy	purification	kit	and	a	QIAGEN	QIAshredder	kit	 according	 to	 the	manufacturer’s	 instructions.	 cDNA	was	generated	using	an	Invitrogen	 SuperScriptTM	 III	 First	 Strand	 Synthesis	 System	 according	 to	 the	manufacturer’s	instructions	and	DNA	concentration	measured	by	optical	density	at	 Abs260/280	 using	 a	 NanoDrop	 (LabTech,	 ND1000	 spectrophotometer)	 and	ND1000	 v3.3	 software.	 RNA	 and	 cDNA	 was	 frozen	 at	 -20oC.	 All	 steps	 were	carried	out	on	ice.	
4.6.3 Reverse	transcription		RNA	was	 reverse	 transcribed	using	 the	 SuperScript™	 III	 First-Strand	 Synthesis	System	 for	 RT-PCR	 (Invitrogen).	 10μl	 of	 RNA	 was	 used	 for	 each	 reaction	 and	random	 hexamers	 are	 used	 as	 primers	 in	 this	 reaction	 to	 ensure	 total	 DNA	amplification.	Incubation	times	were	according	to	manufacturer’s	instruction.		
4.6.4 qPCR		A	 DyNAmoTM	 SYBER©	 Green	 (quantitative	 polymerase	 chain	 reaction)	 kit	(Thermoscientific)	containing	T.	brockianus	DNA	polymerase,	SYBER	Green	I	dye,	optimised	 PCR	 buffer,	 5	mM	MgCl2	and	 dNTP	mix	 including	 dUTP	was	 used	 to	quantify	relative	gene	expression	between	samples.	Sample	cDNA	was	diluted	to	150	 ng/μl	 and	 a	 primer	master	mix	 generated	with	 both	 forward	 and	 reverse	primers	 present	 at	 a	 concentration	 of	 1.2	 μM,	 diluted	 in	 HPLC	 Ultrapure	
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RNase-free	water.	All	 reagents	were	prepared	on	 ice.	Each	 reaction	was	set	up	containing	6.25	μl	150ng/μl	cDNA,	6.25μl	1.2μM	primer	pair	master	mix	and	12.5	μl	 SyberGreen	 per	 well	 of	 a	 96	 well	 PCR	 plate	 (Star	 Lab).	 All	 reactions	 were	carried	out	 in	triplicate	and,	 for	each	sample	used,	amplification	of	actin	mRNA	was	used	as	a	housekeeping	gene	control.	For	each	primer	pair	used,	a	no	DNA	control	 was	 also	 included.	 Plates	 were	 loaded	 on	 an	 Eppendorf	Mastercycler®	epGradient	 thermocycler	 and	 the	 PCR	 programme	 set	 up	 using	 Realplex	software.	Initially,	plates	were	incubated	at	95oC	for	10	minutes	to	free	up	DNA	binding	sites	and	activate	the	SyberGreen.	Reactions	then	progressed	through	40	cycles	of	a	10	second	melting	step	at	95oC,	15	seconds	annealing	at	53-57oC	(5oC	lower	 than	 primer	 Tm)	 and	 15	 seconds	 at	 72oC	 to	 copy	 strands.	 In	 all	 cases,	 a	melting	 curve	 was	 also	 generated	 using	 the	 final	 product	 with	 a	 maximum	temperature	of	95oC	to	check	the	specificity	of	amplification.	The	2-ΔΔC(t)	method	(described	 (172))	was	 used	 to	 calculate	 expression	 levels	 of	 a	 gene	 of	 interest	relative	to	actin	mRNA	levels	by	comparing	the	cycle	number	(C(t))	at	which	PCR	product	increases	exponentially.	The	equations	used	are	as	follows;	ΔC(t)	gene	of	interest	=	transfected	sample	C(t)	–	Mock	C(t)	ΔC(t)	housekeeping	gene	=	transfected	sample	C(t)	–	Mock	C(t)	ΔΔC(t)	=	ΔC(t)	gene	of	interest	‐ΔC(t)	housekeeping	Expression	relative	to	mock	=	2‐	ΔΔC(t)		Method	 described	 as	 in	(68),	 the	 gene	 specific	 primer	 sequences	 are	 detailed	below;	 	
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Table	5	Gene	Specific	Primers	sequences		
Target	Primer	 Primer	Sequences	5’	to	3’	Actin	forward	 TGGTGGTGAAGCTGTAGCC	Actin	reverse	 GCGAGAAGATGACCCAGAT	Muted	 Quantitech	Primer	assay	QT00026831	Snapin	forward	 ATGAGGATAGAAGGTGGCC	Snapin	reverse	 ATTCCCGAATCCAGCATTGC	Pallidin	forward	 GCTTCTTCCCTGTGTTCCCA	Pallidin	reverse	 AGTGTCACTTAAACCAGGCGT	HPS1	forward	 CCACAGTGCCAGCTCCCTGC	HPS1	reverse	 GTCTGTCTCCTGAATGTCGT	HPS4	forward	 GACAAGGTCTCTAGCATCTCCAGC	HPS4	reverse	 GTTCTCCTTCCTGCCATCTG	
	
4.7 Biochemistry	
4.7.1 vWF	secretion	assay			After	HUVECs	were	washed	 three	 times	 to	 remove	any	 residual	dead	 cells,	 the	cells	were	left	for	30	minutes	before	HGM	was	aspirated	and	gently	washed	three	times	with	Release	Media,	RM	(500	ml	M199,	5	ml	1M	HEPES	Tyrode’s	buffer	+	950	mg	BSA	 ,	 filtered	with	0.2	μm	 filter).	Cells	were	 left	 for	15	minutes	before	one	 last	gentle	wash	with	RM,	which	was	aspirated	and	500	μl	of	RM	added	to	each	well	for	60	minutes	to	measure	constitutive	secretion.	Media	was	collected	and	 cells	 incubated	 in	 RM	 with	 either	 histamine	 (100	 μM	 histamine	 (Sigma-Aldrich)	 or	 phorbol	 12-myristate	 13-acetate	 (PMA,	 100	 ng/mL	 Sigma-Aldrich)	for	30	minutes.	Following	this,	media	was	collected	and	cells	lysed	in	lysis	buffer	(10ml	RM	+	50μl	 TritonX100	+	20	μl	 protease	 inhibitor	 cocktail)	 on	 ice	 for	30	minutes.	All	samples	were	subsequently	centrifuged	at	10,000	rpm	for	5	minutes	and	the	supernatant	transferred	to	new	eppendorf	tubes	and	stored	at	-20oC. 	For	 the	purpose	of	 this	 thesis	 the	results	gained	are	displayed	 from	measuring	the	percentage	of	regulated	secretion;	any	contribution	to	vWF	secretion	by	the	constitutive	 (vWF	 from	 non-WPB	 anterograde	 carriers)	 and	 basal	 pathways	
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(vWF	secreted	from	WPBs	that	is	independent	of	secretagogue)	was	removed	by	taking	a	baseline	before	any	secretagogue	was	added	(see	4.7.1).	No	significant	difference	 in	 levels	 of	 vWF	 basal/constitutive	 secretion	 in	 any	 of	 the	 ablation	studies	 was	 observed;	 however,	 the	 levels	 of	 basal/constitutive	 secretion	 are	often	 relatively	 small	 and	 thus	 an	 ELISA-based	 secretion	 assay	 is	 often	 not	sensitive	enough	to	identify	subtle	changes.			The	mock	 or	 luciferase	 control	 siRNA	was	 always	 taken	 from	 the	 same	 vial	 of	cells	(after	reaching	confluency),	if	more	than	a	vial	was	required,	then	multiple	vials	were	mixed	before	the	first	nucleofection.	HUVECs	were	counted	and	plated	at	the	same	density	and	HUVECs	treated	with	the	siRNA	of	interest	were	always	plated	within	the	same	12	well	plates	as	the	control	to	maintain	consistency.	All	experiments	 were	 performed	 with	 cells	 taken	 without	 any	 further	 passaging	from	 frozen	 stocks.	 Two	 rounds	 of	 siRNA	 treatment	 were	 performed,	 and	 the	secretion	 assays	 and	 siRNA	 treatments	 were	 performed	 in	 the	 same	 intervals	after	initial	transfection	of	the	siRNA.		vWF	secretion	from	WPBs	in	HUVECs	has	a	number	of	contributory	factors	that	can	impact	the	consistency	of	results	within	and	between	experiments,	including	plate	 handling,	 cell	 confluency	 and	 inherent	 variability	 within	 primary	 cell	stocks.	Results	demonstrated	by	Howell	et	al.	(173)	and	unpublished	analyses	in	the	Cutler	lab	has	shown	that	confluency	will	affect	the	number	of	WPBs	per	cell	and	subsequently	the	amount	of		vWF	secreted	from	each	cell,	therefore,	HUVEC	confluency	 was	 carefully	 regulated	 by	 maintaining	 the	 same	 cell	 number	between	samples	after	each	passage	and	nucleofection.	
4.7.2 vWF	ELISA			MaxiSorp	plates	(Thermo	Fisher	Scientific)	were	incubated	with	Rabbit	anti-vWF	antibody	at	a	concentration	of	1:600	in	50	μl	of	PBS	for	1hr	RT	shaking	(or	4oC	overnight).	The	 antibody	 solution	was	 then	aspirated	 and	2X	TXEB	 (0.4%	Fish	skin	gelatine,	4%	pH	8.0	EDTA	and	10%	Triton	X100	in	PBS)	was	added	to	block	the	plate	for	at	least	1hr	RT	shaking	(or	4oC	overnight).	Wells	were	then	washed	
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three	times	with	1X	TXEB	(dilute	2X	TXEB	in	PBS).	200	μl	of	sample	was	added	to	each	well	in	duplicates	originating	from	triplicate	(or	quadruplicate)	samples	for	each	condition	from	a	12	well	plate.	Sample	dilutions	were	prepared	as	follows;	Constitutive	 secretion	 –	neat,	Regulated	 Secretion	 –	1:3	 for	PMA	 secretion	 and	1:2	 Histamine	 secretion	 and	 Lysates	 –	 1:10.	 A	 1:2	 serial	 dilution	 of	 human	plasma	diluted	in	1x	TXEB	was	also	present	on	plates	to	provide	a	concentration	standard,	in	addition	to	a	1x	TXEB	‘blank’.	Samples	were	left	for	1	hour	at	room	temperature	shaking	(or	4oC	overnight).	The	wells	were	then	washed	three	times	with	1X	TXEB	and	incubated	with	100	μl	of	secondary	antibody	rabbit	vWF-HRP	conjugated	 at	 a	 concentration	 of	 1:1000	 in	 1X	 TXEB	 for	 1	 hour	 at	 room	temperature	 shaking.	 The	 wells	 were	 subsequently	 washed	 three	 times	 in	 1X	TXEB	 and	washed	 twice	 in	 PBS	 before	 adding	 200	 μl	 of	 development	 solution	(7.43	ml	100	mM	citric	sodium	monohydrate,	14.56	ml	200	mM	dibasic	sodium	phosphate,	 22	 μl	 Hydrogen	 peroxide,	 132	 μl	 o-phenylene-diamine	 (OPD)	saturate	 in	methanol).	A	kinetic	ELISA	was	used,	measuring	absorbance	at	450	nm	and	reading	every	30	seconds	and	shaking	just	before	each	measurement	for	30	minutes.	 Values	 for	 regulated	 secretion	were	 calculated	 as	 a	 percentage	 of	total	 secretion	 (constitutive	 and	 basal	 secretion	was	 removed	 to	 give	 only	 the	vWF	secreted	by	regulated	secretion).	
4.7.3 Multimer	gel	analysis		To	prepare	1.4%	1.5	mm	agarose	gels,	high	gelling	temperature	SeaKem®	HGT	agarose	was	dissolved	in	Tris/glycine	buffer	(200	mM	Tris,	0.1	M	glycine,	0.1%	(w/v)	 SDS	 pH	 9)	 and	 poured	 for	 use	 in	 Bio-Rad	 Mini	 Protean	 IIITM	 tanks,	without	a	separate	stacking	gel,	with	a	10	well	comb.	Gels	were	refrigerated	for	at	least	an	hour	prior	to	use.	Secretion	assay	samples	were	concentrated	using	a	viva500	filter	column,	spun	for	8	minutes	at	13000	rpm	to	collect	proteins	larger	than	100	kDa,	and	then	diluted	in	sample	buffer	(20	mM	Tris,	1	mM	EDTA	pH8.0,	2%	(w/v)	SDS,	8M	urea	and	0.01-0.02%	(v/v)	bromophenol	blue).	To	provide	a	vWF	 standard,	 human	 serum	was	 diluted	 1:200	 in	 sample	 buffer.	 All	 samples	were	then	heated	to	60oC	for	30	minutes	prior	to	loading.	Gels	were	run	at	60V	for	20	minutes	then	40	V	for	several	hours	on	ice	using	SDS-PAGE	running	buffer	
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(National	Diagnostics).	To	improve	efficiency,	transfer	gels	were	washed	in	1	mM	β-mercaptoethanol	 in	 PBS	 for	 10	 minutes	 prior	 to	 transfer.	 Gels	 were	sandwiched	 between	 4	 pieces	 of	 Whatmann	 3M	 filter	 paper	 and	 a	 layer	 of	protran	nitrocellulose	transfer	membrane,	all	soaked	in	transfer	buffer	(25	mM	Tris-HCl,	 192	 mM	 glycine,	 and	 10%	 (v/v)	 methanol,	 pH	 8.3)	 and	 pressed	 to	remove	air.	This	was	 transferred	 to	a	Bio-Rad	mini-trans	blot	 cell	wet	 transfer	system	and	10	V	applied	overnight	at	4oC.	The	membrane	was	 then	blocked	 in	5%	(w/v)	milk	powder,	dissolved	in	PBS-0.2%	(v/v)	Tween®,	overnight	at	4oC.	Blots	were	stained	 for	one	hour	with	Primary	antibody,	vWF	primary	antibody	(DAKO,	1:5000)	diluted	in	block,	with	agitation.	Antibody	was	washed	using	two	rapid	washes	with	 PBS	 then	 two	washes	 for	 15	minutes	with	 PBS-0.2%	 (v/v)	Tween.	 The	 membrane	 was	 then	 incubated	 with	 HRP-conjugated	 secondary	antibody,	 donkey	 anti-sheep	 HRP	 conjugated	 secondary	 antibody	 (1:5000,	diluted	in	block	for	1	hour	with	agitation	and	washed	as	for	primary).	Antibody	was	detected	using	Luminata	crescendo	Western	HRP	substrate	(Millipore)	and	exposed	onto	film	(Amersham	Hyperfilm™,	GE	Healthcare)	using	the	X-OGRAPH	compact	X4	imaging	system.	(Method	from	(68))	
4.8 Patients	
4.8.1 Exome	sequencing	of	HPS	patients		Genetic	analysis	was	performed	by	exome	sequencing	on	the	ThromboGenomics	platform	that	includes	HPS1-9	(see	below).	The	results	from	this	were	given	with	the	patients’	permission	by	Dr.	Keith	Gomez	(Royal	Free	Hospital).			Figure	14	Patient	1	HPS1	mutations		
	Patient	 1	 has	 a	 compound	 heterozygosity	 for	 two	 single	 nucleotide	 deletions	 resulting	 in	 frameshifts	 and	 introducing	premature	stop	codons	in	the	HPS1	gene:	c.418delG	and	c.1189delC	predicted	to	result	in	p.A140Rfs*34	and	p.Q397Sfs*1.	Human	HPS1	gene	consists	of	22	Exons	(green	boxes)	and	2103	Amino	Acids.		Gene	structure	adapted	from	(174,	175)			
	 59	
Figure	15	Patient	2	HPS6	mutations	
	Patient	2	has	a	compound	heterozygosity	for	two	single	nucleotide	duplications	resulting	in	frameshifts	and	introducing	premature	 stop	 codons	 in	 the	 HPS6	 gene:	 c.907dupC	 and	 c.1083dupC	 predicted	 to	 result	 in	 p.T303Hfs*64	 and	p.G362Rfs*5.	Human	HPS6	gene	consists	of	1	Exon	(green	box)	and	2329	Amino	Acids.	Gene	structure	adapted	from	(174,	
175)		Figure	16	Patient	3	HPS5	mutation		
	Patient	 3	 has	 homozygosity	 for	 a	 single	 nucleotide	 change	 introducing	 premature	 stop	 codons	 in	 the	 HPS5	 gene:	c.2232T>A	predicted	 to	 result	 in	p.Cys744Ter.	Human	HPS5	gene	consists	of	23	Exons	 (green	boxes)	and	3390	Amino	Acids.			Gene	structure	adapted	from	(174,	175)		
4.8.2 Controls	and	HPS	patients	for	platelet	studies		Controls	 were	 healthy	 volunteers.	 The	 relevant	 UK	 research	 ethics	 committee	approved	this	work	and	all	participants	gave	their	written	informed	consent.	 	
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5 Chapter	 1	 Are	 genes	 associated	 with	HPS	important	for	WPB	function?	
5.1 Introduction		The	 LROs	 have	 historically	 been	 studied	 due	 to	 their	 specialist	 function.	However,	more	recently	the	discovery	that	single	mutations	can	affect	a	number	of	 LROs	 concurrently	 has	 led	 to	 a	 renewed	 interest	 in	 the	 machinery	 that	 is	common	 amongst	 this	 group	 (1–3,	 110,	 176,	 177).	 The	 grouping	 of	 these	specialised	secretory	organelles	was	facilitated	by	the	observation	that	a	number	of	genetic	disorders	(and	coat	colour	mouse	models	(34))	display	symptoms	that	can	be	attributed	to	defects	in	more	than	one	LRO.	An	example	of	this	is	HPS	(see	2.5.2),	where	patients	suffer	from	symptoms	such	as	albinism,	lung	fibrosis	and	a	bleeding	 disorder;	 all	 of	 which	 have	 or	 could	 be	 attributed	 to	 defective	biogenesis	 and	 maturation	 of	 these	 specialised	 secretory	 organelles	 (2,	 37).	Investigations	into	the	functions	of	HPS-causative	genes	have	revealed	a	number	of	important	complexes	in	LRO	biogenesis,	such	as	the	BLOCs	(see	2.5).	However,	since	this	work	largely	began	by	studying	the	coat	colour	mouse	models,	most	of	the	 research	 has	 been	 focused	 on	 the	 roles	 of	 HPS-associated	 genes	 in	melanosome	biogenesis	and	trafficking	(1,	4,	15,	34,	110,	178).	Consequently,	the	importance	 of	 these	 complexes	 in	 other	 LROs,	 such	 as	 WPBs,	 is	 yet	 to	 be	determined.				The	observation	that	LROs	are	related	has	been	confirmed	by	the	fact	that	single	mutations	 in	 individual	 HPS	 proteins	 have	 been	 shown	 to	 have	 effects	 on	 a	number	of	LROs.	This	highlights	the	importance	of	studying	the	effects	of	these	mutations	on	the	whole	range	of	LROs,	as	they	have	been	found	to	be	responsible	for	 similar	 functions	 in	 different	 cell	 types.	 For	 example,	 AP-3,	 a	 HPS-related	protein	complex	has	been	demonstrated	to	be	important	in	the	delivery	of	cargo	to	 a	 number	 of	 LROs	 (9)	 including;	 OCA2	 to	 melanosomes	 (8,	 179)	 ,	 TLR4	 to	phagosomes	 in	 conventional	dendritic	 cells	 (180),	 CD63	 to	WPBs	 (74),	 toll-like	
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receptor	9	 to	 an	 IRF7-signalling	LRO	 in	plasmacytoid	dendritic	 cells	 (181)	 and	SLC35D3	likely	to	dense	granules	in	platelets	(182).	AP-3	is	also	required	for	the	biogenesis	of	eye	pigment	granules	in	Drosophila	melanogaster	and	gut	granules	in	 Caenorhabditis	 elegans	 (9).	 Likewise,	 the	 HPS	 related	 protein	 Rab27a	 (see	2.6.2)	 is	 important	 for	 the	exocytosis	of	multiple	LROs	 including	 lytic	granules,	WPBs	and	melanosomes	(176).  However,	 there	have	been	only	a	few	examples	of	the	effects	of	these	mutations	demonstrated	in	human	cells	(127,	183)	and	the	role	 of	 HPS-related	 proteins,	 though	 suspected,	 is	 yet	 to	 be	 investigated	 in	 a	number	of	LROs.		One	of	the	symptoms	attributed	to	HPS	is	a	bleeding	disorder	and	this	has	been	attributed	to	the	genetic	malformation	of	platelets	and	their	granules	(184,	185).	However,	 little	 is	 known	 about	 the	 role	 of	WPBs	 and	 it	 is	 even	unclear	 if	 they	have	 a	 role	 in	 the	 bleeding	 phenotype	 seen	 in	 HPS	 patients.	 The	 lack	 of	information	in	this	area	is	surprising,	given	that	quantitative	and/or	qualitative	deficiencies	 in	the	secreted	vWF	multimers	that	are	stored	in	WPBs	lead	to	the	most	 common	 bleeding	 disorder	 in	 humans,	 von	Willebrand’s	 disease	 (63).	 It	was	hypothesised	that	if	HPS-associated	proteins	and	complexes	were	important	for	 the	biogenesis	of	 LROs	and	 the	 secretion	of	 LRO-related	 content,	 then	 they	were	likely	to	have	an	important	role	in	the	secretion	of	vWF	from	WPBs.	In	fact	a	 common	 finding	 in	 the	 literature	 focused	 on	 HPS	 KD/KO	 mouse	 model	 cell	studies	has	been	the	aberrant	secretion	of	proteins	that	are	carried	by	LROs;	skin	cells	 in	 HPS4	 mice	 have	 been	 shown	 to	 have	 decreased	 basal	 secretion	 of	lysosomal	 hydrolases	 (186),	 platelets	 from	 seven	HPS	mouse	 pigment	mutants	have	abnormal	thrombin-stimulated	secretion	of	Serotonin,	B-Glucuronidase	and	B-Galactosidase	(187)	and	lamellar	Bodies	in	lung	alveolar	type	II	epithelial	cells	in	 HPS1	 and	 AP-3	 mice	 have	 decreased	 basal	 and	 ATP-stimulated	 secretory	capacity	for	surfactant	protein	and	phospholipids	(188).	The	secretion	of	vWF	is	in	part	reliant	on	microtubules	that	are	required	for	the	transport	of	WPBs	from	the	perinuclear	region	to	the	cell	periphery	and	have	a	role	in	the	exocytosis	of	vWF	(73,	80,	81).	HPS1	mouse	models	have	demonstrated	defective	microtubule-mediated	organelle	motility	 in	 lysosomes	 in	 fibroblasts	 (121)	 and	HPS2	mouse	
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models	have	shown	defective	microtubule-mediated	organelle	motility	 for	 lytic	granules	in	T	cells	(189).			Since	there	are	instances	of	proteins	associated	with	LRO	biogenesis	performing	similar	 functions	 in	different	cell	 types	and	with	different	LROs,	 it	 is	 likely	 that	HPS-associated	 proteins	 may	 perform	 important	 roles	 in	WPB	 biogenesis	 and	exocytosis.	Whilst	defects	in	patient	platelets	have	been	described,	there	may	be	an	as	yet	undiscovered	defect	in	endothelial	cell	function	(as	a	result	of	defects	in	WPB	biogenesis	or	exocytosis)	 in	these	patients,	which	could	contribute	to	this	bleeding	phenotype.	The	aim	in	this	chapter,	therefore,	is	to	determine	whether	the	HPS-associated	genes,	which	encode	proteins	that	form	the	complexes	BLOC-1	and	BLOC-3	also	have	a	role	in	the	biogenesis	of	WPBs.				BLOC-1	 deficient	 fibroblasts	 (obtained	 from	 pallid	 mice)	 have	 an	 increased	surface	 accumulation	of	CD63	 (114),	 a	 protein	 also	 found	on	 the	membrane	of	WPBs	and	other	LROs	such	as	melanosomes.	BLOC-1	has	also	been	shown	to	be	located	at	 tubular	 early	 endosomes	 that	 are	 in	 close	proximity	 to	 the	TGN,	 the	site	at	which	WPBs	are	formed	(63).	Mouse	mutants	that	cause	BLOC-1	or	AP-3	deficiencies	 affect	 the	 targeting	 of	 PI4KIIα	 (also	 LAMP1	 and	 VAMP7-TI)	 (114)	and	 a	 siRNA	 ablation	 of	 PI4KIIα	 in	 HUVECs	 has	 been	 shown	 to	 lead	 to	 the	formation	of	small,	round,	abnormally	formed	WPBs	(163).	PI4KIIα ablation	does	not	affect	the	secretion	of	vWF	but	was	shown	to	have	an	important	role	in	the	recruitment	 of	 AP-1	 to	 the	 TGN	 as	 well	 for	 WPB	 maturation	 with	 a	 higher	prevalence	of	lower	molecular	weight	multimers.	 	A	method	in	this	chapter	employed	to	destabilise	BLOC-1	used	an	siRNA	targeted	to	the	mRNA	of	pallidin	that	is	translated	to	form	pallidin	a	member	of	the	BLOC-1	complex.	The	pallidin	protein	is	20KDa	in	size	with	no	homology	to	any	known	protein,	 and	 pallidin	 siRNA	 has	 been	 shown	 previously	 to	 be	 sufficient	 to	destabilise	the	entire	BLOC-1	complex	and	has	been	used	as	a	tool	to	KD	BLOC-1	function	in	the	cell	(111,	120).		The	pallidin	mutation	in	humans	is	known	as	HPS	9,	and	it’s	importance	for	the	stability	of	the	entire	complex	is	highlighted	as	in	a	HPS	9	patient	undetectable	 levels	of	pallidin	were	found	and	it	was	shown	that	
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two	other	members	of	 the	BLOC-1	complex	were	also	affected	by	 its	reduction.	Cappuccino	 was	 undetectable	 and	 snapin	 was	 significantly	 reduced	 (190).	Pallidin	 contains	 two	 highly	 alpha-helical	 coiled-coil	 regions	 which	 have	 been	shown	 to	 be	 essential	 to	 binding	 to	 itself	 and	 to	 the	 SNARE,	 syntaxin	 13	 (106,	
190,	191).	Prekeris	et	al.	(192)	demonstrated	using	a	transferrin	recycling	assay	in	permeabilised	PC12	cells	that	syntaxin	13	is	directly	involved	in	the	recycling	of	plasma	membrane	proteins	and	significant	reduction	in	syntaxin	13	is	seen	in	HPS	9	patient	fibroblasts	(190).	Syntaxin	13	has	also	been	shown	to	be	involved	with	 VAMP3	 and	 SNAP23	 dependent	 secretion	 of	 matrix	 metalloproteinases	(193).			The	 BLOC-3	 complex	 (comprising	 of	 HPS1	 and	 HPS4)	 and	 its	 role	 in	 the	biogenesis	 of	 LROs	 has	 yet	 to	 be	 elucidated.	 BLOC-3	 is	 a	 guanine	 nucleotide	exchange	factor	for	the	cell	type-restricted	rab	GTPases	RAB32	and	RAB38,	both	of	which	have	been	implicated	in	the	biogenesis	of	melanosomes	and	other	LROs	(119,	194–197).	Since	the	experiments	in	this	thesis	were	completed,	BLOC-3	has	also	been	shown	to	have	an	important	role	in	VAMP7	recycling,	a	v-SNARE	that	mediates	fusion	of	melanosomes	with	tubular	transport	carriers	that	also	carry	the	cargo	protein	TYRP1	and	that	require	BLOC-1	for	their	formation	(198)	
5.1.1 Methodology	employed		The	secretion	assay	is	an	ideal	tool	to	screen	for	WPB	function,	as	levels	of	vWF	released	give	an	indication	of	WPB	numbers	and	responsiveness,	as	well	as	the	efficiency	of	 exocytic	machinery	 (69).	As	 a	 suitable	 readout,	 the	 values	 of	 vWF	secreted	were	calculated	as	a	percentage	of	the	total	vWF	measured	within	that	sample	 (collected	 using	 a	 lysis	 buffer)	 as	 an	 internal	 control,	 and	 the	basal/constitutive	secretion	(measured	before	secretion)	was	deducted	from	the	stimulated	 secretion.	 The	 final	 value	 was	 divided	 by	 the	 control	 to	 give	 an	indication	 of	 whether	 vWF	 regulated	 secretion	 was	 proportionally	 impaired	(below	1)	or	increased	(above	1).	If	the	final	value	given	(as	in	Table	6)	was,	for	example	1.2,	this	would	indicate	that	vWF	secretion	had	increased	by	20%	as	a	proportion	of	the	total	vWF	within	that	sample,	compared	to	the	amount	of	vWF	
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secreted	 as	 a	 proportion	 of	 total	 vWF	 secreted	 in	 the	 control	 under	 the	 same	conditions;	0.8	would	indicate	a	20%	reduction	(see	4.7.1	for	method).		Once	 an	 aberrant	 secretory	 phenotype	 was	 established,	 the	 next	 step	 was	 to	identify	if	the	formation	of	WPBs	and	the	exocytosis	and	multimeric	state	of	vWF	was	affected.	The	aim	of	 this	was	 to	narrow	down	 the	stage	at	which	 the	HPS-related	protein	of	interest	was	acting.			To	assess	if	the	formation	of	WPBs	had	been	affected,	the	size	of	the	organelles	was	 measured	 by	 their	 feret	 diameter	 using	 fluorescent	 microscopy	 and	 a	morphometric	analysis.	Endothelial	cell	flatness	forces	WPBs	to	orient	parallel	to	the	 substrate,	 this	 spatial	 constraint	 ensures	 that	WPB	 lengths	measured	 from	2D	 confocal	 images	 are	 a	 good	 approximation	 of	 actual	 organelle	 lengths	 (63).		This	 method	 (see	 4.5.1)	 was	 employed	 as	WPB	 size,	 which	 is	 dictated	 by	 the	general	architecture	of	the	Golgi	apparatus	(63),	has	been	shown	to	be	important	in	 modulating	 the	 size	 of	 platelet-decorated	 vWF	 strings	 on	 the	 endothelial	surface	(63)	and	the	adhesive	activity	of	its	vWF	cargo	(199).			To	quantify	if	there	was	an	effect	on	vWF	exocytosis,	the	number	of	exocytic	sites	at	 the	 cell	 membrane	 was	 measured	 using	 an	 assay	 where	 HUVECs	 were	incubated	 and	 subsequently	 labelled	 with	 a	 vWF	 antibody	 before	 and	 after	fixation,	 the	 colocalisation	of	 the	 two	antibodies	was	used	as	a	 readout	 for	 the	number	 of	 exocytic	 sites	 present	 at	 the	 cell	 surface	 after	 stimulation	 with	 a	secretagogue	(see	4.5.4	for	method).			vWF	multimers	were	analysed	as	 the	multimeric	 form	of	 secreted	vWF	 largely	dictates	 its	 haemostatic	 efficacy,	 due	 to	 the	 fact	 that	 higher	 molecular	 weight	vWF	multimers	 have	 a	 higher	 binding	 affinity	 for	 platelets	 during	haemostasis	(200).	A	loss	of	high	molecular	weight	vWF	multimers	has	been	associated	with	haemorrhagic	disorders	such	as	gastrointestinal	bleeding,	epistaxis	or	increased	bleeding	after	dental	procedures	(201–203). To	measure	the	multimeric	state	of	vWF,	multimer	gels	of	secreted	vWF	were	performed	and	analysed	(see	4.7.3	for	method). 
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5.2 Results	-	A	potential	role	for	BLOC-1	in	WPB	function		Previous	work	 to	 investigate	a	potential	 role	 for	BLOC-1	 in	WPB	 function	used	three	siRNAs	(against	muted,	pallidin	and	snapin)	to	target	the	complex	in	human	embryonic	 kidney	cells	293	 (HEK293).	 As	 the	 levels	 of	 vWF	 secreted	 give	 an	indication	of	WPB	numbers	and	responsiveness	to	a	secretagogue	(and	therefore	the	 efficiency	 of	 exocytic	 machinery)	 the	 release	 of	 vWF	 in	 response	 to	 the	secretagogue	 PMA	 was	 measured.	 The	 siRNA	 ablation	 of	 BLOC-1	 complex	proteins	 demonstrated	 a	 strong	 reduction	 in	 the	 amount	 of	 vWF	 released	 in	response	 to	 PMA	 (Figure	 17,	 unpublished	 data	 Tom	 Nightingale),	 it	 was	concluded	that	 ‘BLOC-1	must	play	an	important,	but	as	yet	undescribed	role,	 in	the	biogenesis	of	WPB’.		Figure	17	BLOC-1	KD	in	HEK293	cells	-	vWF	secretion	assay	
	HEK	293	cells	were	either	mock	transfected	or	simultaneously	depleted	of	three	components	of	BLOC-1	(snapin,	pallidin	and	muted)	and	cells	stimulated	with	PMA.	The	amount	of	vWF	released	constitutively	(cons)	and	 in	response	 to	PMA	(PMA	stim)	was	calculated	as	a	percentage	of	total	vWF	from	control	(white	bars)	and	KD	(black	bars)	cells.	Experiment	performed	by	and	reproduced	with	permission	from	Tom	Nightingale.	Error	bars	are	standard	deviation.	Figure	adapted	from	Helen	Zenner’s	PhD	Thesis	(October	2007).		
5.2.1 vWF	secretion	assays	in	HUVECs	depleted	of	BLOC-1			
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The	 secretion	 of	 vWF	 from	BLOC-1	 depleted	 cells	was	 previously	measured	 in	HEK293	cells	(see	Figure	17),	transient	transfection	of	HEK293	cells	with	wild-type	human	vWF	cDNA	leads	to	the	formation	of	numerous	elongated	organelles	that	 very	 closely	 resemble	 WPBs.	 These	 “pseudo-WPBs”	 exhibit	 the	 internal	structure,	 as	 well	 as	 the	 ability	 to	 recruit	 membrane	 proteins	 including	 P-selectin,	 of	 bona	 fide	WPBs	 and	 have	 been	 used	 to	 study	WPB	 biogenesis	 and	function	(204).	To	investigate	a	potential	role	for	BLOC-1	in	primary	endothelial	cells,	which	produce	WPBs	(and	therefore	remove	the	need	to	overexpress	vWF),	HUVECs	were	used	and	the	BLOC-1	complex	proteins	depleted	as	a	three.	As	no	reliable	 antibodies	 against	 BLOC-1	 complex	 proteins	 exist	 an	 indication	 of	 the	efficiency	of	the	KDs	was	provided	by	a	Quantitative	Polymerase	Chain	Reaction	(qPCR)	 to	 measure	 the	 extent	 of	 reduction	 in	 the	 mRNA	 encoding	 the	 target	protein.		 	
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Figure	18	BLOC-1	KD	HUVECs	–	100	pmol	of	siRNA	-	vWF	secretion	assay		
	Three	vWF	secretion	assays	(three	repeats	 termed	BLOC-1a,	BLOC-1b	and	BLOC-1c)	measuring	 the	percentage	of	vWF	secreted	over	30	minutes	from	HUVECs	stimulated	with	100	ng/mL	of	PMA.	Mock	nucleofected	HUVECs	used	as	a	control	(Blue)	 and	 BLOC-1	 siRNA	 ablated	 HUVECs	 (Red)	 treated	 with	 100	 pmol	 of	 pallidin,	muted	 and	 snapin	 siRNA.	 Mean	percentage	release	is	shown	derived	from	four	replicates	per	experiment.	Error	bars	are	standard	deviation.	T-Test	used	to	measure	significance,	*;	p<0.05,	**;	p<0.01.		Table	6	BLOC-1	KD	in	HUVECs	–	100	pmol	of	siRNA	
	 	 	 vWF	secretion	 	
siRNA	 mRNA	remaining	 Control	 BLOC-1	KD	 Fold	change	from	control	
BLOC-1a	 M.	10%	P.	40%	S.	40%	 28%	 21%	 0.78	
BLOC-1b	 M.	35%	P.	60%	S.	75%	 20%	 21%	 1.05	
BLOC-1c	 M.	10%	P.	42%	S.	38%	 22%	 16%	 0.75		Table	of	results	from	Figure	18,	three	vWF	secretion	assay	repeats	(termed	BLOC-1a,	BLOC-1b	and	BLOC-1c)	measuring	the	percentage	of	vWF	secreted	in	30	minutes	from	experiments	shown	in	Figure	18.	Luciferase	(Ct)	siRNA	and	muted	(M)	
pallidin	 (P)	and	snapin	(S)	siRNA	KD	efficiency	measured	by	qPCR	 in	parallel	with	 the	secretion	assay	–	mean	of	 three	qPCR	measurements	taken	from	pooled	lysates	from	2	confluent	wells	of	HUVECs	from	a	12	well	plate.		Two	 out	 of	 the	 three	 of	 these	 initial	 secretion	 assay	 repeats	 did	 display	 a	significant	 secretory	 defect	 (repeat	 BLOC-1a	 and	 BLOC-1c),	 though	 less	 than	previously	observed	in	HEK293	cells	(22-25%	decrease	as	opposed	to	the	60%	decrease	seen	initially).	It	was	hypothesised	that	this	may	be	due	to	a	relatively	poor	 KD	 efficiency	 (Table	 6).	 A	 qPCR	 of	 the	 cell	 lysates	 was	 performed	 to	determine	 the	 percentage	 of	muted,	pallidin	 and	 snapin	mRNA	 silenced	 by	 the	siRNAs	(levels	compared	to	the	Mock	control).	The	percentage	fall	in	secretion	of	vWF	in	BLOC-1-depleted	cells	appeared	to	correlate	with	the	degree	of	BLOC-1	KD.	 In	order	 to	 improve	KD	efficiency	 the	 level	of	 siRNA	was	 increased	 to	200	pmol	for	each	siRNA.	 	
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Figure	19	BLOC-1	KD	HUVECs	–	200	pmol	of	siRNA	-	vWF	secretion	assay	
	Two	 vWF	 secretion	 assays	 (repeats	 termed	 BLOC-1d	 and	 BLOC-1e)	measuring	 the	 percentage	 of	 vWF	 secreted	 in	 30	minutes	by	regulated	secretion	from	HUVECs	when	stimulated	with	100	ng/mL	of	PMA.	Mock	nucleofected	HUVECs	used	as	a	control	(Blue)	and	BLOC-1	siRNA	ablated	HUVECs	(Red)	treated	with	200	pmol	of	pallidin,	muted	and	snapin	siRNA.	Error	bars	are	standard	deviation.	T-Test	used	to	measure	significance,	*;	p<0.05			Table	7	BLOC-1	KD	in	HUVECs	–	200	pmol	of	siRNA	
	 	 	 vWF	secretion	 	
siRNA	 mRNA	remaining	 Control	 BLOC-1	KD	 Fold	Change	from	Control	
BLOC-1d	 M.	35%	P.	59%	S.	77%	 15%	 17%	 1.15	
BLOC-1e	 M.	36%	P.	61%	S.	73%	 15%	 18%	 1.23		Table	 of	 results	 from	 Figure	 19,	 two	 vWF	 secretion	 assays	 repeats	 (termed	 BLOC-1d	 and	 BLOC-1e)	 measuring	 the	percentage	of	vWF	secreted	in	30	minutes	as	above.	Luciferase	(Control)	siRNA	and	muted	(M)	pallidin	(P)	and	snapin	(S)	siRNA	KD	efficiency	measured	by	qPCR	in	parallel	with	the	secretion	assay	–	mean	of	three	qPCR	measurements	taken	from	pooled	lysates	from	2	confluent	wells	of	HUVECs	from	a	12	well	plate.			The	KD	efficiency	as	determined	by	qPCR	did	not	 improve	after	 increasing	 the	amount	of	siRNA	from	100	to	200	pmol.	Unexpectedly,	the	regulated	secretion	of	vWF	 by	 PMA	 in	 BLOC-1	 KD	 cells	 actually	 increased	 (1.15	 to	 1.23	 fold	 change	compared	 to	 mock	 transfection	 (Figure	 19	 and	 Table	 7).	 Therefore,	 after	confirming	 that	 the	 KD	 achieved	 was	 not	 reproducible,	 or	 efficient	 enough,	 a	different	 approach	 was	 taken.	 It	 was	 hypothesised	 that	 using	 lower	concentrations	(100-200	pmol)	of	three	siRNAs	was	limiting	the	effect	of	the	KD,	also	the	effect	of	 the	KD	was	difficult	 to	quantify	as	using	three	siRNAs	may	be	introducing	 the	 potential	 of	 contrasting	 off-target	 effects.	 The	 literature	 had	shown	that	only	one	siRNA	targeted	towards	pallidin	 is	sufficient	 to	destabilise	the	 entire	 BLOC-1	 complex	 (111,	 120).	 Therefore,	 a	 new	 pallidin	 siRNA	 was	
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designed	 termed	 Pallidin	 2	 and	 used	 alone	 in	 an	 attempt	 to	 improve	 KD	efficiency.		Figure	20	Pallidin	2	siRNA	quantification		
		The	percentage	of	pallidin	mRNA	after	200,	800	and	1000	pmol	of	Pallidin	2	siRNA	treatment	 in	HUVECs	compared	to	
luciferase	 siRNA	 treated	 HUVECs.	 Standard	 deviation	 is	 from	 three	 qPCR	 plate	 readings	 	 -	 mean	 of	 three	 qPCR	measurements	taken	from	pooled	lysates	from	2	confluent	wells	of	HUVECs	from	a	12	well	plate		A	 qPCR	was	 performed	 of	 Pallidin	 2	KD	 to	measure	 efficiency	with	 a	 series	 of	siRNA	dilutions	(Figure	20)	and	it	was	determined	that	1000	pmol	of	siRNA	was	producing	 the	most	efficient	 reduction	of	mRNA.	The	effect	of	Pallidin	2	 siRNA	(using	1000	pmol)	on	vWF	secretion	was	then	tested.	The	more	physiologically	relevant	 secretagogue,	 histamine	 was	 used	 to	 stimulate	 cells	 instead	 of	 PMA	(Figure	17).	 	 A	 significant	 increase	 in	 the	 secretion	of	 vWF	was	observed	over	three	secretion	assays	(1.6-2.5	fold	change	from	the	control)	and	an	efficient	KD	of	pallidin	by	qPCR	of	85%	or	more	was	achieved	in	each	(Table	8).									
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Figure	21	Pallidin	2	KD	in	HUVECs	-	vWF	secretion	assay	
	Three	vWF	secretion	assays	 (three	 repeats	within	each	experiment)	 to	measure	 the	percentage	of	vWF	secreted	 in	30	minutes	by	regulated	secretion	from	HUVECs	when	stimulated	with	100	μM	Histamine.	Luciferase	siRNA	ablated	HUVECs	used	as	a	 control	 (Blue)	and	Pallidin	2	 siRNA	ablated	HUVECs	 (Red)	ablated	with	1000	pmol	of	 siRNA.	Error	bars	are	standard	deviation.	T-Test	used	to	measure	significance,	*;	p<0.05,	**;	p<0.01,	***;p<0.01.		Table	8		Pallidin	2	KD	in	HUVECs	
	 	 	 vWF	secretion	 	
Experiment	 mRNA	remaining	 Control	 Pallidin	2	KD	 Fold	change	from	control	
Pallidin	2a	 15%	 3%	 7.5%	 2.5	
Pallidin	2b	 11%	 5.7%	 12.4%	 2.2	
Pallidin	2c	 15%	 4.7%	 7.7%	 1.6		Table	 of	 results	 from	Figure	 17	 -	 a	 vWF	 secretion	 assay	measuring	 the	 percentage	 of	 vWF	 secreted	 in	 30	minutes	 by	regulated	secretion	from	HUVECs	when	stimulated	with	100	μM	Histamine.	Luciferase	(Control)	siRNA	and	pallidin	siRNA	KD	efficiency	measured	by	qPCR	 in	parallel	with	 the	 secretion	assay	 –	mean	of	 three	qPCR	measurements	 taken	 from	pooled	lysates	from	2	confluent	wells	of	HUVECs	from	a	12	well	plate.			To	confirm	this	phenotype	two	additional	siRNAs	targeted	towards	pallidin	were	used	(named	here	Pallidin	3	and	Pallidin	4)	and	a	secretion	assay	performed.	An	increase	 in	vWF	secretion	was	observed	 (1.6-2.2	 fold	change	 from	the	control)	across	 all	 three	 siRNAs	 targeted	 towards	 pallidin,	 with	 the	 highest	 difference	between	 the	 control	 and	 the	KD	being	observed	 in	 the	 condition	 that	 achieved	the	highest	KD	of	pallidin	as	determined	by	qPCR	(Figure	18,	Table	9).						
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Figure	22	Pallidin	2,3	and	4	KD	in	HUVECs	–	vWF	secretion	assays	
		vWF	secretion	assay	to	measure	the	amount	of	vWF	secreted	in	30	minutes	from	HUVECs	when	stimulated	with	100	μM	Histamine.	Regulated	vWF	secretion	percentage	displayed	for	HUVECs	ablated	with	1000	pmol	of	luciferase	and	Pallidin	2,	3	and	4	siRNAs.	Error	bars	are	standard	deviation.	T-Test	used	to	measure	significance,	*;	p<0.05,	**;	p<0.01.				Table	9	Pallidin	2,	3	and	4	KDs	in	HUVECs			
	 	 	 vWF	secretion	 	
siRNA	 mRNA	remaining	 Control	 BLOC-1	KD	 Fold	change	from	control	
Pallidin	2	 27%	 2.6%	 5.5%	 2.2	
Pallidin	3	 31%	 2.6%	 4.4%	 1.7	
Pallidin	4	 44%	 2.6%	 4%	 1.6		Table	 of	 results	 from	 Figure	 18	 -	 vWF	 secretion	 assay	 measuring	 the	 percentage	 of	 vWF	 secreted	 in	 30	 minutes	 by	regulated	secretion	from	HUVECs	when	stimulated	with	100	μM	Histamine.	Luciferase	(Control)	siRNA	and	pallidin	siRNA	KD	efficiency	measured	by	qPCR	 in	parallel	with	 the	 secretion	assay	 –	mean	of	 three	qPCR	measurements	 taken	 from	pooled	lysates	from	2	confluent	wells	of	HUVECs	from	a	12	well	plate.			Since	 the	 siRNA	 ablation	 of	 pallidin	 appeared	 to	 increase	 the	 amount	 of	 vWF	secreted,	 a	 second	 approach	 was	 sought	 confirm	 the	 phenotype.	 Control	 and	
pallidin-depleted	 cells	were	 stimulated	with	 secretagogue	 in	 the	 presence	 of	 a	vWF	antibody	in	order	to	visualise	the	amount	of	vWF	present	on	the	cell	surface	(205,	206).	The	presence	of	the	antibody	in	the	stimulation	medium	inhibits	the	production	of	vWF	strings	(206)	but	leads	to	the	retention	of	vWF	at	the	exocytic	site.	The	number	of	 exocytic	 sites	on	 the	 cell	 surface	 correlates	well	with	vWF	secretion	as	measured	by	secretion	assays	(207).	The	number	of	exocytic	sites	in	control	 and	 pallidin-depleted	 cells	 was	measured	 in	 a	 preliminary	 experiment	(Figure	23).	Indeed,	the	siRNA	ablation	of	Pallidin	2	resulted	in	an	increase	in	the	
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number	of	exocytic	sites	measured,	further	suggesting	that	the	secretion	of	vWF	is	increased	in	these	cells	(see	4.5.4	for	method).		Figure	23	Exocytic	Site	analysis	in	Pallidin	2	KD	HUVECs	
	 	Two	 fluorescent	 confocal	 images	 of	 luciferase	 (A)	 and	 Pallidin	 2	 (B)	 siRNA	 ablated	 HUVECs	 with	 immunofluorescent	labelling	representing;	internal	vWF	(red)	external	vWF	(green)	and	nuclei	(blue).		A	bar	chart	representing	the	number	of	exocytic	sites	per	nucleus	in	Luciferase	siRNA	(5.19)	and	Pallidin	2	siRNA	(9.06)	treated	cells,	10	images	were	taken	for	each	condition	(bottom	right	panel).	Scale	Bars	10	µm		After	 establishing	 that	 the	 secretion	 of	 vWF	 was	 increased	 when	 cells	 were	treated	 with	 pallidin	 siRNAs,	 it	 was	 important	 to	 try	 and	 establish	 the	mechanism	 and	 location	 at	 which	 pallidin	 is	 acting.	 As	 discussed,	 the	 storage	granule	of	vWF	in	endothelial	cells	is	WPBs.	It	has	previously	been	demonstrated	that	WPB	 size	 effects	 vWF	 secretion	 from	HUVECs	 (63).	 Therefore,	WPB	 feret	diameter	 was	 measured.	 For	 this,	 the	 siRNA	 with	 the	 best	 KD	 efficiency	 was	selected	 (Pallidin	 2).	 The	 control	 and	pallidin-depleted	 cells	were	 then	 stained	for	vWF,	imaged,	and	a	high	throughput	morphometric	analysis	performed	(see	4.5.1).	Over	10,000	WPBs	were	analysed	for	both	luciferase	and	Pallidin	2	KD	and	a	 significant	 difference	 was	 observed	 (p	 value	 <	 2.2	 e-16).	 WPBs	 from	 cells	
A B 
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depleted	of	pallidin	had	significantly	smaller	WPBs,	with	an	increase	particularly	in	the	1	μm	size	(Figure	24).		Figure	24	Pallidin	2	KD	in	HUVECs	–	WPB	morphometric	analysis	
	HUVECs	were	treated	with	siRNA	against	either	luciferase	(A)	or	pallidin	(B)	for	48	hours	and	fixed	and	stained	for	vWF	(green),	 TGN46	 (blue)	 and	 the	 nucleus	 (red).	 Images	 were	 acquired	 (Leica	 SP5	 confocal	 microscope)	 using	immunofluorescence	protocol	(4.3.1).	Data	from	a	representative	experiment	is	shown	(A,B).	WPBs	were	segmented	and	feret	diameter	measured	(C,D).	The	feret	diameter	of	over	10,000	WPBs	in	luciferase	control	(red	lines)	and	pallidin	(blue	Lines)	 siRNA	 treated	 cells	 was	 plotted	 with	 the	 cumulative	 frequency	 (C)	 and	 percentage	 frequency	 (D)	 displayed.	Morphometry	was	measured	using	 Image	 J	 (4.5.1)	Significance	was	assessed	using	 the	Kruskal	 –	Wallis	Test	p-value	=	2.2e-16.	Scale	bars	10	μm			The	 next	 aim	 was	 to	 determine	 the	 multimeric	 state	 of	 vWF	 secreted	 from	pallidin-depleted	 cells.	 Therefore,	 the	 vWF	 from	 the	 regulated	 secretion	 from	HUVECs	 following	 a	 secretion	 assay	 were	 isolated	 from	 control	 and	 pallidin-
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depleted	 cells	 and	 were	 run	 on	 a	 multimer	 gel	 to	 measure	 the	 multimeric	composition	of	vWF	(Figure	25).	A	reduction	 in	the	presence	of	high	molecular	weight	multimers	was	 observed	 in	 Pallidin	 siRNA	 treated	 cells.	 To	 analyse	 the	distribution	of	bands,	 line	profiles	were	drawn	from	bottom	to	 top	and	plotted	using	 ImageJ.	 Although	 this	 was	 preliminary	 data	 (n=1),	 it	 is	 suggestive	 of	 a	reduction	 in	high	molecular	weight	bands	as	seen	by	the	right	hand	side	of	 the	plot	and	the	top	of	the	gel.			Figure	25	Pallidin	2	KD	in	HUVECs	–	Multimer	Gel	
	vWF	multimer	gel	(A)	and	pixel	value	line	plot	performed	in	ImageJ	(B)	of	Luciferase,	Pallidin	2,	Pallidin	3	and	Pallidin	4.	Plots	normalised	to	the	position	and	pixel	value	of	 the	 first	band.	A	reduction	 in	high	molecular	weight	multimer	band	intensity	as	a	proportion	of	the	first	band	was	observed.		Altogether,	this	data	suggests	that	siRNA	ablation	of	Pallidin	leads	to	an	increase	in	the	secretion	of	vWF	from	HUVECs	as	measured	by	secretion	assays.	In	three	preliminary	experiments	there	was	a	reduction	in	the	size	of	WPBs,	an	increase	in	the	number	of	vWF-positive	exocytic	sites	and	a	decrease	in	higher	molecular	weight	 vWF	 multimers.	 These	 results	 are	 somewhat	 contradictory,	 as	 it	 has	previously	 been	 shown	 that	 cells	 with	 smaller	 WPBs	 have	 a	 defect	 in	 vWF	secretion	 (199),	 and	 the	 above	 results	 demonstrate	 the	 opposite.	 Therefore,	additional	siRNAs	were	used	to	assess	the	release	of	vWF	measured	by	secretion	assays	in	order	to	try	and	confirm	this	result.	These	(experiments	number	5-7)	however,	 gave	 contradictory	 results	 (Table	 10)	 to	 the	 secretion	 assays	performed	before.			
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	Table	10	Pallidin	KD	experiments	summary	
Experiment	No.	 siRNA	sequence	used	 Pallidin	KD	
Fold	change	from	
control	
1	 Pallidin	2	 15%	 2.48	
2	 Pallidin	2	 11%	 2.17	
3	 Pallidin	2	 15%	 1.64	
	 Pallidin	2	 27%	 2.12	
4	 Pallidin	3	 31%	 1.69	
	 Pallidin	4	 44%	 1.54	
	 Pallidin	2	 16%	 1.37	
5	 Pallidin	3	 14%	 0.82	
	 Pallidin	4	 30%	 0.79	
	 Pallidin	2	 17%	 1.82	
6	 Pallidin	3	 15%	 1.01	
	 Pallidin	4	 28%	 0.69	
	 Pallidin	2	 32%	 1.71	
7	 Pallidin	3	 41%	 0.77	
	 Pallidin	4	 68%	 0.48		vWF	secretion	assay	results	using	pallidin	siRNAs	treated	cells	with	100	μM	histamine	for	30	minutes.	Luciferase	siRNA	was	 used	 as	 a	 control	 and	 Pallidin	 2,3	 and	 4	 to	 deplete	 pallidin.	 Fold	 change	 from	 control	 value	 coded	 green	 for	 an	increase	in	vWF	secretion	and	red	for	decrease	over	15%,	black	for	neither.	The	most	efficient	qPCR	KD	result	for	each	pallidin	siRNA	sequence	also	highlighted	in	bold.		Experiment	 5-7	 did	 not	 demonstrate	 a	 consistent	 increase	 in	 the	 secretion	 of	vWF	that	had	been	observed	in	experiments	1-4	(Table	10)	and	confirmed	that	off-target	effects	could	not	be	ruled	out.	The	three	most	efficient	KDs	by	qPCR	for	the	siRNA	sequences	Pallidin	2,	Pallidin	3	and	Pallidin	4	gave	a	117%	increase,	18%	decrease	and	31%	decrease	in	vWF	secretion	respectively	compared	to	the	control.	 Only	 experiments	 1-4	 were	 in	 agreement	 that	 pallidin	 siRNA	 ablation	resulted	 in	an	 increase	 in	vWF	regulated	 secretion.	To	establish	whether	 there	was	a	significant	relationship	between	KD	efficiency	and	aberrant	secretion,	the	amount	of	vWF	secreted	normalised	to	controls	was	plotted	(Figure	26)	against	the	 percentage	 of	pallidin	mRNA	 remaining	 and	 the	 correlation	was	measured	with	pearson’s	coefficient.							
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Figure	26	Correlation	between	pallidin	KD	efficiency	and	vWF	secretion	in	HUVECs		
	The	percentage	of	pallidin	mRNA	remaining	compared	to	control	in	each	siRNA	ablation	experiment	was	measured	and	plotted	against	 the	 fold	change	 in	vWF	regulated	secretion	 (includes	histamine	and	PMA	results)	 compared	 to	control.	Each	experiment	represented	by	a	black	dot,	trendline	shown	in	black.	Pearson’s	coefficient	R	value	=	-0.4943.	The	result	is	not	significant	at	p	>	0.05.		There	was	only	a	weak	correlation	between	the	effect	of	the	siRNA	on	secretion	as	 expressed	 as	 a	 fold	 change	 from	 control	 HUVECs	 and	 the	 KD	 efficiency	 by	qPCR	(p>0.05).	As	the	levels	of	pallidin	protein	in	the	cells	and	the	efficiency	of	siRNA	KD	on	reducing	this	could	not	be	fully	evaluated,	due	to	a	lack	of	reliable	antibodies,	 it	was	 decided	 to	 not	 continue	with	 the	 exit	 site,	multimer	 gel	 and	WPB	 morphology	 analysis.	 If	 the	 pallidin	 siRNAs	 that	 were	 chosen	 had	 the	potential	to	exhibit	opposite	significant	secretory	phenotypes	then	the	likelihood	that	off-target	effects	would	influence	future	findings	would	be	probable.	During	the	time	that	the	BLOC-1	siRNA	treatment	experiments	were	performed,	another	project	with	the	aim	of	 investigating	the	effect	of	another	HPS	related	complex,	BLOC-3,	on	vWF	secretion	was	also	undertaken.		
5.3 Results	-	A	potential	role	for	BLOC-3	in	WPB	function		BLOC-3	was	selected	as	a	potential	complex	to	investigate	in	tandem	with	BLOC-1	as	 there	 is	 little	known	about	 its	role	 in	LRO	biogenesis.	Since	 there	are	only	two	proteins	that	form	the	complex	(HPS1	and	HPS4),	 it	was	hypothesised	that	
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the	effects	of	siRNA	ablation	on	HPS1	would	give	a	suitable	indicator	of	whether	this	complex	is	important	for	WPB	formation	and	function.	
 As	with	BLOC-1,	there	are	commercially	available	antibodies	available	for	HPS1	and	HPS4,	however,	a	western	blot	revealed	that	they	were	not	specific	enough	(Figure	27)	to	quantify	KD	efficiency,	therefore,	an	indication	of	the	efficiency	of	the	 KDs	 was	 instead	 provided	 by	 a	 qPCR	 Reaction	 to	 measure	 the	 extent	 of	reduction	in	the	mRNA	encoding	the	target	protein.				Figure	27	Western	Blot	to	measure	HPS1	and	HPS4	antibody	specificity		
	Antibodies	 against	 HPS1	 (79KD)	 and	 HPS4	 (90KD)	 were	 tested	 for	 specificity.	 A	 Precision	 Plus	 protein	 dual	 colour	standard	(Biorad)	was	also	loaded	as	a	molecular	weight	(MW)	marker.		Two	siRNA	sequences	targeting	HPS1	were	tested	for	their	efficiency	in	depleting	HPS1	in	HUVECs	(Table	10).			Table	11	HPS1.1	and	HPS1.2	KD	qPCR	
	siRNA	conc.	 HPS1.1	mRNA	remaining	 HPS1.2	mRNA	remaining	200	pmol	 60%	 51%	400	pmol	 38%	 58%	600	pmol	 52%	 28%	800	pmol	 49%	 25%		A	series	of	HPS1	siRNA	concentrations	200-800	pmol	were	used	to	treat	HUVECs	to	measure	the	depletion	of	HPS1	mRNA	as	determined	by	a	qPCR.			(For	siRNA	sequence	see	Table	2)		Neither	 of	 the	 siRNAs,	 named	 HPS1.1	 or	 HPS1.2,	 achieved	 a	 KD	 efficiency	 (as	quantified	 by	 qPCR)	 over	 70%,	 apart	 from	 HPS1.2	 at	 600	 and	 800	 pmol.	Therefore,	 the	siRNA	named	termed	HPS1.2,	was	used	at	1000	pmol	to	deplete	
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HPS1	from	HUVECs	and	secretion	assays	performed	with	the	cells	 treated	with	the	secretagogue	histamine	for	30	minutes.			Figure	28	HPS1.2	KD	in	HUVECs	–	vWF	secretion	assays		
	Three	vWF	secretion	assay	repeats	to	measure	the	amount	of	vWF	secreted	in	30	minutes	from	HUVECs	when	stimulated	with	100	μM	Histamine.	Regulated	vWF	secretion	percentage	displayed	for	HUVECs	ablated	with	1000	pmol	of	luciferase	(blue)	and	three	repeats;	HPS1.2a,	HPS1.2b	and	HPS1.2c	(red)	siRNAs.	Error	bars	are	standard	deviation.	T-Test	used	to	measure	significance,	*;	p<0.05,	**;	p<0.01.		Table	12	HPS1.2	KD	in	HUVECs	–	vWF	secretion	assays		 	 	 vWF	secretion	 	Experiment	 mRNA	remaining	 Control	 HPS1.2	KD	 Fold	change	from	control	HPS1.2a	 18%	 3%	 5%	 1.38	HPS1.2b	 17%	 6%	 10%	 1.52	HPS1.2c	 28%	 3%	 4%	 1.42		Three	vWF	secretion	assay	repeats	measuring	the	percentage	of	vWF	secreted	in	30	minutes	by	regulated	secretion	from	HUVECs	when	stimulated	with	100	μM	Histamine.	Luciferase	(Ct)	siRNA	and	HPS1	siRNA	KD	efficiency	measured	by	qPCR	in	parallel	with	the	secretion	assay	–	mean	of	three	qPCR	measurements	taken	from	pooled	lysates	from	2	confluent	wells	of	HUVECs	from	a	12	well	plate.			There	 was	 no	 improvement	 in	 KD	 efficiency	 by	 increasing	 the	 secretagogue	concentration	 to	 1000	 pmol.	 However,	 encouragingly	 the	 secretion	 of	 vWF	 in	response	to	histamine	in	HPS1	KD	cells	was	significantly	increased	compared	to	control	cells.			To	 confirm	 the	 secretory	 aberration	 observed,	 three	 other	HPS1	 siRNAs	 were	ordered	from	published	sequences	(123)		where	they	had	been	successfully	used	on	 HELA	 and	 MNT-1	 cells	 to	 demonstrate	 the	 mislocalisation	 of	 RAB32	 and	
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RAB38	causing	defects	in	melanosome	maturation	in	MNT-1	cells.	Two	of	these	sequences,	 termed	 ‘HPS1.3’	and	 ‘HPS1.5’	achieved	a	KD	over	75%	at	800	pmol.	Secretion	 assays	 were	 then	 performed	 with	 cells	 treated	 with	 800	 pmol	 of	HPS1.2,	HPS1.3	and	HPS1.5	siRNAs	(Figure	29).			Figure	29	HPS1.2,	1.3	and	1.5	KD	in	HUVECs	–	vWF	secretion	assays	
		vWF	secretion	assays	to	measure	the	amount	of	vWF	secreted	in	30	minutes	from	HUVECs	when	stimulated	with	100	μM	Histamine.	 Regulated	 vWF	 secretion	 percentage	 displayed	 for	HUVECs	 ablated	with	 800	 pmol	 of	 luciferase	 (blue)	 and	HPS1.2	 (red),	 HPS1.3	 (green)	 and	 HPS1.5	 (purple),	 two	 repeats	 for	 each	 siRNA	 are	 shown	 (a	 and	 b).	 	 Error	 bars	 are	standard	deviation.	T-Test	used	to	measure	significance,	*;	p<0.05.			Table	13	HPS1.2,	1.3	and	1.5	KD	in	HUVECs	–	vWF	secretion	assays		siRNA	and	experiment	(a	or	b)	 mRNA	remaining	 Ct	Secretion	 HPS1	siRNA	Secretion	 HPS1/Ct	Secretion	HPS1.2a	 7%	 8%	 8%	 1.03	HPS1.2b	 11%	 5%	 8%	 1.45	HPS1.3a	 21%	 8%	 7%	 0.97	HPS1.3b	 22%	 5%	 7%	 1.21	HPS1.5a	 23%	 8%	 7%	 0.88	HPS1.5b	 21%	 6%	 5%	 0.87		Table	 of	 results	 from	 Figure	 29	 vWF	 secretion	 assays	 measuring	 the	 percentage	 of	 vWF	 secreted	 in	 30	 minutes	 by	regulated	 secretion	 from	HUVECs	when	 stimulated	with	100	μM	Histamine.	Luciferase	 (Ct)	 siRNA	and	HPS1	 siRNA	KD	efficiency	measured	by	qPCR	in	parallel	with	the	secretion	assay	–	two	experiments	for	each	siRNA	are	shown	(a	and	b)		the	mean	of	three	qPCR	measurements	taken	from	pooled	lysates	from	2	confluent	wells	of	HUVECs	from	a	12	well	plate.			The	two	other	HPS1	siRNA	sequences	(HPS1.3	and	HP1.5)	did	not	replicate	the	secretion	increase	observed	in	HPS1.2	treated	cells.	Whilst	a	significant	increase	in	 vWF	 secretion	 was	 observed	 in	 cells	 treated	 with	 the	 HPS1	 siRNA	 termed	HPS1.3,	the	converse	result	was	seen	in	cells	treated	with	the	other	comparative	siRNA	sequence	HPS1.5,	even	though	both	sequences	resulted	in	a	KD	efficiency	of	 over	 75%.	 Also,	 the	 highest	 qPCR	 KD,	 achieved	 by	 the	 HPS1.2	 siRNA	 in	
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experiment	HPS1.2a,	with	a	93%	KD	efficiency,	displayed	no	significant	aberrant	secretion.	 Preliminary	 results	 with	 siRNAs	 targeted	 towards	 HPS4,	 the	 other	BLOC-3	subunit,	proved	unsuccessful	as	a	sufficient	KD	was	not	achieved	(data	not	shown).		Conflicting	secretion	assay	results	with	a	similar	KD	efficiency,	as	measured	by	qPCR,	 lead	 to	 the	 conclusion	 that	 this	 work	 should	 not	 be	 continued,	 as	 the	regulated	 secretion	 of	 vWF	 is	 a	 result	 of	WPB	 formation	 and	 function,	 it	 was	likely	 that	 the	 variation	 seen	 in	 secretory	 phenotypes	would	 also	 be	 observed	when	studying	other	variables.		
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5.4 Discussion			In	 this	 chapter,	 siRNA	 ablation	 experiments	 were	 performed	 with	 the	 aim	 of	determining	 the	 importance	 of	 HPS	 related	 proteins/complexes	 on	 WPB	biogenesis	 and	 function	 in	 a	 primary	 human	 endothelial	 cell	 line.	 Proteins	related	 to	 two	HPS	complexes,	BLOC-1	and	BLOC-3,	were	KD	and	 the	resultant	regulated	 vWF	 secretion	 was	 measured.	 In	 the	 BLOC-1	 KD	 experiments,	 the	morphology	of	WPBs,	 the	number	of	 exocytic	 sites	per	 cell	 and	 the	multimeric	composition	 of	 secreted	 vWF	 was	 also	 measured	 in	 a	 series	 of	 preliminary	experiments.		HPS	has	been	shown	to	affect	LRO	function	 in	a	number	of	studies.	Apart	 from	hypopigmentation,	the	one	phenotype	that	unites	all	the	12	HPS	mouse	models	is	a	 bleeding	 disorder	 (Figure	 7).	 WPBs	 have	 been	 shown	 to	 be	 critical	 to	haemostasis	due	to	 the	 fact	 their	primary	role	 is	 to	carry	 the	protein	vWF	(see	2.4.3).	Despite	 this,	 the	 effect	 of	 depleting	HPS	 related	proteins	 in	human	 cells	and	 the	 resulting	 effect	 of	 vWF	 secretion	 has	 not	 been	 investigated.	 It	 was	expected	 that	 if	a	bleeding	disorder	was	a	common	phenotype	 in	HPS	patients,	then	abnormal	vWF	secretion	by	WPBs	might	be	a	contributor	to	this.		WPBs	are	formed	at	the	TGN	(63)	and	one	of	the	HPS	complexes	whose	function	is	 thought	 to	act	 in	 this	area	 is	BLOC-1	(113),	making	 it	a	good	candidate	 for	a	HPS-related	 complex	 that	 may	 affect	WPB	 biogenesis.	 The	 work	 in	 this	 thesis	initially	focused	on	the	BLOC-1	proteins,	specifically	Muted,	Pallidin	and	Snapin	(see	5.1)	 due	 in	 part	 to	 the	 observation	by	 a	 previous	post-doc	 in	 the	 lab	 that	knocking	 these	 three	 proteins	 down	 in	 HEK	 cells	 expressing	 exogenous	 vWF	caused	 a	 three-fold	 reduction	 in	 vWF	 secretion	 (Figure	 17).	 Although	 initial	results	did	replicate	a	reduction	in	vWF	secretion	(around	30%),	I	was	unable	to	replicate	these	results	due	in	part	to	a	poor	KD	efficiency	and	switched	to	a	focus	on	 ablation	 of	pallidin	 (see	 5.1),	 as	 the	 pallidin	 protein	 has	 been	 shown	 to	 be	required	 to	 stabilize	 the	 BLOC-1	 complex	 (190).	 The	 initial	pallidin	 KD	 results	were	 surprising,	 as	 I	 saw	 a	 dramatic	 increase	 in	 the	 secretion	 of	 vWF	 that	
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appeared	 to	 be	 proportional	 to	 the	 level	 of	 KD	 observed	 from	 the	 qPCR	measurements.	Preliminary	data	also	suggested	that	the	feret	diameter	of	WPBs	was	also	significantly	reduced	(p-value	2.2e-16)	and	an	increase	 in	the	number	of	exocytic	sites	(5.19	in	control	and	9.06	sites	in	pallidin	KD	cells	per	nucleus).	These	 were	 unusual	 observations	 as	 a	 reduction	 in	 WPB	 feret	 diameter	 after	treatment	with	an	AP-1	 siRNA	or	 treating	with	nocodazole	which	disassembles	the	Golgi	 ribbon	by	depolymerising	microtubules,	 results	 in	 a	 decrease	 in	 vWF	secretion	 (63,	 69)	 and	 a	 reduction	 in	 the	 size	 of	 WPBs.	 Initial	 experiments	appeared	 to	 suggest	 a	 reduction	 of	 high	molecular	weight	 vWF	being	 secreted	(Figure	25)	and	also	an	increase	in	the	number	of	exocytic	sites	at	the	cell	surface	(Figure	23)	when	stimulated	with	a	secretagogue	as	compared	 to	controls.	 	An	increase	 in	 the	 vWF	 exocytic	 sites	 could	 be	 a	 possible	 explanation	 for	 the	increase	 in	 secretion	 observed	 in	 the	 secretion	 assays	 and	 a	 lack	 of	 high	molecular	 weight	 multimers	 suggests	 that	 WPBs	 were	 being	 released	prematurely,	however,	this	was	not	confirmed.	It	is	also	counter-intuitive	that	if	BLOC-1	is	a	complex	that	is	important	for	the	biogenesis	and	formation	of	other	LROs,	that	depleting	endothelial	cells	of	this	complex	would	increase	the	levels	of	secretion	 of	 vWF	 from	 WPBs	 unless	 BLOC-1	 was	 performing	 a	 regulatory	function.	 A	 similarity	 can	 be	 seen	with	 Rab27a	 ablation,	where	 an	 increase	 in	secretion,	 a	 reduction	 in	 higher	 molecular	 weight	 multimers	 and	 decrease	 in	vWF	string	length	is	observed	(81).	As	Rab27a	is	only	found	on	mature	WPBs,	it	could	be	possible	that	this	is	an	indicator	that	the	WPBs	in	the	Pallidin	2	KD	were	undergoing	 typical	 maturation,	 but	 it	 does	 not	 explain	 the	 increase	 in	 vWF	exocytic	sites.		Critically,	the	initial	increase	in	vWF	secretion	observed	with	an	siRNA	targeted	to	 pallidin	 was	 not	 reproducible	 with	 other	 siRNAs	 targeted	 to	 the	 same	sequence,	 despite	 a	 similar	 reduction	 mRNA	 being	 observed	 by	 qPCR.	 The	HUVECs	 stocks	 used	 in	 experiments	 5-7	were	 from	 the	 same	 batch	 of	 cells	 as	experiments	1-4,	however,	the	effect	of	the	siRNAs	was	contrasting;	it	is	unclear	why	this	happened	and	could	potentially	be	due	to	reproducibility	issues	within	the	 experimental	 design,	 variability	 within	 HUVEC	 stocks	 and/or	 sensitivity	within	 secretion	 assays,	 yet	 this	 seems	 unlikely.	 Due	 to	 these	 inconsistencies	
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between	siRNAs	it	is	more	likely	that	the	initial	results	seen	with	Pallidin	2	were	due	 to	 off-target	 effects.	 As	 a	 poor	 KD	 efficiency	 was	 observed	 with	 lower	concentrations	of	siRNA,	the	increase	in	siRNA	used	may	have	improved	the	KD	of	pallidin	 but	 this	 also	 increases	 the	 likelihood	 of	 off-target	 effects	 (208).	 The	results	 that	 are	 demonstrated	with	 these	 sequences	 in	 published	 literature	 do	not	 report	 off-target	 effects	 and	 this	 could	 be	 due	 to	 the	 fact	 these	 siRNA	sequences	 were	 employed	 in	 different	 cell	 lines	 and	 focused	 on	 the	mislocalisation	of	proteins	observed	by	fluorescent	microscopy	and	thus	the	off-target	 effects	 affecting	 secretion	 were	 not	 observed	 (111).	 To	 investigate	 this	further,	 a	BLAST	 (209)	 search	was	performed	on	 the	 siRNA	 sequence	used	 for	
pallidin	and	this	showed	that	there	were	no	matches	with	a	high	similarity	(over	70%).	It	is	still	possible	that	the	effect	on	vWF	secretion,	size	of	WPBs,	reduction	in	 low	 molecular	 weight	 multimers	 in	 secreted	 vWF	 and	 the	 increase	 in	 the	number	of	exocytic	sites	could	be	due	to	a	pallidin	KD,	however,	due	to	a	lack	or	reliable	 antibodies,	 time	 constraints	 and	 contradictory	 results,	 this	 was	 not	pursued	and	attention	turned	to	promising	early	results	using	a	HPS1	siRNA	to	investigate	the	function	of	the	BLOC-3	complex.		
Despite	 early	 results	 suggesting	 that	 a	 HPS1	 KD	 was	 causing	 a	 significant	increase	 in	 vWF	 secretion,	 when	 the	 secretion	 assays	 were	 repeated	 with	additional	siRNAs	to	KD	HPS1,	the	secretion	increase	was	not	replicated,	despite	the	 sequences	 being	 taken	 from	 a	 publication	 where	 these	 siRNAs	 were	successfully	 used	 to	 KD	 HPS1	 in	 HELA	 and	 MNT-1	 cells	 to	 demonstrate	 the	mislocalisation	or	RAB32	and	RAB38	and	defects	 in	melanosome	maturation	in	MNT-1	cells	(123).	Like	with	the	pallidin	ablation	studies,	 it	 is	possible	 that	 the	off-target	effects	were	cell	and	assay	specific.			Preliminary	 experiments	 used	 to	 KD	 HPS4,	 the	 other	 member	 of	 the	 BLOC-3	complex	 did	 not	 achieve	 a	 KD	 of	 over	 50%	 as	 measured	 by	 qPCR	 (data	 not	shown).	Due	to	the	contradictory	results	observed	and	an	inability	to	test	protein	levels	of	HPS1	and	HPS4	by	a	western	blot,	a	conclusion	about	the	role	of	BLOC-3	in	WPB	secretion	was	not	possible.			
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Despite	 promising	 results	with	 siRNAs	 against	 BLOC-1	 and	BLOC-3,	 it	was	 not	possible	 to	 achieve	 the	 original	 aim	 of	 conclusively	 answering	 the	 question	 of	whether	 there	 is	 a	 role	 for	 the	HPS	 proteins	 in	 the	 biogenesis	 and	 function	 of	WPBs	 and	 thus	 this	 question	was	 not	 taken	 further.	 It	 was	 surprising	 that	 an	increase	 in	 secretion	 was	 observed,	 given	 that	 BLOC-1	 and	 BLOC-3	 related	diseases	have	a	bleeding	disorder,	however,	 it	could	not	be	discounted	that	the	bleeding	disorder	seen	in	these	patients	may	be	as	a	result	of	defective	platelet	granule	formation	and	the	effect	on	WPBs	could	be	secondary	to	this.	In	future,	different	approaches	to	achieve	a	stable	KD	of	HPS	proteins	in	human	endothelial	cells	 must	 be	 sought.	 These	 may	 include	 techniques	 such	 as	 producing	 blood	outgrowth	 endothelial	 cells	 from	 HPS	 patients	 (210),	 or	 Crispr/cas9	 gene	ablations	 (210).	 Only	 when	 a	 reliable	 and	 quantifiable	 KD	 of	 HPS	 proteins	 is	achieved	 can	 greater	 conclusions	 about	 the	 role	 of	 these	 proteins	 in	 WPB	formation	 and	 function	 be	 drawn.	 During	 this	 research,	 a	 paper	 from	Flaumenhaft	and	co-workers	(211)	using	siRNA	to	KD	HPS6	in	HUVECs	(BLOC-2	complex)	 demonstrated	 impaired	 PDI	 secretion	 and	 exocytosis	 of	 WPBs;	currently	 it	 is	 not	 clear	 why	 this	 study	 succeeded	 and	 the	 secretion	 assays	highlighted	in	this	chapter	did	not.			It	is	clear	that	to	be	able	to	assess	the	role	of	LROs	in	LRO-related	disorders,	new	techniques	must	be	developed	to	study	and	analyse	them.	To	further	this	pursuit,	efforts	were	turned	to	improve	the	diagnosis	of	disorders	relating	to	another	set	of	LROs,	the	platelet	granules.		
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6 Chapter	2	A	Super	Resolution	method	to	 study	 Platelet	 Granules	 and	 their	related	disorders	
6.1 Introduction		Platelets	 contain	 alpha	 granules,	 dense	 granules,	 multivesicular	 bodies,	 and	lysosomes	(25).		In	recent	years,	new	methods	have	challenged	the	classical	view	that	alpha	and	dense	granules	represent	homogeneous	populations	 (9,	25,	212,	
213)	 and	 consequently,	 the	 basis	 on	 which	 diagnosis	 and	 definition	 of	 their	related	disorders	 rests	has	 come	 into	question.	 In	 this	 chapter	new	 techniques	are	 investigated	 for	 analysing	platelet	 granules,	 not	only	 to	 revisit	 some	of	 the	uncertainty	in	their	analysis,	but	also	to	potentially	apply	these	new	techniques	to	the	diagnosis	of	genetic	disorders.	In	this	chapter	steps	taken	to	develop	a	new	technique	 for	 analysing	 two	 LROs	 are	 reported;	 platelet	 alpha	 and	 dense	granules,	using	two	SRM	techniques;	dSTORM	and	SIM.		
6.1.1 Alpha	granules		Alpha	granules	are	the	major	storage	and	secretory	organelle	in	the	platelet,	they	are	also	the	most	abundant	granules	numbering	around	50-80	per	platelet	(39).	Formed	from	multivesicular	precursor	organelles,	they	acquire	cargo	from	both	the	endocytic	and	biosynthetic	routes.	Alpha	granules	contain	over	300	distinct	molecules	 (40)	 that	 comprise	 the	 bulk	 of	 the	 platelet	 secretome	 including	haemostatic	 factors	 (e.g.,	 Factor	 V,	 vWF,	 fibrinogen),	 angiogenic	 factors	 (e.g.,	angiogenin,	VEGF),	anti-angiogenic	factors	(e.g.,	angiostatin,	PF4),	growth	factors	(e.g.,	PDGF,	bFGF,	SDF1α),	proteases	 (e.g.,	MMP2,	MMP9),	necrotic	 factors	 (e.g.,	TNFα,	TNFβ)	and	other	cytokines	(40).		Alpha	granules,	given	their	content,	have	the	 properties	 of	 both	 secretory	 organelles	 and	 late	 endosomes,	 which	 justify	their	 characterisation	 as	 an	LRO.	Historically,	morphological	 features	 observed	
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by	 EM	 have	 led	 to	 recognition	 of	 alpha	 granules	 as	 a	 distinct	 organelle.	 These	identifiable	 features	 include;	1)	 the	peripheral	membrane	of	 the	granule,	2)	an	electron	 dense	 nucleoid	 that	 contains	 chemokines	 and	 proteoglycan,	 3)	 a	 less	electron-dense	area	adjacent	 to	 the	nucleoid	 that	 contains	 fibrinogen,	 and	4)	 a	peripheral	 electron-lucent	 zone	 that	 contains	 vWF	 ((28)	 see	 Figure	 31	 for	 an	example	 TEM	 image).	 Absence	 of	 a	 particular	 alpha	 granule	 marker	 does	 not	preclude	classification	of	a	vesicular	 structure	as	an	alpha	granule,	 as	even	 the	major	 storage	 proteins	 of	 alpha	 granules,	 vWF	 and	 Fibrinogen,	 have	 limited	colocalisation	 by	 immunofluorescent	 confocal	 microscopy	 (214).	 Indeed,	 a	colocalisation	analysis	by	Kamykowski	et	al.	found	considerable	variation	in	co-distributions	and	little	cargo	clustering	with	15	separate	alpha	granule	markers	(212).	Thus,	the	definition	of	alpha	granules	may	yet	undergo	further	refinement	as	we	 learn	more	about	 their	 formation,	structure,	and	content.	The	conflicting	functions	(e.g.,	proangiogenic	and	antiangiogenic)	of	the	proteins	stored	in	alpha	granules	 gives	 rise	 to	 the	 theory	 that	 there	 could	 be	 functionally	 distinct	populations	 of	 these	 granules	 which	 are	 released	 differentially	 in	 response	 to	their	relevant	stimuli.		Alpha	granule	biogenesis	is	affected	in	three	inherited	human	disorders:	Quebec	Platelet	 Disorder,	 GPS	 and	 ARC	 (arthrogryposis,	 renal	 dysfunction	 and	cholestasis)	 syndrome.	 In	 GPS	 the	 amount	 of	 protein	 synthesised	 in	 MKs	 is	significantly	 reduced,	 although	 endocytosed	 alpha	 granule	 content	 is	 less	affected	 (42).	 It	 has	 recently	 been	 demonstrated	 that	 mutations	 in	 the	Neurobeachin-like	2	(NBEAL2)	gene	cause	GPS	(42)	and	these	mutations	appear	to	 be	 involved	 in	 the	 packing	 of	 endogenously	 synthesised	 secretory	 proteins	into	developing	alpha	granules	(see	also	2.5.1	for	GPS).		 	
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6.1.2 Dense	granules			Dense	 granules	 are	 around	150	nm	 in	 size	 and	 also	 originate	 from	 endosomal	precursors.	There	are	typically	3-8	(215)	of	these	organelles	per	platelet.	Dense	granules	 are	 acidic	 and	 therefore	 accumulate	 acidic	 dyes	 such	 as	 mepacrine	(216)	and	acridine	orange	(44).	In	terms	of	content	they	are	much	more	simple	than	 alpha	 granules	 and	 contain	 serotonin,	 histamine,	 ADP,	 ATP,	 GDP,	 GTP,	magnesium	 pyrophosphate	 (47)	 and	 polyphosphate	 (46).	 Dense	 Granules	 also	carry	 the	 lysosomal	 membrane	 proteins	 CD63	 and	 LAMP1/2	 but	 also	 non-lysosomal	proteins	such	as	P-Selectin	(50),	GPIb	(217)	and	αII-β3	integrin	(218).	Some	 structural	 information	 about	 dense	 granules	 can	 be	 obtained	 using	 the	whole	mount	EM	technique	(36,	219)	and	this	is	currently	the	gold	standard	for	assessing	 the	number	 of	 dense	 granules	 per	 platelet.	Here,	 a	 patient’s	 blood	 is	spun	in	a	centrifuge	to	form	PRP	and	a	drop	of	PRP	is	placed	on	a	formvar-coated	grid	and	visualised,	without	fixation,	using	EM	(Figure	30).		
6.1.3 Currently	available	PSD	diagnostic	tools		The	 established	 tools	 available	 to	 clinicians	 for	 diagnosing	 PSDs	 are	 currently	limited,	and	discussion	within	the	clinical	community	suggests	that	there	is	room	for	 additional	 new	 techniques,	 for	 example	 as	 in	 recent	 reports	 (220,	 221)	suggesting	 the	 further	 use	 of	 FACS-based	 assays	 as	 a	 diagnostic	 tool	 in	 this	context.	 	 Currently,	 assays	 for	 diagnosing	 a	 potential	 dense	 granule	 disorder	include	aggregation	in	response	to	a	panel	of	agonists,	measurement	of	platelet	nucleotides	and/or	ATP	release	and	direct	counting	of	dense	granules	using	EM.			Platelet	aggregation	is	measured	by	Light	transmission	aggregometry	(LTA)	and	was	developed	in	1962	by	Born	(222)	and	O'Brien	(223).		It	is	still	considered	the	gold	 standard	 for	 testing	 platelet	 function.	 The	 change	 in	 optical	 density	 of	 a	rapidly	 stirred	 sample	 of	 platelet-rich	 plasma	 (PRP)	 at	 37	°C	 is	measured	 by	 a	photometer	 and	 compared	 with	 normal	 values	 after	 the	 addition	 of	 platelet	agonists	 such	 as	 arachidonic	 acid,	 thrombin,	 ADP,	 epinephrine,	 collagen	 and	ristocetin	 (37).	 Despite	 its	 widespread	 use,	 there	 are	 a	 number	 of	 caveats	
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regarding	 LTA	 results.	 Primarily,	 it	 is	 not	 strictly	 comparable	 to	 physiological	platelet	 aggregation	 as	 the	 separated	 platelets	 in	 PRP	 only	 form	 aggregates	following	the	addition	of	soluble	agonists	under	low	shear	conditions	(stirring).	LTA	results	are	also	difficult	to	interpret	and	different	haematology	centres	(and	often	doctors)	will	only	trust	results	taken	from	their	own	lab	(conversation	with	Dr.	Keith	Gomez,	Haematology	consultant	at	the	Royal	Free	Hospital,	London).	In	2013	 a	 consensus	 of	 the	 working	 party	 from	 the	 platelet	 physiology	subcommittee	 of	 SSC/ISTH	 concluded	 that;	 ‘LTA	 is	 a	 time-consuming	 and	technically	 challenging	 technique	 that	 is	 affected	 by	 many	 pre-analytical	 and	analytical	 variables,	 and	 these	 must	 be	 carefully	 controlled	 for	 by	 expert	personnel.	 For	 this	 reason,	 LTA	 should	 be	 performed	 only	 in	 specialised	laboratories’	(224).	The	test	itself	is	inherently	variable	as	LTA	can	be	affected	by	a	number	of	 factors	including	the	patient’s	medication.	In	an	ideal	situation	the	samples	 for	 platelet	 function	 studies	 should	 only	 be	 collected	 from	 fasting	subjects	 who	 have	 refrained	 from	 smoking	 and	 caffeine	 for	 24	 hours	 before	testing.	If	the	patient	is	taking	medication	known	to	affect	platelet	function,	e.g.	antibiotics,	 anti-depressants,	 beta-blockers,	 non-steroidal	 anti-inflammatory	drugs	 (225),	 then	 the	 test	 should	be	deferred	 for	at	 least	10	days	after	 the	 last	dose.	Herbal	remedies,	garlic,	alcohol	and	certain	foods	may	also	cause	acquired	platelet	 dysfunction	 (225).	 In	 normal	 clinical	 practice	 it	 is	 often	 impossible	 to	avoid	 all	 of	 these	 patient-related	 variables	 and	 so	 a	 practical	 approach	 is	 to	proceed	with	the	platelet	function	tests,	but	if	they	are	abnormal,	to	then	collect	a	new	sample	under	stricter	conditions	(224).  
 Perhaps	 the	major	 drawback	 of	 aggregometry	 and	 nucleotide	measurement	 is	that	these	tests	tell	us	little	about	platelet	structure.	In	genetic	disorders	such	as	HPS/GPS,	 characterised	by	a	 reduction	 in	platelet	granules,	 the	ability	 to	count	the	 number	 of	 dense/alpha	 granules	 per	 platelet	 efficiently	 would	 immensely	improve	 diagnosis.	 Using	 whole	 mount	 EM	 to	 resolve	 platelet	 granules	 is	currently	the	gold	standard	for	identifying	a	lack	of	dense	granules	but	is	rarely	used	due	to	a	number	of	caveats.	Quantitative	EM	analysis	requires	an	electron	microscope,	 specialised	 skills,	 is	 time-consuming,	 and	 is	 very	 difficult	 to	automate.	Without	markers,	granules	are	difficult	to	define	and	identification	can	
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differ	 depending	 on	 the	 analyst	 (12,	 4.2.2).	 An	 absence	 or	 reduction	 of	 dense	granules,	due	to	mutations	in	the	cellular	machinery	used	in	granule	formation,	is	 found	 in	patients	with	genetic	disorders	 such	as	HPS	and	CHS	(36)	and	 is	 in	keeping	with	a	global	effect	on	the	biogenesis	other	LROs	in	these	disorders	(see	2.5.2).	However,	the	contrast	within	the	image	is	often	variable	and	can	lead	to	difficulties	in	classification.	Other	EM	methods	such	as	serial	sectioning	TEM	or	EM	tomography	are	currently	too	impractical	to	perform	in	a	clinical	context	or	on	a	large	dataset	(25).			Figure	30	Dense	Granule	counting	in	a	test	sample		
		Images	 from	 Hayward	 et	 al.	 (162)	 A)	Whole	 mount	 EM	 image	 of	 a	 normal	 platelet	 that	 was	 given	 to	 participants	 to	estimate	 the	 numbers	 of	 dense	 granules	 contained	 in	 this	 platelet,	 estimates	 ranged	 from	 6-24	 dense	 granules.	 Bar	indicates	500	nm.	B)	Whole	mount	EM	image	of	a	normal	platelet	with	sequentially	numbered,	 labelled	structures	that	were	provided	to	participants	to	indicate	which	structures	they	would	count	as	dense	granules.	Structures	counted	(Y)	or	not	counted	(N)	and	the	level	of	consensus	(c,	complete;	g,	good	or	86%;	m,	moderate	or	57%–71%)	are	indicated.	White	arrows	 highlight	 an	 example	 of	 two	 similar	 structures;	 46	 is	moderately	 declared	 not	 a	 dense	 granule,	whereas	 47	 is	confidently	determined	a	dense	granule	and	highlights	the	difficulty	in	defining	dense	granules	by	this	method.	Scale	bar	in	A	500	nm,	Scale	bar	in	B	200	nm.		An	example	of	the	variability	seen	in	whole	mount	EM	dense	granule	counting	is	discussed	 by	 Hayward	 et	 al.	 (162)	 where	 a	 number	 of	 sites	 across	 the	 North	American	Specialised	Coagulation	Laboratory	Association	were	asked	to	evaluate	the	 number	 of	 dense	 granules	 in	 one	 image	 of	 one	 platelet	 (Figure	 30).	 The	number	of	dense	granules	reported	ranged	from	15	to	24	for	experienced	sites	and	one	 ‘inexperienced	site’	counted	only	6	 (162).	 It	must	be	stressed	that	 this	variability	was	observed	from	counting	a	single	image.	It	was	discovered	during	the	work	in	this	thesis	that	different	grids	and	even	different	areas	of	the	same	grid	 can	 potentially	 provide	 images	 with	 differing	 contrast	 (data	 not	 shown).	Adding	to	this	is	the	heterogeneity	in	the	number	of	dense	granules	per	platelet	in	 the	population,	 the	 variability	when	using	different	TEMs	 to	 image	platelets	
A B
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and	 the	 inevitable	 variation	 in	 the	 sample	 preparation	 at	 different	 sites,	 this	means	that	a	standardised	methodology	is	almost	impossible	without	centralised	facilities.	 Therefore,	 new	 techniques	 are	 highly	 desirable	 for	 counting	 dense	granules	if	conclusions	about	genetic	disorders	such	as	HPS	are	to	be	effectively	drawn	 in	 a	 clinical	 context.	 To	 further	 complicate	 the	 diagnosis	 of	 these	disorders	the	equipment	and	specialised	techniques	required	for	these	analyses	are	not	available	in	most	hospitals,	requiring	patients	with	platelet	disorders	to	travel	 long	 distances	 to	 a	 specialised	 centre,	 leading	 to	 these	 centres	 being	oversubscribed	and	ultimately	results	in	patients	receiving	limited	care.	The	first	aim	 is	 to	 speed	up	 and	provide	 a	more	 efficient	 and	 accurate	diagnosis,	which	will	also	in	turn	improve	our	understanding	of	PSDs	and	LROs.		As	discussed	above,	alpha	and	dense	granules	have	historically	been	defined	by	their	appearance	in	EM,	however,	there	is	no	current	method	for	easily	analysing	both	granules	in	one	sample	that	does	not	require	EM	methodology	which	would	not	be	appropriate	 in	a	clinical	context.	Given	 the	difficulty	 in	 identifying	 these	granules	 in	 their	 corresponding	 standard	 EM	 approaches,	 new	 techniques	 for	defining	and	analysing	these	populations	of	both	granules	are	needed.	Platelets	are	 2	 to	 5	 μm	 in	 diameter;	 their	 dense	 granules	 are	 around	150	nm	 and	 their	alpha	granules	200-400	nm	(226).	While	confocal	microscopy	 typically	offers	a	lateral	 spatial	 resolution	 of	 250	 to	 300	 nm,	 the	 new	 SRM	methods	 (154,	 227,	
228),	 use	 a	 variety	of	different	 strategies	 to	overcome	 the	diffraction	 limit	 and	can	 resolve	 structures	 in	 the	 10-200	 nm	 range.	 It	was	 hypothesised	 that	 their	ability	 to	resolve	small	objects	would	allow	them	to	 identify	 individual	platelet	granules	 and	 that	 this	 could	 prove	 a	 useful	 technique	 with	 which	 to	 study	platelet	 granule	 morphology	 with	 a	 further	 aim	 of	 applying	 these	 methods	 to	diagnose	 PSDs,	 such	 as	 GPS	 and	HPS.	Markers	 for	 alpha	 (vWF,	 P-Selectin)	 and	dense	 (serotonin,	 CD63)	 granules	 could	 be	 analysed	 without	 the	 need	 for	laborious	 EM	 techniques	 that	 relied	 upon	 subjective	 criteria	 for	 categorising	granules.	It	was	hypothesised	that	it	would	be	advantageous	therefore,	to	focus	on	the	shared	content	between	populations	of	granules	as	oppose	to	focusing	on	the	identification	of	the	granules	themselves.	Indeed,	a	reduction	in	the	number	of	CD63	positive	granules	in	HPS	patients	has	been	suggested	(35)	and	similarly	
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vWF	 in	 GPS	 (91).	 However,	 these	 observations	 have	 relied	 upon	 subjective	counting	techniques	and	imaging	methodology	that	cannot	fully	resolve	a	single	granule.	 There	 are	 therefore,	 three	 main	 requirements	 for	 a	 new	 diagnostic	technique;	1)	A	simple,	robust	protocol	where	samples	can	be	taken	easily	at	a	local	hospital	and	transported	to	a	central	facility	for	analysis	and	re-analysis	if	required	 2)	 An	 imaging	 technique	 that	 has	 sufficient	 resolution	 to	 effectively	image	small	objects	such	as	platelet	granules.	3)	A	method	that	is	integrated	with	an	unbiased	analysis	that	can	give	clinicians	clear	quantitative	data	to	diagnose	a	disorder.				To	achieve	these	aims	an	SRM	imaging	approach	was	undertaken	that	would	be	analysed	 using	 an	 automated	 morphometric	 analytical	 workflow	 redesigned	from	similar	methods	applied	by	the	Cutler	 lab	to	analyse	WPBs	(63,	163).	The	aim	was	to	introduce	a	non-biased,	reliable	method	of	assessing	the	numbers	of	organelles	 found	 in	 a	 sample	 of	 platelets,	 without	 the	 need	 to	 perform	 any	laborious	and/or	subjective	techniques.		
6.2 Results		To	validate	our	findings	using	new	SRM	immunofluorescence	techniques	it	was	important	 first,	 despite	 their	 limitations,	 to	 establish	 comparator	 protocols	 to	analyse	 the	platelet	granules	by	 the	classical	EM	techniques.	To	visualise	alpha	granules,	 platelets	 were	 fixed,	 dehydrated	 and	 embedded	 in	 epon	 before	sectioning	(see	4.4.1)	whereas	to	be	able	visualise/count	dense	granules	the	gold	standard	whole	mount	EM	approach	(see	4.4.2)	was	employed.	It	was	important	to	 set	 strict	 criteria	 for	 counting	 dense	 granules	 as	 seen	 in	 EM.	 This	 was	particularly	important	given	the	variability	in	analysis	observed	in	the	literature	(162).		 	
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6.2.1 Imaging	platelet	alpha	granules	by	TEM		Figure	31	Thin	Section	TEM	image	of	a	Control	Platelet	
		Thin	 section	of	platelet	 observed	by	TEM	after	 fixation,	 dehydration	and	embedding	 in	 epon	 (see	4.4.1)	White	 arrows	mark	the	platelet	alpha	granules,	other	alpha	granule-like	structures	are	marked	by	grey	arrows,	although	it	is	difficult	to	be	completely	sure	of	the	classification.	In	this	thin	section	no	dense	granules	could	be	identified.	Scale	bar	500	nm		First	 platelets	 were	 prepared	 for	 TEM	 (Figure	 31).	 Thin	 sections	 of	 Platelets	(TEM)	 have	 contributed	 much	 to	 the	 present	 understanding	 of	 both	 platelet	ultrastructure	 and	 have	 also	 been	 used	 to	 characterise	 disorders	 such	 as	 GPS,	where	 patients’	 platelets	 display	 a	 reduction	 in	 alpha	 granules	 (88,	 229).	Although	the	 identification	of	alpha	granules	by	thin	section	TEM	images	relies	on	 the	 subjective	 identification	 of	 what	 is	 an	 alpha	 granule	 in	 a	 given	 image	(Figure	 31),	 we	 established	 a	method	 for	 imaging	 alpha	 granules	 in	 a	 platelet	sample	 to	 use	 as	 a	 comparator	 for	 new	 methods	 using	 immunofluorescent	staining	of	alpha	granules	imaged	by	SRM.		 	
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6.2.2 Imaging	platelet	dense	granules	by	Whole	mount	EM		Figure	32	Whole	mount	EM	of	platelets	
	Three	 typical	 examples	 of	 control	 platelets	 imaged	 by	Whole	mount	 EM.	 Scale	 bars	 500	 nm.	 An	 inherent	 variation	 in	granules	morphology,	contrast	and	size	can	be	seen.	Platelet	granules	are	often	difficult	to	define	over	similar	structures	in	 the	platelet	 (left	 panel),	 can	be	 small	 (middle	 panel)	 and	 in	 some	 cases	 are	 difficult	 to	 resolve	 due	 to	 high	 internal	contrast	in	the	platelet	(right	panel)		Whole	 mount	 EM	 imaging	 of	 platelet	 granules	 is	 still	 considered	 mainly	 a	research	 tool	 and	 has	 not	 been	 thoroughly	 validated	 and	 standardised	 as	 a	clinical	 test.	 However,	 despite	 this,	 it	 is	 still	 considered	 the	 gold	 standard	 for	counting	 the	number	of	dense	granules	 in	platelets	 (230).	 In	 initial	attempts	 to	perform	 this	 technique	we	 found	 that	 very	 few	platelets	were	 attaching	 to	 the	grid	 and	 this	 made	 the	 acquisition	 of	 quantitative	 data	 time-consuming	 and	impractical.	A	 large	 improvement	 in	 this	was	 seen	when	 centrifuging	platelets,	without	fixation,	onto	formvar	coated	copper	grids	(see	4.4.2);	three	examples	of	platelets	prepared	in	this	way	are	shown	(Figure	32).	As	discussed	(see	4.4.2	for	whole	mount	EM	dense	granule	counting	criteria),	consistency	in	the	counting	of	dense	granules	has	a	number	of	challenges.	Despite	this,	we	established	a	strict	protocol	 for	 counting	 granules	 that	 improved	 reliability	 and	proved	 a	 valuable	comparator	 for	 new	 methods	 using	 immunofluorescent	 staining	 of	 dense	granules	imaged	by	SRM.		6.2.3 Imaging	platelet	alpha	granules	by	dSTORM		For	 the	purpose	of	applying	SRM	to	 image	platelet	granules	we	began	with	 the	methodology	 delivering	 the	 best	 resolution;	 localisation	microscopy.	 A	 type	 of	localisation	 microscopy	 (dSTORM)	 was	 the	 first	 technique	 used	 (see	 2.7.2.1).		Platelets	 were	 prepared	 and	 stained	 for	 vWF	 (a	 marker	 of	 alpha	 granules),	
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images	 were	 then	 acquired	 using	 both	 a	 widefield	 microscopy	 technique	 and	dSTORM	for	comparison	(Figure	33).		Figure	33	dSTORM	image	of	platelet	immunolabelled	with	vWF	
		Widefield	(A),	dSTORM	reconstructed	image	(B),	dSTORM	reconstructed	–	contrast	enhanced	and	lookup	table	changed	to	red	hot	(C).		The	improvement	in	resolution	and	the	signal	to	noise	is	immediately	apparent.		A	typical	resolution	of	20-25	nm	was	achieved	according	to	Rees	et	al.	methodology	to	estimate	SRM	resolution	(159)	Scale	Bar	1	μm.		The	improvement	in	resolution	and	the	signal	to	noise	is	immediately	apparent	when	 platelets	 are	 labelled	 with	 vWF	 and	 imaged	 by	 dSTORM	 imaging	techniques	(Figure	33)	compared	to	widefield	images.	 	
	 95	
Figure	34	dSTORM	imaging	of	vWF	in	platelets	
			Representative	dSTORM	images	of	vWF	in	control	platlelets.	A	typical	resolution	of	20-25	nm	was	achieved	according	to	Rees	et	al.	methodology	to	estimate	SRM	resolution	(159).	Scale	bars	500	nm.		Despite	a	considerable	improvement	in	the	resolution	achieved,	there	were	two	main	problems	with	the	initial	attempts	at	imaging	platelets	by	dSTORM.	Firstly,	the	 fluorescent	 signal	 appeared	 to	 be	 dispersed	 and	 a	 kind	 of	 connectivity	between	 the	 large	 concentrations	 that	we	 assumed	 represented	 platelet	 alpha	granules	within	 the	platelets	was	visible;	not	 simply	 contained	within	granule-like	structures	as	expected.	It	was	noted	that	dSTORM	data	can	often	be	difficult	to	 interpret	 as	 labelling	density,	 the	algorithm	selected	and	 the	brightness	and	density	of	blinking	events	can	change	the	appearance	of	the	final	image	and	have	implications	for	image	interpretation	and	analysis	(157).	Also	without	any	other	examples	 of	 localisation	 microscopy	 techniques	 used	 in	 this	 context	 it	 was	difficult	 to	 confirm	 our	 observations.	 Secondly,	 only	 one	 colour	 imaging	 was	available	on	this	system	at	this	time,	with	no	labelling	to	demarcate	the	edge	of	the	platelet,	it	was	difficult	to	predict	whether	vWF	signal	was	from	the	platelet	
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identified,	 from	non-specific	 labelling	on	 the	coverslip	or	 from	another	platelet	nearby.	Following	these	results,	the	dSTORM	system	used	was	updated	and	two-colour	 imaging	 is	 now	 available.	 Therefore,	 an	 antibody	 against	 β-tubulin	(referred	to	here	as	tubulin)	was	used,	as	had	been	in	the	literature	(231),	 	as	a	label	 for	 the	 perimeter	 of	 platelets	 and	 a	 widefield	 image	 taken	 to	 locate	individual	platelets.	 	Figure	35	dSTORM	imaging	of	vWF	and	tubulin	in	platelets	
		Widefield	Tubulin	(A)	allowed	identification	of	the	location	of	platelet	vWF	(B).	Scale	bars	2	μm.		
6.2.4 STORM	imaging	of	platelets	from	patients	with	GPS		Although	 our	 SRM	 method	 was	 still	 in	 development,	 in	 order	 to	 see	 if	 this	method	could	work	we	needed	to	test	it	on	patients	with	a	known	PSD.	Samples	were	obtained	 from	patients	with	GPS,	although	this	 is	only	a	preliminary	data	set	 (2	 patients	 and	 2	 controls),	 it	was	 used	 to	 test	 our	 hypothesis	 that	 a	 SRM	methodology	could	be	used	to	detect	differences	between	a	LRO-related	genetic	disorder	(in	this	case	GPS)	and	controls.			There	have	only	been	around	60	cases	of	GPS	reported	worldwide	and	through	collaboration	with	Dr.	Keith	Gomez	 (Royal	Free	Hospital),	 I	 analysed	 the	blood	from	 two	patients	with	GPS.	These	 two	patients	would	 typically	visit	 the	 clinic	once	 a	 year	 (conversation	 with	 Keith	 Gomez)	 and	 were	 brother	 and	 sister,	presenting	 with	 a	 mild	 thrombocytopenia	 and	 mild	 bleeding	 symptoms,	 their	
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father	had	been	diagnosed	with	 leukaemia	which	 is	what	 led	 to	 them	 to	being	screened,	implying	that	he	may	also	have	had	GPS.			We	first	processed	the	patient	samples	for	TEM.	Thin	section	TEM	images	of	the	patient’s	platelets	compared	with	two	controls	(Figure	36)	confirm	the	absence	of	 alpha	 granules	 from	 both	 patient’s	 platelets	 and	 suggest	 a	 disorganised	canalicular	 membrane	 system.	 We	 next	 prepared	 samples	 to	 image	 with	dSTORM	(Figure	37)	and	stained	for	two	markers	of	alpha	granules,	vWF	and	P-selectin.
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Figure	36	TEM	of	Control	and	GPS	platelets		
		TEM	thin	sections	of	control	(A)	and	two	GPS	patient’s	(B,C)	platelets	were	prepared	(as	in	4.4.1)	Granules	assumed	to	be	alpha	granules	can	be	seen	in	the	control	and	absent	from	the	GPS	patients	(white	arrows).	Scale	bars	500	nm.		Figure	37	GPS	patient	platelets	–	dSTORM	labelled	with	vWF	and	P-Selectin	
		Representative	dSTORM	images	from	control	(A,C)	and	GPS	patient	(B,D),	immunolabelled	for	vWF	(A,B)	and	P-Selectin	(C,D).	Scale	bars	500	nm.		
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When	analysed	by	dSTORM	the	antibodies	targeted	to	vWF	and	P-Selectin	were	more	diffuse	in	GPS	patient	platelets	compared	to	controls	(Figure	37).	However,	as	 discussed,	 the	 dSTORM	 technique	 and	 preparation	 methods	 limited	 the	number	of	platelet	 images	 that	were	 taken	due	 to	 the	 time	taken	to	acquire	an	image.	 To	 gain	 sufficient	 quantitative	 results	 more	 data	 was	 needed.	 These	images,	however,	provided	a	first	proof	of	principle	that	an	SRM	technique	would	be	 capable	 of	 distinguishing	 between	 controls	 and	 patients	with	 a	 PSD	 that	 is	characterised	 by	 a	 lack	 of	 granules	 (such	 as	 alpha	 granules	 in	 GPS);	 it	 also	provided	the	first	indication	that	the	content	of	these	granules	may	not	be	absent	but	diffuse/mislocalised	within	the	platelet.		Because	of	the	odd	distribution	of	vWF,	showing	what	appears	to	be	connectivity	between	 what	 we	 assumed	 to	 be	 the	 granules,	 we	 wondered	 whether	 this	phenomenon	was	associated	with	alpha	granules	only,	and	whether	 this	would	also	could	be	seen	with	a	membrane	protein	marker	of	another	LRO,	the	dense	granule.	 Therefore,	 the	 potential	 of	 using	 immunofluorescence	 of	 a	 known	marker	 of	 dense	 granules,	 CD63,	 was	 explored.	 CD63	 is	 an	 itinerant	 integral	membrane	 protein	 that	 traffics	 between	 post-Golgi	 organelles	 and	 has	 been	found	to	be	present	on	many	secretory	granules,	endosomes	and	 lysosomes,	as	well	as	LROs	(82).	Importantly,	it	has	not	only	been	shown	to	be	present	in	dense	granules	but	also	has	been	 reported	 to	have	 fewer	CD63	positive	 structures	 in	HPS	 patients	 (35,	 232),	 a	 disorder	 characterised	 by	 a	 lack	 of	 dense	 granules.	Given	 the	 diffuse	 staining	 observed	 in	 dSTORM	 images	 of	 vWF	 and	 with	 P-Selectin	(Figure	32	and	33)	a	new	SRM	technique	was	employed,	SIM.	As	platelet	granules	 do	not	 require	 the	 resolution	 achieved	 in	 dSTORM	 (around	25	nm	 in	these	 images),	SIM	(which	can	achieve	a	resolution	around	100	nm)	could	be	a	suitable	technique.	Furthermore,	the	images	generated	from	SIM	are	not	a	result	of	 post-processing	 localisation	 steps,	 therefore	 limiting	 the	 generation	 of	potential	artefacts	and	can	produce	images	in	a	small	fraction	of	the	time	taken	to	image	by	dSTORM.		
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6.2.5 Imaging	CD63	in	platelets	by	SIM		Figure	38	Imaging	CD63	in	platelets	by	SIM	
	(A)	Platelets	were	 imaged	by	SIM	 (cut-away	bottom	right)	with	 a	diffraction-limited	widefield	microscopy	 image	 (cut-away	upper	left)	shown	for	comparison.	The	images	show	the	platelet	perimeter	(marginal	band)	labelled	(red)	with	anti-tubulin	and	 the	 internal	 structures	 (green),	 largely	dense	granules,	 labelled	with	anti-CD63	(B)	The	 improved	contrast	and	resolution	in	the	SIM	image	(right)	 is	clearly	apparent	from	a	600	nm	line	profile	(lower	panel)	taken	through	two	closely	adjacent	structures.	Scale	bar:	1	μm				The	 improved	 spatial	 resolution	 and	 removal	 of	 out	 of	 focus	 background	obtained	 by	 SIM	 is	 clearly	 apparent	 when	 compared	 to	 widefield	 microscopy	(Figure	 38).	 Platelets	 imaged	 using	 SIM	 and	 stained	 for	 tubulin	 and	 CD63	allowed	 us	 to	 clearly	 visualise	 granule-like	 structures	 within	 platelets	 (Figure	38).	The	resolution	achieved	with	SIM	meant	individual	granules	could	be	clearly	delineated.	 As	 such,	 we	 sought	 to	 develop	 an	 image-processing	 pipeline	 to	segment	CD63	positive-granules	and	platelets	in	SIM	images.			Using	a	segmentation	workflow	established	in	collaboration	with	William	Grimes	(164)	 platelets	 were	 identified	 by	 their	 tubulin	 labelled	 structures	 and	 CD63	positive	 structures	 segmented.	Examples	of	 the	outcome	of	 these	 steps	 (Figure	39,	Figure	40)	are	shown	below	(see	also	(164).	
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Figure	39	Platelet	tubulin	segmentation	
		SIM	 image	 of	 tubulin	 labelled	 platelets	 (A)	 and	 image	 output	 with	 segmentation	 contours	 (B)	 that	 demonstrates	 the	success	of	the	segmentation	protocol	employed.	Scale	bars	1	μm.		Figure	40	Platelet	CD63	segmentation	
	The	major	 sequence	 of	 processes	 involved	 in	 segmentation	 of	 CD63-positive	 granules.	 A	 raw	CD63	 channel	 image	 (A)	after	moment-preserving	thresholding	applied	in	ImageJ	(B).	A	watershed	transform	was	used	to	distinguish	overlapping	structures	(C).	Segmentation	contours	applied	over	the	original	raw	CD63	image	(D),	yellow	magnified	regions	are	used	to	 demonstrate	 the	 accuracy	 of	 the	 segmentation.	 	 Segmentation	 protocol	 developed	 in	 collaboration	 with	 William	Grimes,	images	from	(164).	Scale	Bars	1.5	μm.		
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Once	 a	 protocol	 was	 established	 for	 identifying	 individual	 platelets	 and	segmenting	 the	 CD63	 positive	 granule	 content,	 an	 automated	 workflow	 was	established	 (Figure	 41)	 this	 allowed	 a	 bank	 of	 images	 of	 CD63	 and	 tubulin	labelled	 platelets	 to	 be	 rapidly	 analysed	 using	 an	 automated	 workflow	 that	would	 automatically	 produce	 data	 regarding	 the	 number	 of	 CD63	 positive	structures	per	platelet.			Figure	41	SIM	Segmentation	workflow	
	SIM	images	were	analysed	as	follows;	platelets	were	segmented	using	the	image	of	the	tubulin	and	corresponding	CD63	image	(A)	and	then	filled	(B).	Platelets	were	distinguished	from	debris	by	their	area	and	circularity.	Granules	within	the	filled	area	(B)	were	segmented	according	to	a	threshold	value	obtained	from	Moment-preserving	thresholding	(C).	The	platelet	 in	which	 each	 CD63	 granule	 is	 located	was	 recorded	 (D)	 and	morphometric	 features	 (including	 area)	 of	 each	granule	were	measured.	Scale	bars:	1	μm.		Dense	 granules	 were	 identified	 by	 the	 presence	 of	 CD63	 (35).	 As	 it	 has	 been	reported	that	CD63	is	present	on	dense	granules,	alpha	granules	and	lysosomes	(25,	35),	attempts	were	made	to	localise	CD63	to	dense	granules	by	a	correlative	light	and	EM	approach.	Initially,	it	would	have	been	attractive	to	simply	compare	CD63	immunofluorescent	labelling,	which	relies	on	fixing	and	permeabilising	the	cells,	 directly	 with	 dense	 granules	 as	 visualised	 by	 the	 whole	 mount	 EM	technique.	 However,	 a	 different	 approach	 was	 needed	 as	 dense	 granules	 as	observed	by	whole	mount	EM	were	found	to	lose	contrast	after	fixation	(Figure	42).		 	
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Figure	42	Fixed	Platelets	imaged	by	Whole	mount	EM		
	A	 representative	 image	 (n=10)	 to	 demonstrate	 that	 dense	 granules	 could	 not	 be	 identified	 by	whole	mount	 EM	 after	fixation	with	4%	PFA	for	15	minutes	and	centrifuged	onto	formvar	coated	copper	EM	grids.	Scale	bar	2	μm		A	live-stain	of	dense	granules,	Mepacrine,	was	trialled	as	a	potential	comparator	as	 it	 has	 been	 characterised	 as	 a	 label	 of	 dense	 granules	when	 compared	with	whole	mount	EM	detection	of	dense	granules	(216).	 	
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Figure	43	Mepacrine	labelling	of	platelets	
	Mepacrine	(green)	labelled	platelets	(middle	panel	A,	B)	imaged	within	1	hour	(A)	and	24	hours	(B)	of	15	minutes	fixation	with	4%	PFA,	images	taken	by	fluorescent	confocal	microscopy	and	localization	confirmed	with	transmission	light	images	(left	panel,	A,B).	Mepacrine	labelled	platelets	(left	Panel,	C)	colocalised	with	CD63	(middle	panel,	C)	and	combined	image	with	 transmission	 light	 (right	 panel,	 C)	 demonstrate	 that	 CD63	 is	 labelling	 more	 structures	 within	 the	 platelet	 than	mepacrine	that	has	been	labelled	and	imaged	within	24	hours	of	fixation	with	4%	PFA.	Scale	Bars	10	um	(Panels	A	and	B	scale	bars	10	um,	Panel	C	scale	bars	2	μm)		Despite	 the	widespread	use	of	mepacrine	 in	 the	 literature,	 during	 this	 study	 it	was	found	that	fluorescent	labelling	rapidly	bleaches	and	granules	pop	if	looked	at	 under	 the	 confocal	 microscope	 for	 more	 than	 around	 10	 seconds,	 and	heterogeneous	staining	was	also	observed	across	the	slide	and	between	samples	(data	not	shown).		The	mepacrine	labelled	fluorescence	was	also	degraded	after	fixation	 (Figure	 43A	 and	 B)	 and	 even	 though	 correlative	 images	 of	 CD63	 and	mepacrine	labelled	platelets	were	attempted	(Figure	43C),	the	irregularity	of	the	staining	and	the	decay	after	fixation	rendered	this	approach	unusable.		
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As	an	alternative	to	characterise	CD63	localisation	a	comparison	between	CD63	and	 other	 known	 granule	 markers	 by	 confocal	 microscopy	 was	 performed,	 to	observe	 if	 there	 was	 any	 significant	 co-clustering	 between	 common	 granule	markers	 reported	 in	 the	 literature.	 For	 this	 purpose	 the	 following	 antibodies	were	 chosen;	 serotonin	 a	 marker	 of	 content	 in	 dense	 granules	 (233),	 vWF	 a	marker	of	alpha	granules	(40)		and	P-Selectin	which	is	found	on	the	membranes	of	both	alpha	and	dense	granules	(217).		Figure	44	Immunofluorescent	colocalisation	of	CD63	in	Platelets	
	Representative	images	of	platelet	CD63	(A,B,C	red)	colocalisation	imaged	by	confocal	microscopy	with	vWF	to	mark	alpha	granules	 (A,	Green),	P-Selectin	 to	mark	alpha	and	dense	granules	 (B,	Green)	and	Serotonin	 to	mark	dense	granules	 (C	Green).	Scale	Bars	2	μm		Table	14	Colocalisation	of	CD63	with	other	platelet	granule	markers		 %	colocalisation	with	CD63	 %	colocalisation	of	CD63	with	vWF	 23%	 7%	P-Selectin	 60%	 43%	Serotonin	 39%	 17%		The	colocalisation	of	CD63	with	a	reported	marker	of	alpha	granules	(vWF),	dense	granules	(Serotonin)	and	both	alpha	and	dense	 granules	 (P-Selectin)	was	 explored.	Using	 ‘Imaris	 Coloc’,	 automatic	 thresholds	were	 set	 and	 the	percentage	colocalisation	of	three	given	markers	(vWF,	P-Selectin	and	Serotonin)	was	measured.		There	was	a	weak	positive	correlation	with	vWF	(Pearson's	coefficient	in	dataset	volume;	0.22),	moderate	with	Serotonin	(Pearson’s	coefficient	in	dataset	volume;	0.54)	 and	 a	 strong	 correlation	with	 P-Selectin	 (Pearson’s	 coefficient	 in	 dataset	volume;	0.72),	 correlation	 conclusions	determined	as	 in	Dunn	et	 al.	 (234).	This	may	be	explained	by	the	fact	that	both	CD63	and	P-Selectin	have	been	reported	to	be	found	on	the	membranes	of	alpha	and	dense	granules	(30,	217).	CD63	has	historically	 been	 described	 as	 a	 dense	 granule	 marker	 (35),	 and	 a	 stronger	
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correlation	with	the	dense	granule	marker	serotonin	was	observed	than	with	the	alpha	 granule	 marker	 vWF.	 Since	 there	 was	 clearly	 some	 co-clustering	 with	markers	of	both	alpha	and	dense	granule	markers	 it	was	concluded	that	 it	was	not	possible	 to	 locate	CD63	 to	a	 specific	granule.	However,	 it	 is	 likely	 that	 it	 is	most	 similar	 to	 the	 distribution	 of	 P-selectin	 from	 the	 markers	 selected.	 This	reaffirmed	 the	 belief	 that	 the	 focus	 on	 associating	 our	 analysis	 with	 which	granule	 an	 antibody	 is	 labelling	 should	 be	 abandoned,	 and	 instead	 the	distribution	 and	 number	 of	 granules	 relating	 to	 a	 given	marker,	 regardless	 of	which	 granules	 they	 were,	 was	 a	 more	 attractive	 and	 pragmatic	 method	 to	characterise	a	PSD	in	this	context.		
6.2.6 Imaging	CD63	in	patients	with	HPS		The	 next	 aim	 was	 to	 use	 the	 segmentation	 protocol	 to	 image	 samples	 from	patients	with	PSDs.	To	achieve	the	aim	of	diagnosing	a	PSD,	SIM	was	chosen	for	its	 simplicity	 of	 sample	 preparation,	 compatibility	 with	 routinely	 used	fluorescent	labels	and	fast	image	acquisition	rates.	Platelet	samples	prepared	by	a	simple	robust	protocol	(see	4.1.2	for	methods)	were	imaged	on	a	custom-built	SIM	and,	 in	parallel,	by	whole	mount	EM	to	provide	a	gold-standard	diagnostic	image-set	for	comparison.			Fixed	 platelets	were	 centrifuged	 onto	 Poly-L-lysine	 coverslips	 to	 create	 a	 high	density	 of	 platelets	 to	 analyse,	 since	 this	 dramatically	 reduces	 imaging	 time.	Platelets	were	co-stained	as	before,	using	tubulin	to	demarcate	the	perimeter	of	individual	 platelets,	 within	 which	 segmented	 CD63-positive	 structures	“granules”	were	individually	located		(Figure	43).	This	allowed	the	calculation	of	the	 number	 of	 granules	 per	 platelet,	 thus	 giving	 a	more	 sensitive	 readout	 and	allowed	populations	of	individual	platelets	and	content	to	be	analysed.			Samples	of	platelets	taken	from	three	patients	with	HPS	and	from	seven	healthy	volunteers	 were	 used	 to	 test	 the	 ability	 of	 SIM	 to	 differentiate	 between	 these	groups.	The	three	patients	with	HPS	had	a	similar	clinical	phenotype,	as	all	were	
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recorded	 as	 having	 oculocutaneous	 albinism	 from	 birth	 and	 a	 history	 of	excessive	bleeding	after	trauma.	Patient	1	presented	with	pulmonary	fibrosis	but	patients	2	 and	3	did	not.	Platelet	 function	assays	performed	by	 the	Royal	Free	Hospital	showed	similar	results	between	the	patients	in	all	three	cases	(data	not	shown)	with	reduced	aggregometry	to	a	standard	panel	of	agonists	and	very	low	levels	of	platelet	ADP	documented	by	bioluminescent	assay	of	nucleotide	content	in	lysed	platelets.	A	genetic	analysis	was	performed	by	exome	sequencing	on	the	ThromboGenomics	platform	(more	 information	see	4.8.1)	 that	 includes	HPS1-9	and	 revealed	 that	 Patient	 1	 had	 compound	 heterozygosity	 for	 two	 single	nucleotide	 deletions	 resulting	 in	 frameshifts	 and	 introducing	 premature	 stop	codons	 in	 the	 HPS1	 gene	 (member	 of	 the	 BLOC-3	 complex).	 Patient	 2	 had	compound	 heterozygosity	 for	 two	 single	 nucleotide	 duplications	 resulting	 in	frameshifts	and	 introducing	premature	stop	codons	 in	 the	HPS6	gene	(member	of	 the	 BLOC-2	 complex).	 Patient	 3	 had	 homozygosity	 for	 a	 single	 nucleotide	change	 introducing	 premature	 stop	 codons	 in	 the	HPS5	 gene	 (member	 of	 the	BLOC-2	complex),	the	controls	were	healthy	volunteers.			Figure	45	Whole	mount	EM	of	Platelets	
Analysis	of	dense	granules	by	whole	mount	EM	may	be	regarded	as	the	“gold	standard”	for	determining	numbers	of	these	organelles	per	platelet.	Examples	of	single	platelets	from	one	of	the	7	healthy	volunteers	(A)	and	from	each	HPS	Patient	1,	2	and	3	(B,C,D)	used	in	this	study	are	shown.	Note	the	lack	of	dense	granules	(black	spots)	seen	in	the	HPS	patients.	The	criteria	for	counting	dense	granules	are	described	(see	4.4.2).	Scale	bars:	1	µm.		To	 compare	 with	 the	 current	 gold-standard	 technique,	 patient	 and	 control	samples	were	processed	for	whole	mount	EM	(Figure	45).	A	criteria	was	chosen	to	count	dense	granules	(see	4.4.2)	to	reduce	as	much	as	possible	the	subjectivity	in	 counting,	 the	 platelet	 images	 were	 taken	 by	 Jemima	 Burden	 (Head	 of	 EM	facility	 LMCB)	 and	 the	 images	 randomised.	 Following	 this	 1008	platelets	were	counted	 blindly	 by	 one	 person	 to	 remove	 any	 variation	 between	 analysts;	 a	significant	difference	(99%	confidence)	was	observed	as	very	few	of	the	patient	
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platelets	had	any	dense	granules	when	employing	a	strict	methodology	(Figure	46A).			An	 empirical	 cumulative	 distribution	 function	 (ECDF)	 plot	 (Figure	 46B)	 of	 the	number	 of	 dense	 granules	 per	 platelet	 demonstrates	 the	 clear	 distinction	between	 the	 control	 and	 HPS	 patient	 populations.	 A	 Kruskal-Wallis	 (non-parametric)	test	was	employed	to	compare	the	results	from	the	two	groups	(due	to	 the	Poisson-like	distribution	of	 the	dense	granule	 counts),	was	used	 (Figure	46C).	 A	 significant	 difference	 was	 observed	 between	 the	 patient	 and	 control	groups	 (99%	 confidence)	 and	 between	 each	 of	 the	 patients	 and	 all	 of	 the	controls.			Figure	46	Whole	mount	EM	analysis
	Dense	 granules	were	manually	 counted	 in	 1008	platelets	 from	 randomised	EM	 images	 of	 samples	 from	 seven	healthy	volunteers	and	three	patients	with	HPS.	There	is	a	significant	difference	(99%	confidence)	between	the	mean	number	of	dense	 granules	 per	 platelet	 between	 the	 seven	 controls	 and	 the	 three	 patients	 with	 HPS	 (A),	 when	 a	 strict	 counting	protocol	was	employed	(errors	bars	represent	standard	error	of	the	mean).	A	cumulative	frequency	graph	(B)	reveals	the	spread	of	the	data.	A	Kruskal	Wallis	Multiple	Comparison	Test	(C)	was	used	as	the	data	had	a	Poisson-like	distribution	and	 thus	a	non-parametric	 test	was	needed.	The	mean	rank	of	 the	 three	HPS	patients	was	significantly	different	 (99%	confidence)	from	all	of	the	controls.	Figure	from	(235)		Having	 established	 that	 the	 three	HPS	patients	 lack	 dense	 granules	 as	 seen	by	EM,	 the	 same	blood	 samples	were	 analysed	by	 SRM,	 co-labelling	 for	CD63	and	tubulin	 and	 counting	 the	number	of	 CD63-positive	 structures	by	 SIM,	using	 an	automatic	workflow	(4.5.2)	that	did	not	rely	on	subjective	counting	methods.	
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Figure	47	SIM	imaging	of	platelets	from	control	and	HPS	patients	
	Example	SIM	images	of	platelets	 from	one	of	 the	7	healthy	volunteers	(A)	and	from	each	HPS	Patient	1,2	and	3	(B,C,D)	used.	The	images	in	the	first	column	are	an	example	of	the	raw	SIM	data	as	analysed	(Figure	46),	images	in	the	second	and	third	 column	 have	 been	 similarly	 contrast	 enhanced	 for	 presentation.	 z-stacks	 are	 displayed	 as	 maximum	 intensity	projections	created	using	ImageJ.		Scale	bars:	4	μm	for	columns	1	and	2,	1.5	μm	for	column	3.	Dashed	boxes	in	column	2	highlight	the	area	of	the	image	displayed	in	column	3.	CD63	(Green),	Tubulin	(Red).Figure	from	(235)		
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Figure	48	Analysis	of	SIM	data	
	The	number	of	CD63	objects	per	platelet	was	counted	for	2812	platelets	across	7	controls	and	3	patients	with	HPS	after	segmentation.	(A)	A	significant	difference	(99%	confidence)	was	observed	between	the	mean	of	the	controls	and	the	HPS	patients	(error	bars	represent	standard	error	of	the	mean).	A	cumulative	frequency	graph	(B)	demonstrates	the	spread	of	the	 data.	 A	 Kruskal	Wallis	multiple	 comparison	 test	 (C)	was	 used	 and	 the	mean	 rank	 of	 the	 three	HPS	 patients	were	significantly	 different	 (99%	 confidence)	 from	 all	 of	 the	 controls.	 An	 example	 of	 a	 potential	 readout	 for	 clinical	 use	 is	displayed	(D)	in	which	the	data	is	displayed	as	the	percentage	of	platelets	containing	4	or	more	CD63	positive	structures.		The	mean	number	 of	 CD63-positive	 structures	 per	 platelet	 determined	by	 SIM	was	 6.8	 for	 controls,	 whereas	 for	 HPS	 patients	 it	 was	 2.4	 (Figure	 48).	 A	significant	difference	 (99%	confidence)	was	observed	between	 the	numbers	of	CD63	 positive	 structures	 present	 in	 the	 platelets	 from	 the	 HPS	 patients	compared	 to	 control	 (Figure	 48A).	 An	 ECDF	 plot	 (Figure	 48B)	 demonstrates	 a	clear	 distinction	 between	 the	 control	 and	 HPS	 patient	 populations.	 As	 a	 non-parametric	 test	 was	 required	 to	 analyse	 significance	 (due	 to	 a	 Poisson-	 like	distribution	of	the	CD63	data),	a	Kruskal-Wallis	multi	comparison	test	was	used	to	 compare	 the	 results	 (Figure	 48C)	 and	 a	 significant	 difference	 was	 seen	between	 the	 controls	 and	 the	 patient	 groups	 (99%	 confidence)	 and	 between	each	 of	 the	 patients	 and	 all	 of	 the	 controls,	 using	 a	 multiple	 comparison	 test	
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(99%	 confidence).	 To	 achieve	 a	 simplified	 readout	 that	 could	 be	 used	 as	 in	 a	clinical	context	to	rapidly	assess	the	likelihood	of	a	significant	reduction	in	CD63-positive	 structures,	 a	 threshold	 of	 4	 or	 more	 CD63-positive	 structures	 per	platelet	 was	 chosen	 and	 the	 proportion	 of	 platelets	 above	 this	 threshold	 was	plotted	 in	 a	 bar	 chart	 (Figure	 48D)	 this	 clearly	 demonstrates	 the	 differences	between	 all	 the	 patients	 in	 the	 studies,	 and	 crucially,	 the	 significant	 difference	between	controls	and	patients.			During	 the	SIM	 imaging	of	CD63	positive	structures	 in	platelets	 from	both	HPS	patients	and	controls,	an	accumulation	of	CD63	fluorescent	signal	was	observed	close	 to	 the	 tubulin	 ring.	 This	 was	 not	 caused	 by	 bleed-through	(fluorescence	from	a	neighbouring	channel	incorrectly	observed	in	the	image	of	the	 channel	 of	 interest),	 evidenced	 by	 the	 fact	 that	 the	 tubulin	 signal	 did	 not	always	 overlap	 with	 the	 CD63	 signal	 at	 the	 surface.	 Interestingly,	 this	phenomenon	 appeared	 only	 in	 the	HPS	 patient	 data.	 	 This	 phenomenon	 aligns	with	 other	 results	 observed	 in	HPS	 studies	where	BLOC-1	deficient	 fibroblasts	have	 been	 shown	 to	 present	 surface	 accumulation	 of	 CD63	 (114)	 and	 AP-3	deficiency		has	also	been	shown	to	result	in	the	increased	surface	expression	of	the	lysosomal	membrane	proteins	such	as	CD63	and	therefore,	this	observation	that	CD63	appeared	mislocalised	was	further	investigated.		Together	with	William	Grimes	(PhD	student	Cutler	Lab)	a	method	to	analyse	the	distribution	 of	 CD63	 in	 patient	 and	 control	 platelets	 was	 created.	 The	development	of	this	technique	did	not	require	additional	samples	to	be	collected	or	more	images	to	be	taken	as	the	images	used	to	count	CD63	positive	structures	could	be	re-analysed.	To	quantify	the	potential	CD63	mislocalisation	a	number	of	factors	 were	 taken	 into	 consideration.	 As	 platelets	 can	 vary	 in	 size,	 it	 was	important	that	the	distance	of	the	CD63	signal	measured	from	the	centre	of	each	platelet	was	relative	to	the	size	of	the	platelet	 it	was	found.	To	achieve	this	the	algorithm	was	designed	so	 that	each	platelet	was	 first	segregated	and	given	 its	own	identity,	the	centre	of	the	platelet	plotted,	a	proportional	length	from	centre	to	tubulin	ring	established	(0	to	1,	see	Figure	49)	and	any	pixels	that	displayed	immunofluorescent	 signal	 representing	CD63	were	plotted	 according	 to	where	
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this	signal	was	found	in	along	a	series	of	concentric	rings.	This	was	repeated	for	every	platelet	 in	 a	 set	 of	 images	 and	 the	data	displayed	 in	 a	 normalised	 radial	distance	plot	(Figure	50E,F).		Figure	49	Schematic	of	Radial	profile	algorithm.	
		A	SIM	image	of	a	Control	platelet	(left);	the	platelet	perimeter	(marginal	band)	was	labelled	(red)	with	anti-tubulin	and	the	internal	structures	(green),	largely	dense	granules,	labelled	with	anti-CD63.	The	centre	of	the	platelet	is	marked	as	0	and	the	tubulin	ring	as	1.	The	platelet	radius	is	defined	as	the	distance	from	the	centre	of	the	platelet	to	the	outer	ring,	where	the	outer	ring	is	the	maximum	integrated	intensity	ring	in	the	tubulin	channel.	The	integrated	intensity	values	are	normalised	 for	each	concentric	 ring	by	division	of	 the	maximum	integrated	 intensity	ring	of	 the	platelet.		Similarly,	 for	each	platelet,	radial	distances	are	normalised	by	division	of	the	platelet	radius.	Normalization	of	both	the	radial	distance	and	radial	integrated	intensity	allows	platelet	distributions	to	be	compared	independent	of	the	size	of	the	platelet	and	the	pixel	intensities.		 	
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	Figure	50	CD63	at	the	platelet	surface	in	HPS	platelets		
	A	 platelet	 from	 Control	 5	 (A)	 and	 one	 from	 each	 of	 the	 HPS	 patients	 (B,	 C,	 D)	 imaged	 using	 SIM.	 Platelet	 perimeter	(marginal	band)	labelled	(red)	with	anti-tubulin	in	column	1	and	the	internal	structures	(green),	largely	dense	granules,	labelled	with	anti-CD63	in	column	2.	All	CD63	images	contrast	enhanced	to	highlight	surface	staining.	E	represents	the	mean	values	of	the	controls	and	patients	from	F.	All	images	were	taken	with	identical	settings	for	laser	power,	exposure	time	and	background	out-of	focus	light	post-processing.	Scale	bars:	1	μm.	Figure	from	(235)		A	representative	platelet	is	shown	from	the	controls	(Figure	50A)	and	each	of	the	HPS	patients	(Figure	50B,C	and	D).	The	radial	profile	algorithm	analysis,	which	calculates	the	normalised	integrated	intensity	in	a	set	of	concentric	rings	(Figure	49),	 from	 the	 centre	 of	 each	 platelet	 (0	 on	 the	 x	 axis	 in	 Figure	 49e,f)	 to	 the	platelet	radius	(1	on	the	X	axis	in	Figure	50e,f),	highlighted	the	difference	in	the	location	of	CD63	in	the	HPS	patients.	Unlike	the	control,	 the	three	HPS	patients	have	an	accumulation	of	CD63	at	the	platelet	surface,	which	had	not	previously	been	 observed	 in	 platelets	 from	 HPS	 patients.	 This	 finding	 strengthens	 our	overall	conclusions	and	shows	how	a	simple	sample	preparation	imaged	by	SRM	can	provide	two	independent	fully	quantitative	measures	of	a	PSD	such	as	HPS.
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6.3 Discussion		The	relationship	between	and	roles	of	 the	different	LROs	and	 their	biogenesis-associated	complexes	are	still	to	be	fully	elucidated.	This	chapter	focussed	on	the	identification	of	LROs	using	different	microscopy	techniques	with	the	aim	of	not	only	developing	new	techniques	with	which	to	study	these	organelles,	but	also	to	improve	diagnosis	 in	LRO	related	disorders.	A	new	approach	to	define,	 identify	and	 diagnose	 disorders	 that	 are	 related	 to	 both	 alpha	 and	 dense	 granules	 is	required.	 In	 HPS,	 whilst	 it	 is	 well	 known	 that	 dense	 granules	 are	 reduced	 in	number	(35)	there	is	no	viable	method	of	diagnosing	a	patient	based	on	this	fact,	as	 all	 current	 techniques	 (including	 whole	 mount	 EM	 (limitations	 already	discussed))	 are	 difficult	 to	 standardise	 and/or	 require	 time	 consuming	techniques	 (such	 as	 tomography,	 or	 serial	 section	 immuno-gold	 labelling	cryosection	 TEM).	 Similarly,	 in	 GPS,	 the	 number	 of	 alpha	 granules	 is	 reduced	(88);	TEM	of	 thin	sections	of	 fixed	embedded	platelets	can	be	used	 to	visualise	alpha	 granules	 but	 sample	 preparation	 to	 achieve	 this	 is	 time-consuming	 and	requires	 highly	 skilled	 technicians,	 and	 is	 therefore	 not	 practical	 to	 routinely	implement	in	a	clinical	context.	Recently,	published	FACs	methods	for	diagnosing	PSDs	(220,	221)	do	demonstrate	additional	ways	to	carry	out	functional	tests	of	platelets,	but	as	with	all	functional	assays	including	LTA,	can	only	be	carried	out	immediately	on	site	after	the	collection	of	samples.	As	discussed,	LTA	results	are	also	difficult	to	interpret	and	often	haematology	centres	will	only	trust	their	own	results,	making	comparisons	difficult.	The	aim	in	this	chapter,	therefore,	was	to	improve	the	diagnosis	of	these	disorders	with	the	use	of	SRM.	
	The	first	technique	employed	was	dSTORM.	Despite	this	technique	achieving	the	best	 resolution	of	 the	 currently	 available	 SRM	 techniques,	 the	 imaging	process	has	a	number	of	caveats	so	that	it	would	be	difficult	to	automate	and	simplify	in	a	clinical	context.	The	development	of	 this	 technique	 for	platelet	diagnostics	was	not	 sufficient	 to	 generate	 a	 data	 set	 large	 enough	 to	 quantify,	 however,	 a	reduction	in	the	punctate	staining	of	these	alpha	granule	markers	was	observed,	
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providing	 an	 indication	 that	 a	 SRM	 approach	 should	 be	 able	 to	 distinguish	between	patients	and	controls.	The	advanced	 imagine	 facility	at	NPL	was	used,	which	due	to	the	distance	from	the	 lab	at	UCL	and	the	Royal	Free	Hospital	and	the	need	to	book	time	on	the	microscope	weeks	in	advance,	limited	the	amount	of	 time	 available	 on	 the	microscope.	 Although	 inconvenient,	 the	 lessons	 learnt	from	 using	 dSTORM	 in	 this	 manner	 were	 invaluable	 for	 determining	 the	conditions	 that	were	 to	 be	 needed	 for	 a	 SRM	 technique	 to	 be	 transferred	 to	 a	clinical	 setting.	 The	 complications	 found	 with	 sample	 transport,	 speed	 of	acquisition,	 analysis	 and	 the	 variation	 seen	 in	 post-processing	 results	 were	important	considerations	for	designing	a	protocol	more	suitable	for	analysing	a	PSD	 that	 would	 be	 practical	 in	 a	 clinical	 setting.	 Firstly,	 to	 collect	 even	 a	 2D	image	 this	 method	 relies	 on	 localisation	 software	 to	 plot	 the	 average	 point	spread	 functions	 of	 a	 large	 number	 of	 images	 (15,000	 images	 typically	 in	 this	study).	 Compared	 to	 other	 SRM	 techniques	 this	 reduces	 the	 speed	 of	 image	acquisition	 possible,	 creates	 data-heavy	 results	 and	 introduces	 too	many	user-defined	variables.	Dependent	on	the	density	of	the	immuno-fluorescent	labelling	and	the	blink	rate	of	the	switching	fluorophores,	an	experienced	user	will	often	change	 parameters	 such	 as	 the	 laser	 power	 and	 the	 time	 at	 which	 data	 is	collected,	 depending	 on	when	 the	 optimum	 blinking	 period	 is	 typically	 found.	The	 time	 taken	 to	 acquire	 an	 image	 in	 this	 study	 was	 typically	 around	 5-10	minutes	which	would	 create	 a	 bottle-neck	 in	 a	 clinical	 setting	 and	 require	 lab	technicians	to	be	trained	to	be	reproducible	in	the	imaging	parameters	that	were	changed	between	 samples.	 As	 discussed,	 the	main	problems	 that	 are	 currently	seen	 with	 PSD	 imaging	 techniques	 are	 reproducibility,	 variability	 in	 sample	preparation	 and	 complexity	 of	 image	 acquisition;	 dSTORM	 seems	 unlikely	 to	solve	these	issues.	Samples	prepared	for	dSTORM	are	also	impractical	to	handle	in	 a	 clinical	 setting	 as	 the	 glass	 bottom	dishes	 or	 specially	 designed	 chambers	required	 are	 relatively	 expensive	 compared	 to	 glass	 slides	 and	 coverslips,	 and	the	method	 relies	 on	 the	 sample	 being	 kept	 in	 liquid	 before	 the	 application	 of	switching	buffer,	making	the	samples	difficult	to	transport	and	store.	Finally,	and	crucially,	 the	 resolution	 improvement	 gained	 by	 localisation	 microscopy	techniques	such	as	dSTORM,	as	compared	to	other	SRM	techniques	such	as	SIM,	is	 not	 required	 for	 the	 analysis	 of	 immunofluorescent	 antibodies	 that	 label	
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platelet	 granules;	 dense	 granules	 are	 around	 150	 nm	 and	 alpha	 granules	 200-400	nm	in	diameter	(226).	 	The	resolution	achieved	by	the	custom	built	SIM	in	NPL	 was	 typically	 around	 100	 nm.	 Therefore,	 despite	 promising	 early	 results	seen	with	dSTORM	analysing	GPS	(6.2.4),	SIM	was	investigated	as	a	possible	tool	for	PSD	disorder	analysis.	
	From	the	currently	available	methods	of	SRM,	SIM	is	the	simplest	of	this	class	of	instruments	to	use,	as	samples	can	be	easily	fixed	in	the	same	way	that	a	typical	sample	would	be	prepared	for	fluorescent	microscopy	(see	4.3.3	for	method).	To	acquire	an	image	a	Z-stack	series	of	20	images	would	typically	take	less	than	10	seconds,	 allowing	 rapid	 acquisition	 of	 3D	 images	 of	 platelets	 to	 be	 produced.	Apart	 from	bringing	the	platelets	 into	 focus	(which	can	be	automated),	no	user	input	 was	 required	 before	 imaging.	 The	 samples	 could	 be	 ‘dry’	 fixed	 on	coverslips	using	Prolong	Gold,	which	is	inexpensive,	requires	no	switching	buffer	and	could	be	transported	easily.	 In	a	clinical	context,	simply	collecting	PRP	and	mixing	 the	platelets	with	 fix	 for	15	mins	before	sending	 to	a	central	 facility	 for	further	 processing	would	 be	 possible.	 The	 resolution	 improvement	 seen	 using	SIM	was	 sufficient	 (Figure	 38)	 to	 gain	 reproducible,	 significant	 results	 (Figure	48)	 that	 could	 be	 re-analysed	 at	 a	 later	 date	 for	 other	 variables	 (Figure	 50).	Further,	 it	 is	more	 intuitive	 in	a	 clinical	 context	 to	acquire	high	 resolution	and	high	contrast	data	directly,	rather	than	the	user	having	to	make	decisions	based	on	 localisation	 and	 labelling	 efficiency	 to	 improve	 image	 quality	 and	 thus	potentially	altering	the	result	seen.		The	dense	granule	abnormalities	caused	by	HPS	were	investigated	using	CD63	as	a	marker.	CD63	is	an	itinerant	integral	membrane	protein	that	traffics	between	post-Golgi	organelles	(82)	and	was	selected	as	it	has	been	shown	to	be	present	in	dense	granules	and	reported	to	have	an	altered	distribution	in	HPS	patients	with	a	 lower	 number	 of	 CD63-positive	 structures	 counted	 (35,	 232).	 However,	 the	published	data	was	achieved	 in	 a	 low	 throughput	manner	and	performed	with	microscopy	techniques	that	do	not	have	the	resolution	to	accurately	count	these	structures,	and	this	may	help	explain	why,	to	date,	immunofluorescent	antibody	labelling	techniques	have	not	been	utilised	for	clinical	diagnosis.	
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	Using	immunofluorescent	antibodies	to	count	alpha	and	dense	granules	does	not	come	without	caveats.	The	platelet	granules	are	distinct	but	many	markers	that	are	 claimed	 to	 label	 alpha	 granules	 and	dense	 granules	do	not	 share	 the	 same	structures	when	analysed	by	immunofluorescence.	For	example,	Kamykowski	et	al.	report	that	15	different	markers	for	alpha	granules	fail	to	show	any	significant	co-clustering	 (212).	 Also	 CD63,	 a	 reported	 marker	 of	 dense	 granules	 can	 also	label	 lysosomes	 and	 alpha	 granules	 (25).	 This	 could	 be	 seen	 as	 a	weakness	 or	strength	of	an	immunofluorescent	labelling	approach.	The	platelet	granules	have	historically	been	defined	by	 their	 appearance	 in	EM	and	 for	 routine	diagnostic	purposes	it	could	be	argued	that	it	 is	counter-productive	to	categorise	granules	as	alpha	and	dense	granules	in	this	manner,	as	there	is	no	efficient	technique	to	analyse	both	within	a	large	number	of	platelets	and	there	are	no	techniques	that	are	 devoid	 of	 subjective	 identification.	 An	 unbiased,	 automated	 technique	 of	counting	structures	that	are	positive	for	antibodies	that	are	known	to	be	reduced	in	 a	 PSD,	 is	 potentially	 a	more	 accurate	 and	 reproducible	method	 for	 defining	both	PSD	and	granules	themselves	and	this	approach	could	improve	the	chances	of	detecting	new	markers	of	disease.			The	 sensitivity	 of	 this	 analysis	 by	 SIM	 is	 demonstrated	 by	 the	 ability	 of	 this	technique	 to	 distinguish	 between	 three	HPS	 patients	 and	 seven	 controls	 (99%	confidence)	 in	 the	 number	 of	 CD63	 positive	 structures	 and	 also	 in	 the	distribution	of	CD63	within	the	platelets.	After	using	a	one-sample	t-test	for	the	two	populations	(patients	versus	controls)	it	was	concluded	that	a	sample	size	of	just	25	platelets	would	be	sufficient	to	give	a	similar	probability	of	detection	of	HPS	 from	 the	 platelets	 analysed	 in	 this	 study.	 In	 this	 study	 an	 average	 of	 281	platelets	per	person	was	analysed.	HPS,	however,	is	a	very	clearly	differentiated	defect,	 therefore,	since	sampling	a	 large	number	of	platelets	does	not	affect	the	time,	 cost	 or	 sample	 size	 required,	 this	 method	 could	 potentially	 be	 used	 to	detect	 much	 less	 severe	 phenotypes	 if	 needed.	 If	 required,	 it	 would	 also	 be	relatively	 easy	 to	 analyse	 even	 larger	 numbers	 of	 platelets	 to	 further	 increase	sensitivity	for	other	disorders.		The	counting	of	CD63-positive	structures	by	SIM	on	2812	platelets	(in	total)	was	achieved	in	our	study	in	less	than	5%	of	the	time	
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needed	for	the	manual	analysis	of	1008	platelets	(in	total)	by	the	gold	standard	whole	mount	EM	 technique,	 yet	both	gave	a	 significant	difference	between	 the	HPS	patients	and	the	controls.	The	mean	number	of	CD63-positive	structures	for	controls	is	roughly	twice	as	many	as	for	dense	granules	as	counted	by	EM;	3.5	as	opposed	 to	 6.8.	 	 This	 may	 be	 in	 part	 due	 to	 the	 presence	 of	 CD63	 on	 other	organelles	 within	 the	 platelets,	 as	 expected	 for	 such	 an	 itinerant	 membrane	protein,	this	could	also	be	due	to	the	criteria	set	to	count	dense	granules	in	whole	mount	EM	which	was	intentionally	strict	(4.4.2).	However,	despite	this	difference	in	baseline,	the	important	conclusion	is	that	either	by	whole	mount	EM	or	SIM,	a	highly	significant	difference	between	controls	and	patients	was	observed	(Figure	46,	Figure	48),	and	therefore	SRM	could	replace	whole	mount	EM	as	an	effective	determinant	of	a	platelet	dense	granule	disorder.	
	The	improved	resolution	possible	with	SRM	compared	to	other	light	microscopy	techniques	potentially	allows	subtle	changes	of	morphology	from	large	datasets	to	be	detected;	helping	clinicians	to	diagnose	patients	with	more	certainty.	This	may	also	lead	to	the	identification	of	novel	symptoms	within	genetic	subtypes	of	a	disorder	such	as	HPS,	which	until	now	have	not	been	observed.	To	analyse	the	images	 an	 automated	workflow	was	written	 as	 an	 ImageJ	macro	 that	 allowed	CD63	 positive	 structures	 to	 be	 counted	 rapidly	 and	 without	 subjectivity.	 An	automatic	 thresholding	 value	 set	 by	 ‘Moments’	 in	 ImageJ	 (169)	 selected	 the	parameters	 automatically	 and	 thus	 results	 could	 be	 easily	 compared	 between	different	analysts	without	any	subjective	analysis.	The	methodology	detailed	 in	this	study	could	be	further	automated	with	a	microscope	capable	of	autofocusing	and	screening	a	number	of	 samples	at	a	 time.	An	example	of	a	 simple	 readout,	the	 percentage	 of	 platelets	 with	 4	 or	 more	 CD63	 positive	 structures	 could	 be	used	as	an	initial	detection	of	HPS	(Figure	48).	An	improvement	in	the	efficiency	of	 platelet	 imaging	was	 also	 explored,	 as	 centrifugation	 of	 fixed	 platelets	 onto	poly-lysine	coated	coverslips	reduced	the	amount	of	PRP	required	to	produce	96	coverslips	of	platelets	with	a	high	density	in	each	image,	to	less	than	1	ml.	As	all	patients	 with	 HPS	 have	 a	 bleeding	 disorder	 (37),	 it	 would	 therefore	 be	 an	attractive	 proposition	 to	 potentially	 scale	 down	 the	 collection	 of	 blood	 to	 a	simple	pin	prick.		
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	The	advantage	of	a	high-throughput	quantitative	automated	methodology	is	that	it	 can	 be	 further	 extended	 by	 the	 addition	 of	 other	 marker-specific	 immuno-probes	 to	 simultaneously	 quantify	 other	 platelet	 structures	 if	 needed.	Parameters	such	as	size	and	the	shape	of	organelles,	as	well	as	novel	parameters	that	arise,	such	as	the	fraction	of	any	membrane	protein	on	the	platelet	surface,	could	 also	 be	 easily	 extracted	 from	 the	 morphometric	 datasets.	 This	 would	expand	 the	number	of	disorder	markers	within	one	data	 set,	without	 the	need	for	a	patient	to	revisit	the	clinic.	An	example	of	this	was	discovered	during	this	study	when	a	surface	accumulation	of	CD63	was	observed	(Figure	50)	and	found	to	be	significantly	different	in	HPS	patients	compared	to	controls.	The	ability	to	be	 able	 to	 revisit	 the	 data	 and	 look	 for	 a	 different	 marker	 of	 HPS	 revealed	 a	potential	new	disease	phenotype	of	HPS	that	could	help	improve	the	sensitivity	of	 detection.	 This	 is	 important	 as	 new	 approaches	 to	 PSD	 diagnostics	 are	required,	 in	2013	 it	was	 reported	 that	76%	of	patients	with	HPS	were	 initially	misdiagnosed	and	28%	of	patients	had	to	see	4	to	6	specialists	before	receiving	the	correct	diagnosis	 (98).		 Fixed	platelets	are	 stable	 for	 several	months	at	4oC	and	 could	 be	 sent	 to	 a	 central	 facility	 for	 diagnosis	 by	 SIM	 and	 imaged/re-analysed	 at	 a	 later	 date	 if	 required,	 relieving	 local	 hospitals	 of	 the	 burden	 of	equipment	acquisition	and	training.		Although	SRM	has	not	been	used	in	a	clinical	setting,	it	is	likely	to	become	much	more	widely	available	as	the	benefits	are	demonstrated.	Publications	relating	to	SIM	 have	 increased	 rapidly	 (Figure	 51)	 since	 the	 first	 demonstration	 of	 this	technique	 by	 Gustaffson	 in	 2000	 (147),	 and	 therefore	 it	 is	 should	 not	 be	considered	a	negative	point	that	this	technique	has	not	yet	been	employed,	but	rather	considered	a	matter	of	time.	
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	Figure	51	Publications	related	to	SIM	
	The	frequency	of	publications	per	year	related	to	SIM	since	2000,	data	acquired	from	www.pubmed.gov	
	In	this	chapter	two	SRM	techniques,	STORM	and	SIM,	were	employed	to	analyse	markers	of	platelet	 granules	 in	patients	with	PSDs.	Our	 results	 suggest	 that	 an	immunofluorescent	 diagnosis	 using	 SIM	 could	make	 a	 valuable	 addition	 to	 the	diagnosis	 of	 patients	 with	 PSDs.	 The	 data	 in	 this	 chapter	 demonstrates	 that	 a	SRM	approach	coupled	to	morphometric	analyses	could	be	an	effective	and	rapid	approach	 to	differentiating	between	a	patient	with	a	platelet	bleeding	disorder	and	healthy	volunteers.	
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7 Summary	
Firstly,	 the	 roles	 of	 the	 proteins	 that	 are	mutated	 in	 an	 LRO-related	 disorder,	HPS,	 were	 further	 explored.	 There	 is	 little	 evidence	 in	 the	 literature	 of	 the	function	of	HPS-related	proteins	and	their	complexes	in	human	cells	and	no	link	between	 these	 and	 WPBs	 in	 endothelial	 cells.	 The	 secretion	 of	 vWF	 into	 the	blood	flow	is	one	of	the	primary	functions	of	WPBs	and	attempts	were	made	to	measure	 the	 effect	 of	 siRNA	ablation	on	HPS	 related	proteins	on	 the	 regulated	secretion	of	vWF	in	culture	HUVECs.	Initially,	a	KD	of	BLOC-1	by	a	siRNA	targeted	to	 Pallidin	 resulted	 in	 a	 significant	 increase	 in	 vWF	 secretion.	 A	 significant	reduction	in	WPB	feret	diameter	was	also	observed	and	preliminary	experiments	suggested	that	there	was	a	reduction	in	high	molecular	weight	multimers	of	vWF	and	an	increase	in	vWF	exocytic	sites.	However,	when	the	secretion	of	vWF	was	further	 tested	with	 other	 siRNAs	 targeted	 towards	Pallidin	 the	 phenotype	was	not	 reproducible.	 As	 there	 is	 a	 lack	 of	 reliable	 antibodies	 to	 measure	 the	efficiency	 of	 the	 BLOC-1	 protein	 levels	 by	 a	 western	 blot,	 this	meant	 that	 off-target	 effects	 could	 not	 be	 ruled	 out.	 Similarly	 a	 KD	 of	 BLOC-3,	 by	 a	 siRNA	targeted	 towards	 HPS1,	 also	 resulted	 in	 an	 increase	 in	 vWF	 secretion.	 This	phenotype	was	not	reproducible	when	the	secretion	assays	were	performed	with	other	HPS1	siRNA	sequences	and	as	there	is	also	a	lack	of	reliable	antibodies	to	measure	 the	efficiency	of	BLOC-3	protein	 levels	 in	 the	cell,	 this	meant	 that	off-target	effects	could	not	be	ruled	out.	In	conclusion,	we	were	not	able	to	confirm	the	role	of	HPS-related	proteins	in	WPB	formation	and	function.		In	 parallel	 a	method	 to	 improve	 the	 detection,	 quantification	 and	 diagnosis	 of	LRO-related	disorders	was	undertaken.	Current	methodology	does	not	allow	the	morphology	 or	 number	 of	 platelet	 alpha	 and	 dense	 granules	 to	 be	 reliably	assessed	 in	 patients	 with	 a	 PSD.	 An	 automated,	 unbiased	 methodology	 was	employed	 using	 SRM	 which	 allowed	 platelet	 granules	 to	 be	 resolved	 and	 in	preliminary	data	demonstrated	a	difference	 in	 the	 localisation	of	platelet	alpha	granule	markers	 vWF	 and	 P-selectin,	 between	 two	 patients	with	 GPS	 and	 two	controls	using	dSTORM.	The	methodology	was	improved	when	using	SIM,	as	the	
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resolution	 improvement	 over	 SIM,	 achieved	 in	 dSTORM,	 was	 not	 required	 to	resolve	 platelet	 granules	 and	 the	 simpler	 preparation	 and	 analysis	 of	 platelet	samples	would	be	more	suitable	 in	a	clinical	context.	An	analysis	of	SIM	on	the	number	 of	 CD63	positive	 structures	 (a	marker	 primarily	 of	 dense	 granules)	 in	platelets	 from	 patients	 with	 HPS,	 concluded	 that	 a	 significant	 reduction	 in	number	of	these	structures	per	platelet	was	observed	in	three	patients	compared	to	seven	controls.	This	result	was	comparable	to	that	achieved	with	whole	mount	EM	of	dense	granules	and	was	achieved	without	subjective	counting,	in	less	time	and	 was	 performed	 on	 fixed	 platelets	 that	 could	 be	 easily	 transported	 or	 re-analysed	 in	 a	 clinical	 setting.	 The	 ability	 to	 measure	 a	 PSD	 using	immunofluorescence	microscopy	has	many	advantages	and	will	hopefully	lead	to	a	more	sensitive	analysis,	not	only	of	HPS,	but	other	PSDs	where	a	change	in	the	morphology,	 location	 or	 number	 of	 platelet	 granule	markers	 could	 be	 used	 to	diagnose	patients.	An	example	of	the	power	of	this	analysis	was	provided	when	an	observation	that	 the	 location	of	CD63	within	the	platelet	had	altered	 in	HPS	patients	was	 tested.	Without	 the	need	 to	obtain	 further	samples,	an	automated	and	 unbiased	 methodology	 was	 developed	 to	 measure	 the	 location	 of	 CD63	within	 each	 platelet	 and	 from	 this	 a	 significant	 difference	 between	 the	 three	patients	and	seven	controls	was	observed.	This	new	diagnostic	method	has	the	potential	 to	 improve	 PSD	 diagnosis;	 an	 automated	 SRM	 could	 aid	 the	characterisation	 of	 HPS	 and	 other	 PSDs	 and	 also	 improve	 the	 sensitivity	 of	diagnosis	by	 enabling	 the	detection	of	 specific	populations	of	 granules	 and	 the	localisation	of	markers	that	are	affected	by	a	given	mutation.		The	current	literature	has	emphasised	the	similarities	between	LROs,	yet	despite	this,	the	molecular	and	cellular	basis	for	this	group	is	still	incomplete.	To	expand	on	this	research,	it	will	be	necessary	to	continue	to	explore	the	effects	of	proteins	mutated	in	LRO-related	disorders	in	their	host	cells,	to	gain	further	information	about	 their	 roles	 in	 intracellular	 trafficking.	 This	 will	 not	 only	 improve	 our	understanding	 of	 LRO	 formation	 and	 function,	 but	 also	 facilitate	 in	 the	categorisation	 of	 this	 group	 of	 organelles	 as	whole.	 In	 parallel	 new	 diagnostic	techniques	 are	not	 only	needed	 to	 improve	 the	 treatment	 of	 patients	 suffering	
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from	 these	 disorders	 but	 are	 also	 important	 for	 potentially	 improving	 the	analysis	of	future	LRO-related	studies.	
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